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TERMS AND ABBREVIATIONS
TERMS

M enopause:

cessation of the m enses

Perim enopause:

begins at age 35 with declining estrogen levels

Postm enopause:

years beyond m enopause

Postm enopausal:

no menstrual period for 12 months

Estrogen:

female sex hormone dominant in follicular phase of
menstruation

Progesterone:

female sex hormone dominant in luteal phase of
m enstruation

Ovariectomized:

surgical removal of the ovaries

Sham :

surgery without the removal of the ovaries

Luteal phase:

12-14 days following ovulation

Follicular phase:

12-14 days prior to ovulation

Estrus:

recurring period of maximum sexual receptivity in
most female mammals

Diestrus

interval between periods of estrus

Proestrus:

period immediately following estrus

Metestrus:

period following estrus and preceding diestrus

Negative allesthesia:

hunger or appetite

Hyperphagia:

hunger or increase in appetite and food
consumption

Hypophagia:

satiety or decrease in appetite and food
consumption

Hyperplasia:

build-up of the endometrial lining

x

ABBREVIATIONS

BW:

Body weight

OV:

Ovariectomized

S:

Sham surgery

E:

Estrogen or Estradiol

P:

Progesterone

H

Hormone

PRO:

Protein

CHO:

Carbohydrate

C:

Chocolate

FAT:

Fat

g:

Grams

BMI:

Body M ass Index: weight in kilograms divided
height in m eters (squared)

kcal:

Kilocalories

HDL:

High density lipoproteins

Choi:

Cholesterol

LH:

Luteinizing hormone

FSH:

Follicle stimulating hormone

GnRH:

Gonadotropin-releasing hormone

HRT:

Hormone replacem ent therapy

CHD:

Coronary heart disease

ABSTRACT
Hormone replacement therapy (HRT) is chosen by a growing segm ent
of the postm enopausal population. Mid-life body weight gain is perceived to
increase further with exogenous HRT. To exam ine hormonal effects on caloric
intake (Cl), carbohydrate (CHO), FAT, protein (PRO), chocolate and body
weight (BW) in a female model, Sprague-Dawley postbreeder (n=55) rats (10
mos., 10 litters of pups) were ovariectomized (OV) and implanted with 17 p
estradiol (E) and/or progesterone (P), or placebo in three separate studies
(phases) of 10 days each. Uterine weights (p=.0001) and radioim m unoassay
confirmed hormonal bioactivity. The sham (S) group with placebo implant w as
used for comparison.
In phase I, 3 food cups containing CHO, FAT, and PRO were presented
ad libitum to all treatments. Estrogen decreased the rate of body weight gain
(p=.001) com pared to OV, P, and S with no significant differences in caloric
intake (trend of estrogen p=.052). In phase II, all except S received 4 food
cups; 2 CHO choices, (sweet, AIN 76 and nonsw eet AIN 93), FAT and PRO.
The body weight of the P and S groups com pared to OV (p=.009) in phase II
adapted and did not continue to increase. OV produced a carbohydrate
appetite for both SW & NSW (p=.007), E&P chose 3 tim es more SW than NSW
(p=.001). For phase III 4 caloric levels of chocolate were added (except for S).
Chocolate w as consum ed at 40% to 53% of total caloric intake with or without
HRT with reduced nutrient dense macronutrient consumption. Thus a c c e ss to
chocolate eliminated both the reduced rate of weight gain caused by E (phase
I) and the body weight adaptation by P in phase II. Variations in % fat intake
(40% to 60%) did not result in treatm ent differences in body composition

(p=.0945).

The

OV group

which

consum ed

the

most calories

carbohydrate (p=.001)t gained the most overall BW (p=.001).

from

The rats

consum ing the most fat (S 57%) gained the least amount of body weight
(p=.001). Caloric conversion ratios (weight gain/by caloric intake x 1000)
varied among treatm ents (p=.003). Additional research on the metabolism of
the postm enopausal female taking hormone replacem ent therapy is needed.

CH A PTER 1:

INTRODUCTION

There are 470 million women aged 50 years and older living in the
world today (World Health Organization [WHO]: World Health Statistics
Annual, 1990).

T hese women are older than the average age of natural

m enopause throughout recorded history.

Only 50 years ago, even in

developed countries the average woman did not live to be 50 years of age.
On a global basis, there are large populations of women for whom the risks of
estrogen deficiency are undefined. The largest potential benefit of estrogen
replacem ent therapy is the prevention of heart disease, the major cause of
death in the female. In countries with a relatively high risk of heart d isease,
current studies suggest that estrogen reduces that risk by 50% (WHO, 1990).
Due to recently reported clinical trials showing the cardioprotective effects of
horm one replacem ent therapy, a large num ber of women in the USA and
other developed countries may be prescribed extended estrogen replacem ent
therapy (HRT) to reduce cardiovascular disease (The Writing Group for the
PEPI Trial, 1995).

Very little is known about the effects of exogenous

horm ones on energy balance in women. The common perception is that they
may increase body weight (personal interviews with OB/GYN physicians).
Between puberty and m enopause, serum estrogen and progesterone
levels vary throughout the menstrual cycle. The follicular phase is estrogen
dominant with high concentrations of estrogen and low progesterone levels.
During the luteal phase, the progesterone levels rise to a degree that neither
horm one is dominant. During pregnancy, levels of estrogen and progesterone
rise steadily until they reach a plateau w eeks before delivery.

Circulating

estrogen levels begin to decline in the perimenopausal years. At m enopause,
1

the level of estradiol, produced primarily by the ovary, falls and is replaced by
a less active estrogen, estrone, produced

primarily by conversion

of

androstendione in adipose tissue. After the m enopause there is little further
d ecrease in endogenous estrogens with advancing age.

Progesterone

ap p ears to decline at the sam e rate a s estrogens. There is a w idespread
perception among women that this signal of m enopause is responsible for
weight gain after age 50. This belief is held both by women who are already
overweight when they reach m enopause, a s well a s those whose weight is
normal prior to m enopause.
A recent report by Willett, et al., (1995) at the Nutrition Center at Harvard
University School of Public Health is being debated for validity.

They report

that obesity is a major risk factor for a variety of medical conditions:
cardiovascular disease, hypertension, diabetes mellitus, reproductive cancers,
arthritis, and kidney disease, and that if m enopause is found to accelerate
weight gain am ong women who are already obese and at medical risk, then
steps need to be taken prior to the m enopause to minimize its impact on
weight gain among those who are most vulnerable. Body weight m aintenance
to reduce risks is prudent however, often this kind of reporting can create
negative health behaviors. The rates of anorexia nervosa and bulimia are
increasing. We se e the impact of this concept in the fact that $33 billion is
spent yearly on weight control in this country (Atkinson,1990). Low fat diets
and body weight reduction in the female have becom e national obsessions.
Therefore, the issue

of whether

m enopause,

ag e

or

horm one

replacem ent therapy provokes weight gain must be exam ined critically.

It is

important to know what effect hormone replacem ent has on food choices and

weight gain. Due to the current em phasis on thinness and low fat diets (Ley,
et ai, 1992), the female often resists any involvement in exogenous agents that
could cau se body weight gain regardless of the potential positive effects.
Som e reports in the early

1990s on the effect of obesity on

cardiovascular risk in women (n=115,886) show that after adjusting for a g e
and smoking, the risk is 3.3 times higher in women with a body m ass index
(BMI) of >29.0 com pared to a BMI of <21.0 for non obese women.

T hese

authors have concluded that the risk of coronary heart disease (CHD) in
middle-aged women increases even among those who were only m oderately
overweight (Manson, Willett, & Stampfer, 1995). The priority of body weight
se em s to su p ersed e all other concerns. Therefore, if the female feels that
horm one replacem ent can cau se body weight gain sh e may decline its use or
fail to comply with the physician’s prescription.

Recent reports have show n

that compliance drops to 8% after three years and that 50% of the fem ales
given the prescription for hormone replacement therapy (HRT) never have the
prescription filled (Lerner, 1995).
Health implications surrounding body weight and HRT are also relevant
b e ca u se it is known that obesity increases the risk of breast cancer in
postm enopausal women (Vatten, & Kvinnsland, 1990; Sellers, et al., 1992;
Troisi, 1995). The dilemma of taking HRT is com pounded if the perception
also exists that the protective effect will be offset by the increased weight gain.
M enopause is thought to be associated with a shift to upper body adiposity,
which may be related to increased risk for cardiovascular disease, diabetes
mellitus and breast cancer. Endometrial cancer has been strongly associated
with obesity in postm enopausal women (Folsom, et. al.,1989). Unlike breast

cancer, it is linked to the amount rather than the distribution of fat stores. The
issue of whether hormone replacement therapy initiates additional body
weight gain should be scientifically m easured and reported.

At present,

reports are not conclusive.
The positive effects of HRT are evident. However a recent report on the
negative side effects of hormone replacem ent therapy stated that 50% of the
women for whom hormone replacem ent medication had been prescribed had
discontinued taking their medication in under 1 year. Earlier publications have
cited a wide range of compliance problems, and the overall

rate of

discontinuation is surprisingly high. Among the list of negative side effects are
persistent bleeding complications,

severe

mood changes and

adaptation and response to manipulation of therapy programs.

lack of

Body weight

gain and an increase in abdominal fat and enlarged breasts are often reported
to physicians (Lemer, 1995). Many of the early complaints occurred when 10
mg of progesterone w as the accepted dosage to maximally d ecrease the risk
of reproductive cancer. Current Food and Drug Administration (FDA) clinical
trials are using 2.5 continuous or 5 mg cyclically of progesterone com bined
with .625 mg of estrogen. The 10 mg dosage is no longer recom mended. The
new est

combined

levels

are

being

tested

for

effectiveness

against

osteoporosis, heart disease with maximum endometrial protection.

T hese

trials will provide the “Guidance of Clinical Evaluation of Combination
Estrogen/Progestin-Containing

Drug

Products

Used

for

Hormone

Replacem ent Therapy of Postm enopausal Women.” The earliest reports by
leaders in the field, state that in clinical trials the “new” drugs should (a) initially
com pare the rate of endometrial hyperplasia in the treated group to that in a

placebo group,

(b) report the lowest progestin dose which is protective

against endometrial hyperplasia, (c) establish the minimum effective dose of
a specific progestin for any given dose of a specific estrogen (Grady &
Cummings: 1995, Andrews, 1995, Gambrell, 1995, FDA HRT Working Group,
1995).

Perhaps th ese new guidelines will correct earlier m isconceptions,

d e crea se

negative

compliance rates.

physiological

side

effects,

and

ultimately

increase

However, when the perception of increased body weight is

one of those side effects, the problem is often greater to overcome. More than
vanity is at stake. According to the National Institute of Health, up to one third
of all Americans are overweight, and they spend more than $30 billion per
year in their efforts to trim the fat (Barinaga, 1995).
The current em phasis on dietary fat intake has created a national
paranoia regarding anything that might trigger a fat appetite. Dietary fat intake
may not be a s strongly linked to a number of nutrition-related disorders,
including obesity, heart disease and cancer, a s earlier believed.

The

consumption of fat may be related to its palatability, high energy density, and
ultimately positive physiological effects.

Additional research is n eeded to

understand how the sensory qualities of fat and individual differences in
preferences for dietary fat influence human food intake and body composition
and health related implications (Rolls, 1992). C hanges in food intake during
aging may also change the nutrient intake patterns related to the process of
aging, not debilitating d ise ases (Kimura, 1992).

Is there a chance that the

appetite can be trusted and that m oderate am ounts of fat intake daily could
again be considered a healthy choice?

Is there hope that compliance to a

cardiovascular regime would be followed if women knew the body weight
consequences of HRT? This author believes more information is needed.
This study w as designed to examine hormonal effects on macronutrient
food choices reflected in caloric intake and body weight.

The metabolic

implications within an aging animal model in a controlled environment may
provide new information with potential implications for the mature hum an
female. The purpose of this study w as to examine patterns of caloric intake,
macronutrient composition, and body weight gain in the female rat model
(postbreeder)

as

affected

by exogenous

17

(3 estradiol

(E)

and/or

progesterone (P), following ovariectomy. T hese are the horm ones most often
prescribed by physicians to treat m enopausal symptoms. It is hoped that the
study will yield data and provide new information to help understand how
ingestive behavior, specific appetites, hunger motivation and body weight vary
in relation to female sex hormones, following hysterectomy or natural
m enopause in mature women. This research design provides a controlled
method of examining the effects of female sex horm ones E, E&P, and P on
food intake and body weight through administration of exogenous estrogen
and progesterone in the retired breeder female rat(s) following ovariectomy.
PURPOSE AND OBJECTIVES
The overall purpose is to identify and quantify the effects of exogenou s
fem ale sex horm ones E, E&P, and P on food intake in ovariectom ized
postbreeder female rats. The specific objectives of the project are to:
1. Evaluate the effects of female sex horm ones E, E&P, and P on total
caloric intake and body weight gain.

2. M easure the effects of female sex hormones E, E&P, and P on nutrient
composition (fats, carbohydrates [sweet and nonsweet] and proteins) of
ad libitum food intake.
3. M easure the effects of female sex horm ones E, E&P, and P on food
choices of chocolate with high fat/high sugar, high fat/low sugar, low
fat/high sugar and low fat/low sugar content.
4. M easure bioactivity of the horm ones by assessing serum horm one
levels of E, P and testosterone and m easure
cholesterol, organ weights,
composition.

cholesterol,

HDL

fat content of livers and total body

CH A PTER 2:

REVIEW O F L IT E R A T U R E

Human health is a complex and multidetermined issue, influenced by a
wide variety of factors: physiological, biochemical, nutritional, psychological,
environmental, and social (Rodin & Salovey, 1989).

Women’s health is a

priority of the 218t century. A number of health concerns are unique to women.
Even for health issues that affect both women and men, most research h as
been limited to male subjects, leaving a large gap in our knowledge b a se
concerning wom en’s health.
The 1988 Surgeon General’s Report on Nutrition and Health reports
obesity to be the nation's number one nutritional problem (Public Health
Service, 1988).

The Healthy People 2000

(U.S. Printing Office, 1990)

document reports that for 2 out of 3 Americans who neither sm oke nor drink,
eating patterns may shape their long-term health prospects more than any
other choice. Due to increased longevity, the average U.S. woman will spen d
one-third of her life a s a postm enopausal individual (Greendale & Judd, 1993).
Recent census data from the U.S. indicates that in the 1990s the num ber of
women above the age of 50 years will approach 40 million, and that a 50-yearold h as a 30 year projected life-span. The quality of life during th ese years
has been shown to be improved through hormone replacem ent therapy.
Recently the results of the Postm enopausal Estrogen/Progestin Interventions
(PEPI) study were reported revealing cardioprotective effects of horm one
replacem ent therapy (The PEPI Writing Group, 1995).

However, due to

m isconceptions regarding its implications to body weight gain many wom en
are not choosing to take hormone replacement therapy and are therefore
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depriving them selves of the advantages provided by its cardiovascular
protective effects (Barrett-Conner, Bush, 1991).
MENOPAUSE AND POSTMENOPAUSAL THERAPY
In the perim enopausal woman, estrogen and progesterone levels
d e crea se and luteinizing hormone (LH) and follicle stimulating hormone (FSH)
becom e elevated, indicating the approaching m enopause.

The ovarian

follicles grow in response to FSH. The estrogen produced in turn d e c re a se s
delivery of gonadotropin-releasing hormone (GnRH). The d ecrease of GnRH
then su p p resses FSH and LH. As the ovaries age during natural m enopause,
the follicle store is depleted and estrogen production declines (Block, et al,
1952). In postm enopause, the depleted follicular status is generally the sam e
regardless of the ag e at which m enopause occurs.

Without estrogen

feedback, GnRH increases and, thus, FSH and LH rise substantially (Utian,
1978). Levels of FSH increase 10-20 times and LH three tim es within 1 to 3
years after m enopause. T hese high levels are conclusive proof of m enopause
for a woman of m enopausal age. In the postm enopausal woman, the m ean
daily level of estrogen production falls from 50-500 pg/d to 5-10 ng/d (for men,
estrogen levels are 2 to 25 pg/day, equal to the urinary estrogens of a wom an
during the first week of her menstrual cycle). T hese estrogens result from the
conversion of adrenal steroids (such a s androstenedione) to estrone and
estradiol. Levels of androstenedione post-m enopause, however, are only half
those prior to m enopause. Testosterone levels do not decline significantly and
may even rise in the postm enopausal woman (Zichella, 1993).
Symptomatic m enopausal women who experience hot flashes, night
sw eats, sleep disturbances, mood disturbances, impairment of memory and
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concentration, and muscle and joint pains with or without lower genital tract
atrophy may actively seek hormone replacement therapy (Marsh & W hitehead,
1992). The safety and efficacy of a daily combination of micronized estradiol
(E2) (0.7-1.05 mg) and progesterone (200-300 mg) were evaluated in ten
m enopausal women with m oderate to severe vasom otor symptoms and/or
vaginal atrophy over a 12-month study interval. Resulting evidence revealed
symptomatic improvement, minimal side effects, an improved lipid profile, and
am enorrhea without endometrial proliferation or hyperplasia in m enopausal
women (Hargrove, et. al., 1989).

The micronized form of progesterone is

extracted from a natural source such a s soybean or yam s and w as shown in
the PEPI investigation to be the most effective form of progesterone (The PEPI
Writing Group, 1995). Currently, the most widely used exogenous female sex
horm ones by postm enopausal women are Premarin® and Provera®.

The

decision to utilize these or other exogenous forms of exogenous female sex
horm ones

generally

occurs

during

the

perim enopausat

period

when

sym ptoms can intensify and alter the quality of life a s previously mentioned.
Physiologically following the perim enopause, menstrual cycles c e a s e
and

the

secretion

of steroid

horm ones

and

gonadotropin

changes.

Postm enopausal levels of circulating estradiol are lower than levels se en
during the menstrual cycle (Judd, Judd, & Lucas, 1974). The major source of
estradiol becom es the peripheral conversion of estrone and testosterone.

In

contrast to the ratio seen in prem enopausal women, postm enopausal estrone
levels are higher than estradiol levels.

Postm enopausal estrone is also

derived from the peripheral conversion of androstenedione and testosterone.
Small am ounts of progesterone are m ade by the adrenal gland.

After
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m enopause, androgens do not change uniformly.

Androstenedione, the

principal ovarian androgen, is reduced by about 50%.

The adrenal gland

contributes 80% of the postm enopausal androstenedione, while the ovary
continues to produce 20% (Chang & Judd, 1981).
Monitoring endogenous production so that exogenous d o sag es can be
individually prescribed would appear to contribute valuable information to the
female and her physician.

However, existing tests are expensive and can

often be unreliable. Most postm enopausal hormone therapy is intended to
increase the blood levels of estradiol. The hormone progesterone is not
normally produced at all in postm enopausal women. When progesterone is
given to m enopausal women (mainly for women with an intact uterus) it is
primarily used to protect the endometrium (Bass, Westhoff, & Bush, 1995).
Currently oral forms of estrogen and progesterone, Premarin® and
Provera® in the form of tablets, are the most widely used exogenous fem ale
sex hormones. With Premarin® the standard human dose for estrogen
replacem ent therapy is 0.625 mg daily. It protects against postm enopausal
osteoporosis

(Type I) and

cardiovascular disease

postm enopausal women (Stanczyk, et. al, 1995).

in the

majority

The annual

of

rate of

endometrial hyperplasia (excessive proliferation of normal cells) at this dose is
estim ated to be betw een 7% and 15%.

With Provera®, the most widely

prescribed human progestational agent for use in conjunction with estrogen
replacem ent therapy d o sag es vary from 2.5 mg, 5 mg and 10 mg.

The

regimen that is most convincingly shown to prevent hyperplasia has been 10
mg at days 13-28 of each cycle. This above described treatm ent is most
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generally prescribed by the physician following either surgical or natural
m enopause (Grady & Cummings, 1995).
While

th ese

cardioprotective

exogenous

effects,

they

female
have

sex

also

horm ones

been

have

positive

to

increase

reported

macronutrient food intake and thus increase caloric intake (W ade and
Schneider, 1992). More recently it h as been reported that the addition of 10
to 15 lbs. of body weight gain has been shown to occur when circulating
estrogen levels begin to decline in the perim enopausal years (Wing, 1992;
Troisi, et al, 1995).

Physiologically, perim enopause is a time of erratic

menstrual periods prior to m enopause between the a g es of 35 and 45.
Estrogens have num erous actions on several biologic system s. Such system s
include lipid metabolism, coagulation param eters, and blood pressure.
The

effect

of

hormone

replacement

therapy

on

carbohydrate

metabolism in m enopausal women has been reviewed by Notelovitz and
T onnessen (1993). Early markers of negative effects were short term with no
effects on body weight increase. Estrogen treatment w as shown to have a biphasic effect; abnormal glucose tolerance with a normal insulin

level

commonly found within 3 months of treatment, followed by normalization of the
glycemia when treatm ent is extended beyond one year. Progestogens have
adverse short-term effects on carbohydrate metabolism and on lipid and
lipoprotein profile, lowering the ratio of high-density lipoprotein:
lipoprotein

(HDLLDL)

cholesterol

com pared

to

unopposed

low-density
estrogen

replacem ent therapy (ERT) (Gambrell, 1995).
Longer term trials of more than I year, including the recently published
PEPI trial ( The PEPI Writing Group, 1995), indicate that time modifies th ese
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effects. The duration of treatm ent w as concluded to be important. This w as
first comm ented upon by diPaola, Robinson and Nicholson (1970), who noted
that with estrogen treatm ent most of the abnormal glucose tolerance tests
occurred betw een the first and third months of treatm ent and d e c rea se d
thereafter until the ninth month, by which time normal blood glucose levels had
returned. Therefore those who experience early appetite shifts may find that
with time normalization occurs.
In extreme c a se s the profile of endogenous female sex horm ones can
be monitored, however in the population dosages are generally based on
symptomology provided through patient communication with her physician.
Plasm a levels of FSH, LH and estradiol were m easured serially in eleven
prem enopausal patients before and after hysterectomy. One week after the
operation an incremental dosage regime of conjugated estrogens in tablet
form w as com m enced on the basis of two weeks of therapy with each dose
interspersed with two weeks without therapy.

FSH, LH and estradiol levels

were m easured at the end of each period with and without therapy.

Estradiol

levels fell within 24 hours of operation while FSH and LH levels rose
gradually. In only one instance did conjugated estrogens succeed in reducing
FSH to prem enopausal levels, and that w as at a dosage of 2.5 mg. It should
therefore be noted that usual conjugated estrogen treatm ent after surgical
m enopause does not represent physiologic “hormone replacem ent therapy,” if
defined a s the dosage to maintain prem enopausal circulating concentrations
of reproductive horm ones (Utian,1978; Lerner, 1995).
Additional physiological

studies

in postm enopausal

women

are

needed. An early study by Notelovitz (1982) w as conducted to exam ine blood

14

pressure and body weight of postm enopausal women after one year of
estrogen-progestin therapy. Twenty naturally m enopausal women received
either

0.625

or

1.25

mg

conjugated

estrogens

with

10

mg

m edroxyprogesterone acetate for one year. Eighteen women of similar ag e
and m enopausal status were followed for the sam e time period with no
treatment. Blood pressure and body weight were a sse ss e d at baseline, six
months, and one year.

No significant changes in blood pressure or body

weight occurred in either group nor were there any treatm ent-related
differences betw een the groups. More recent data (The PEPI Writing Group,
1995) indicate preliminarily no significant differences in body weight gain in
postm enopausal fem ales taking hormone replacem ent therapy (n=875) over a
three year study.

This data is expected to be reported in detail in later

publications.
Few studies have exam ined in-depth the implications of female sex
horm ones on food intake and body weight. Many of the earlier studies w ere
conducted on normally cycling younger females. One such recent study
exam ined the ch anges in dietary intake, urinary nitrogen and urinary volume
acro ss the m enstrual cycle in women confined to a metabolic unit,

T hese

subjects were maintained at a constant activity level, and fed an ad libitum,
rotating, staff-weighed diet.

No significant changes in intakes of energy,

protein, and fat occurred throughout the menstrual cycle (Fong & Kretsch,
1986).
One of the few current reports on postm enopausal women utilized a
written survey to exam ine body weight gain in m enopause (Wurtman, O’Leary,
& McDermott, 1992). This survey of free living subjects (n=490) asked for
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reports on changes in body weight, food intake and activity levels in the early
postm enopause.

The majority reported weight gain since the onset of

m enopause, regardless of whether m enopause w as natural or surgical, and
w hether the subjects w ere obese or nonobese prior to m enopause.

This

report revealed that weight gain occurred among 64% of the women who w ere
normal weight prior to m enopause and among 96% of the women already
o b ese prior to m enopause. The traditional perceived c au se s of weight gain:
increased caloric intake, decreased activity, did not seem related to weight
gain in the women involved in the study. Women who were not o b ese prior to
m enopause gained an average of 10-15 lbs; women who were o b ese gained
an average of 21-23 lbs. The National Health and Nutrition Examination
Survey (NHANES III) study does not currently report body weight param eters
in this segm ent of the population. A $625 million study entitled “The W omen’s
Health Initiative” is presently being conducted charting body weight ch an g e s
over a 15 year period. T hese results should provide much of the missing
information (Healy, 1993). The m easurem ent of fat intake and body weight is
included in the experimental design. Reports should be available in 2010.
A research study on body weight increase in 290 women w as recently
conducted (Wing, 1992). The study reported that age, and not m enopausal
status, w as shown to be the cau se of body weight increase. Other literature
confirms that the hormonal changes in m enopause, are associated with
ch an g es

in

body

composition

and

fat distribution.

With time,

the

postm enopausal female d ecreases in lean body m ass and increases in fat
m ass (Young, et. al., 1963). Ley and colleagues (1992) investigated the
differences in body composition and regional fat distribution among m en and
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pre-and postm enopausal women.

Using dual-energy X-ray absorptiometry

(DEXA), they found that postm enopausal women had 20% greater fat m ass
than prem enopausal women. An increase in the percentile of abdominal fat
during early m enopause also w as reported (Haarbo, et al., 1991).

However,

the latest information (Troisi, et al., 1995) shows a change in distribution to be
more pronounced than percentage of body fat changes, and that waist to hip
ratios were significantly lower in postm enopausal women taking exogenous
female sex horm ones.
The National Research Council Committee on Diet and

Health:

Implications for Reducing Chronic D isease Risk, reports that th ese shifts in
body fat distribution in extreme degrees of obesity increase the risk of coronary
heart disease. Shifts in upper body fat has been shown to be an indicator of
the predisposition to cardiovascular disease and diabetes in the female. A
more important fact which involves a greater percent of the mature population
are the m odest d eg rees of overweight, and

the implications

on

risk

assessm ent. The issue of m oderate body weight gain has been distorted by
the popular p ress and has been used synonomousiy with obesity. It should be
noted that m oderate body weight gain has also been associated with
increased immunity and longevity (Bouchard, 1995).
HORMONAL IMPLICATIONS ON HEALTH AND DISEASE
The issue of body weight, fat intake, longevity and su b seq u en t
implications on morbidity a s reported in the current media has caused national
concern. Dr. Richard Atkinson, president of the American Society for Clinical
Nutrition stated in a recent report that $33 billion dollars were spent on weight
loss in this country last year.

Research surrounding the segm ent of the
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population incurring th ese expenses should be conducted. This m anipulation
of the public in the U.S. is not se en globally. A French study showing higher
national levels of fat consumption but lower incidences of heart disease is one
exam ple (Criqui & Ringel, 1995). The mission statem ent of the newly formed
Office of Research on W omen’s Health show s that research surrounding
prevention, diagnosis, and treatm ent of illness and disease conditions in
women should be conducted. T hese studies may reveal a very different profile
than is currently perceived in this country.
Current reports correlate increased fat intake and implied increased
body fat stores with disease states. T hese may not be confirmed in future
research.

Age and genetics may be the primary reasons for body weight

increase. The transition from prem enopausal to postm enopausal status h a s
been related to an increase in coronary heart disease risk. An additional fact
often not mentioned in mortality studies Is that “reason for death” on coroner’s
reports in the past only included 4 categories, and heart disease w as listed
first. Mortality records in this country may reflect skewed bias in favor of heart
disease for this reason. The effect of weight changes on coronary d ise a se risk
factors in a population-based sam ple of 485 m iddle-aged women spanning
three years (Wing, et al., 1991) revealed that weight gain w as significantly
associated with increases in blood pressure and levels of total cholesterol,
low-density lipoprotein cholesterol, triglycerides and fasting insulin. However,
it should be noted that these increases were associated primarily with age.
Aging and m enopause are natural phenom ena which should be considered
and correlated statistically a s th ese results are reported. T hese physiological
param eters are not surprising.
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The correlation between weight change and coronary heart d ise a se
(CHD) in women w as recently presented (Willett, et al., 1995).

The

researchers a sse ss e d the validity of the 1990 U.S. weight guidelines for
women. The results show that in a follow-up of the Nurses Study (total of
115,818 women 30 to 55 years of age without a history of coronary heart
disease), that only (1,292) 12% c a se s of coronary heart d isease w ere
ascertained.

T hese data which were analyzed after controlling for age,

smoking, m enopausal status, postm enopausal hormone use, and parental
history of CHD, revealed that the women who gained weight within the BMI
range of 18 to 25 kg/m2 from 18 years of age were strongly predicted to
develop CHD. Willett, et al. report that higher levels of body weight within the
“normal” range, a s well a s m odest weight gains after 18 years of age, a p p e a r
to increase risks of CHD in middle-aged women. T hese data are currently in
question. National averages show that only 12% of the population is presently
affected, and that baseline data calculated from body weight at the ag e at 18
may not reflect meaningful information.
Further, Willett et al. reported that current recom m ended weight
guidelines may be falsely reassuring to that segm ent of the population of
women older than 35 years who fall within those guidelines. The report states
that som e risks of CHD could be avoided if body weight guidelines w ere
lowered.

This report may cau se unwarranted alarm, and create the mental

stimulation for the astronomical $33 billion spent on weight loss a s m entioned
earlier by Dr. Atkinson. Further increases in anorexia nervosa and bulimia
may be seen a s the result of the information reported by Willett, et al.

In all

fairness, it should also be noted and reported that 88% of the women did not
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suffer from the reported cardiovascular weight related implications.

The

pattern of alarming 100% of the population when 10-15% suffer from a healthrelated problem has becom e the norm in this country and is often used to
market high cost food items.

This form of marketing can be term ed a

manipulation of the health conscious aging American and has becom e a
major source of income for vendors. The scientific accuracy upon which th ese
claims are m ade should be questioned and examined further.
The Center for Science for the Public Interest may be the source of the
current perceptions and misconceptions on fat which are being m anipulated
and used for marketing ploys in the U.S. population. Recently a report
revealed the self-selected contents of the refrigerator at the Center a s being
high in fat for its em ployees. Clearly the body fat issue n eed s definitive and
conclusive evidence not currently in place in the literature a s it relates to
health param eters and disease states. T hese human eating

behavior

param eters are the focus of this research.
The question of hormonal effects on food choice and future impact on
health param eters is not known. Female sex horm ones are an obvious choice
to exam ine since increasing num bers in the female population are choosing a
supplem ental form to address health related implications. The most recent
data suggest that estrogen therapy reduces heart disease (The PEPI Writing
Group, 1995).

T hese reports show that exogenous estrogen su p p re sse s

hepatic lipase activity, thereby raising the level of high-density lipoprotein
cholesterol (HDL). Barrett-Conner and Bush (1991) noted that betw een 25%
and 50% of the beneficial action of estrogen on coronary heart disease risk
could be ascribed to changes in HDL-cholesterol and LDL-cholesterol.
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Hormone replacem ent therapy (HRT) is currently accepted for relief of
m enopausal symptoms, and for the reduction in risk for osteoporosis and
cardiovascular disease. With increasing num bers of fem ales choosing HRT,
long term unknown health concerns should be addressed.
very clear:

One fact se em s

preliminary clinical and laboratory work-up prior to horm one

replacem ent therapy in postm enopausal women (Pardo, et. al., 1992) should
consist of mammography test for malignancy exclusion, confirmation of
m enopause by FSH and estrogen, and also the confirmation of normal lipid
metabolism. Baseline data is essential to the strength of reported results.
Additionally, the assessm en t of dosages may be an area of concern for
postm enopausal women considering hormone replacem ent therapy. It should
be noted that it is rare that investigators have included biologic m easures of
serum female sex horm ones before, during or after drug administration.
Without such data, d o sag es administered and the classification of pre-, peri-,
or postm enopausal status provide only a rough yardstick with which to
evaluate subject or treatm ent characteristics. One such study revealed the
effects of estrogen-progestin replacem ent therapy in postm enopausal women
(Ortega, Cuadros, Gonzalez, & Ruiz, 1993).
estradiol and progesterone were m easured.

Serum levels of LH, FSH,
M easurem ents were collected

before and after four different estrogen-progestin replacem ent therapies. The
results show ed that serum levels of LH and FSH dropped significantly in all
four groups, that estradiol levels increased in all groups but that progesterone
levels rem ained relatively unchanged.
New studies on micronized progestins (the natural form found in such
food sources a s soybeans and yams) a s opposed to m edroxyprogesterone
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are providing evidence of decreased

side effects (which affect compliance)

with micronized progestins (The PEPI Writing Group, 1995).

Negative side

effects can be prem enstrual syndrome, bloating, depression, weight gain and
uncontrolled eating bouts. The micronized progesterone used in the PEPI trial
w as produced by Schering Plough, Kenilworth, NJ. Synthetic progesterone
produces different more pronounced side effects than the natural plant
so u rces

(Hargrove,

et

al.,

1989).

However,

micronized

progestin

bioavailability may be lower and d o sag es may therefore need to be increased.
Progesterone receptor site levels are significantly lower in postm enopausal
women

(Becker, et al., 1990).

Side effects may directly correlate to

compliance rates in the postm enopausal female. Additional research showing
endogenous levels prior to administration of d o sag es and com parisons with
m edroxyprogesterone (Provera®) are needed in the human postm enopausal
female. More specifically, m echanism s and physiological implications of all
sources of exogenous female sex horm ones should be investigated.
The varieties in the mode of presentation of exogenous sex horm ones
h as increased recently:

oral, suppositories, vaginal cream s, patches and

subderm al implants given cyclically, continuously or at 3 to 6 month intervals.
The d o sa g es that provide the greatest degree of cardioprotection with
i

minimum

side

effects

should

be

investigated.

An

earlier

study

of

postm enopausal women given exogenous esterified sources of estrogen
0.625

mg

(Estratab),

m ethyltestosterone

esterified

estrogen

0.625

(Estratest H.S.), or conjugated

mg

plus

estrogen

1.25

mg

0.625

mg

(Premarin®), show ed no significant differences among treatm ent groups
(Jurgens, et. al.,1992). Serum levels of estradiol remained unchanged. There
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are

often

correlations

postm enopausal

women

betw een
which

estrogen
provide

receptors

and

estradiol

biomarkers

for

cancer

in
and

cardiovascular disease (Perez-Lopez, et al., 1993). The dem and is increasing
a s cardioprotection studies are released and osteoporosis

prevention is

further investigated. In the absence of serum tests for steroid levels, the current
m ethod of m easurem ent requires verbal feedback from the patient to the
physician.

And very often hormone replacem ent is discontinued before the

physician is contacted.
Much of the current popular interest in exogenous female sex horm ones
com es from the effect on a disease state such a s CHD or osteoporosis.
Although the initial decision often surrounds com pensating for negative
m enopausal symptoms, the continuation of exogenous fem ale sex horm ones
may have other less obvious reasons and compliance is abandoned. The
implications of body weight gain a s affected by varying d o sa g es of HRT in the
healthy female who chooses hormone therapy have not been thoroughly
investigated. Higher levels of progesterone often prescribed for women with a
family history of breast cancer may initiate a fat appetite which can further
compound the problem (Rolls personal communication,

1993, (Ob/Gyn.

physicians personal communications, 1994).
A recent study conducted at the University of Vienna, Department of
Obstetrics and Gynecology, show s that after long term therapy with estrogen
implants, a 13% increase of prolactin w as reported (Metka, et al., 1994). This
increase se em s to be dose related. Further work is needed to exam ine body
weight implications. Another related study by Bennet and Ingram (1990) w as
designed to investigate the possible m echanism s by which dietary fat m ay
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influence the development of breast cancer by influencing the concentration of
fem ale sex hormones. They investigated the effect of the type of fat consum ed
on concentrations of female sex horm ones in serum. They found that when
nutrient consumption was correlated with hormone concentrations, prolactin
w as directly associated with fat consumption, and sex-horm one-binding
globulin

w as

inversely

associated

with

fat

consumption

cholesterol consumption), and that the proportion

(particularly

of nonprotein-bound

estradiol w as directly associated with complex carbohydrate consumption.
Currently, a laboratory in Boston is reducing prolactin levels and
altering body weight without altering caloric intake. Cincotta and Meier (1986)
have shown that altering circadian rhythms can create desirable metabolic
outcom es on body weight and diabetic states. Reductions of prolactin
secretion by bromocriptine treatm ent for 24 days reduces fat stores in
ham sters by 25-49% compared with control animals.
and food consumption were not affected.

However, body weight

T hese results document the

important role for prolactin in regulation of fat metabolism and indicate that
bromocriptine might be used to d ecrease fat stores. More recently, a report
from this laboratory has shown a 600% decrease in caloric intake in the
OB/OB m ouse with a return to normal body weight following a state of obesity
(Dr. A.H. Meier, personal communication, 1995). Their work takes us beyond
the current findings in the female rat and may in the future provide answ ers to
the perplexing questions surrounding body weight gain and various d ise a se
sta te s such a s diabetes mellitus.
There appears to be a growing body of evidence that hormonal profiles
affect food intake choices. The clinical analysis of hormonal levels prior to
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d o sage determination and prescription in the human may be appropriate in
the future for a variety of reasons.
The m anagem ent of the peri- or postm enopausal woman, w hether
symptomatic or asymptomatic, involves a careful assessm en t of the problem s
and expectations. The effects of the physiological implications of m en o p au se
and treatm ent on immediate and long-term health must be taken into account.
This may involve aspects of medical topics a s diverse a s physiology,
gynecology, endocrinology, nutrition, psychology, oncology and cardiology.
Although the benefits of estrogen therapy are well established, the response to
therapy must be carefully monitored, seeking out adverse effects both in
individuals and populations.
HORMONAL EFFECTS ON ENERGY BALANCE
Although very little information is available from the hum an studies,
many scientists have m easured

the effects of both endogenous

and

exogenous fluctuating levels of gonadal horm ones in animal models.

The

most descriptive work w as reported by W ade and Gray in the 1970s. Much of
the earlier research to m easure control of body weight (e.g. food intake and
voluntary exercise) w as conducted in the albino rat (Wade & Zucker, 1969;
W ade & Gray, 1979; W ade, Gray, & Bartness, 1985; W ade and Blaustein,
1978).

In female rats estrogens decrease food intake, body weight, and

adiposity, while progestins increase these param eters (W ade and Schneider,
1992). In the male rat adiposity is suppressed by testosterone in a wide range
of d iseases. In female rat studies, the ag e of the rat is often not reported. Due
to reproductive four day estrus cycles and gestational patterns, this information
ap p ears relevant to progesterone levels and research results.
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While W ade’s research in the animal has provided a great deal of
information on the basic endocrinology of body weight a s affected by fem ale
sex hormones, very little is known about the physiological or biochemical
m echanism s by which ovarian and testicular horm ones act to influence body
weight, total body composition and behavioral food choices in the human. In a
theoretical review W ade and Gray (1979) reported selected asp ects of sex
hormone actions on body weight and composition, metabolism, and behaviors
in the rat.

This work is needed in the human to show empirically the

investigations conducted in the rat, female sex hormone effects on adiposity
and the relationship to eating behavior and food choices.

If the results of

earlier work in the animal can be applied to the human, then gonadal steroids
may be shown to influence adiposity by direct action on a few peripheral
adipose tissues which control triglyceride storage with subsequent metabolic
implications. If this is true, changes in macronutrient food choices and caloric
regulation may be altered by varying levels of circulating horm ones with
resulting metabolic benefits overtim e (Jorgensen, et. al., 1994).
Behavioral and physiological controls of macronutrient choices and
energy balance vary with reproductive condition in female rats. Experimental
manipulations of circulating hormone levels (ovariectomy and horm one
replacem ent therapy) indicate that the regulatory changes that are se en over
estrus cycles are due in large part to fluctuations in levels of estradiol and
progesterone (Wade, 1976; W ade & Gray, 1979). Estradiol acts both centrally
and peripherally to induce a coordinated array of changes in the procurement,
ingestion, metabolism, storage, and expenditure of metabolic fuels. In young
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rats, estradiol d ecrea se s the intake and increases the expenditure of energy,
thereby decreasing body fat stores.
In general, progesterone reverses nearly all of the effects of estradiol
and, thus promotes fat storage in rats. In the younger model, it h as been
suggested that body weight changes are som ehow related to estradiolinduced shifts in a hypothetical body weight setpoint.

That is, changes in

voluntary exercise and metabolic expenditure persist only until body weight is
brought into line with a new regulated level. A recent release in the New
England Journal of Medicine conducted by scientists at Rockefeller University
reported dynamic effects of setpoint in both obese and non-obese subjects
(Leibel, Rosenbaum, & Hirsch, 1995). Earlier reports by Fantino and C a b an ac
(1984) have shown hoarding behavior a s an indicator of food deprivation
effects on set point in body weight studies.
In adult female rats, withdrawal of ovarian horm ones by ovariectomy
induces a hyperphagia (hunger) and weight gain which lasts for approximately
one month (Wade & Gray, 1979). Then the hyperphagia subsides, and body
weight is maintained at 20-25% above the level of sham -operated controls
(Gentry & W ade, 1976; Salhanick, et al., 1969).

Running wheel activity is

permanently suppressed by ovariectomy (Wang, 1923).

The effects of the

ovariectomy can be reversed by treatm ent with estradiol alone. Treatment of
ovariectomized rats with physiological d o ses of estradiol produces a transient
hypophasia (satiety) and decline in body weight.

Body weights of estradiol

treated rats are lower than, a s well a s parallel to, the ovariectomized controls
(Mook, et al., 1972; Wade, 1975). As long a s estradiol is given, running wheel
activity remains elevated (Wade, 1975). Leshner and Collier (1973) found that
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ovariectomy doubled carcass fat content in weanling female rats. Treatment
with estradiol has been shown to reverse the increase in adiposity caused by
the ovariectomy (Roy & W ade, 1977; Salans, et al, 1971).
Earlier studies have shown that progesterone has no effect on food
intake,

voluntary

exercise,

body

weight,

or

carcass

composition

in

ovariectomized rats (Galletti & Klopper, 1964; Hervey & Hervey, 1967; Rodier,
1971; Ross & Zucker, 1974). However, in the presence of estradiol (in cycling
fem ales or in ovariectomized female rats given estradiol), treatm ent with high
d o se s of progesterone (5 mg/day) increased body weight and food intake.
The hyperphagia and increased body weight gain during progesterone
treatm ent are transient, just a s after the ovariectomy (Hervey & Hervey, 1967;
Roberts, et al., 1972). During pregnancy and pseudopregnancy, when plasm a
progesterone levels are elevated, eating (Hashimote, Hendricks, Anderson, &
Melampy, 1968), weight gain, and fat depositions are also elevated (Knopp,
Saudek, Arkey, & O’Sullivan, 1973; Slonaker, 1924; W ade & Zucker, 1969), a s
they are during exogenous progesterone treatment.
C arcass analyses indicate that the weight gain during progesterone
treatm ent in the presence of estradiol is due primarily to the increase of fat
tissue (Galletti & Klopper, 1964; Hervey & Hervey, 1967), similar to that se e n
with ovariectomy. It should be noted that the ag e of these anim als is not in
evidence in all cases, and that no studies are reported in the postbreeder rat.
Sexual and hormonal variables have been shown to significantly affect
the rat’s preference for sw eet taste. T aste tests in rats have been conducted in
w ater bottle fluid consumption flavored with quinine (bitter)

and

sw eet

(saccharin). The decrease in fluid consumption w as proportionately greater
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for intact than ovariectomized fem ales when the water supply w as adulterated
with quinine sulfate.

Quinine acceptance by ovariectomized rats w as

unaffected by treatm ent with estradiol benzoate or progesterone alone.

In

combination, th ese horm ones were effective in decreasing intake of the bitter
solution.

In intact females, estrogens and

progestins

appear to act

synergistically to increase reactivity to the aversive taste stimulus.
d ecrease in fluid consumption attributable to the quinine,

The

perhaps is due to

the d e crea se in estradiol and increase in progesterone secretion in pregnant
and pseudopregnant fem ales com pared to unmated females.

It is further

suggested that the decrease in sw eet effect is due to the d ecrease in estradiol
and

increase

in

progesterone

secretion

characteristics of these endocrine states.

and

subsequent

bioactivity

Possible neural m echanism s

account for th ese different effects (Wade & Schneider, 1992).
Behavioral change h as been widely assum ed to be the contributing
factor in the changes in body weight and fat depositions which follow
fluctuations in ovarian hormones. The action of ovarian horm ones in the brain
which could alter food intake and voluntary exercise might then influence fat
deposition and body weight gain.

In the normally cycling rat, there is an

excellent correlation between changes in body weight, food choice and level
of activity. During estrus cycles (when estrogen levels are high) the d e c re a se
in body weight occurs a s a result of increased voluntary exercise and a
d ecrease in food intake (Brobeck, Wheatland, & Strominger, 1947).
However, there are several lines of evidence that suggest that no
simple causal relationship exists between sex hormones, behavior, and fat
deposition. Fluctuations in food intake and hormonal levels correspond quite
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closely but running wheel activity is perm anent a s long a s the exogenous
hormonal levels remain constant. The changes in activity persist long after the
changes in body weight gain have subsided (Mook, et al., 1972).
Hormone

induced

changes

on

accom panied by changes in food intake.

body

weight

are

not

alw ays

Hervey and Hervey (1967) found

that progesterone treatm ent significantly increased body weight in cycling
fem ale rats even when the normally-occurring ex cess food intake patterns
were prevented by restricting their food intake to pre-treatment levels. In fact,
Roy and W ade (1977) found the ovariectomized fem ales had to be restricted to
80% of their normal consumption to prevent the castrated weight gain. Thus
ex cess intake of calories is not necessary for either progesterone or
ovariectomy induced body weight gain and leading to obesity.
A num ber of studies, mainly conducted in genetically o b ese and
overfed rodents (Rothwell & Stock, 1979; Trayhurn, 1984) have shown that
brown adipose tissue may play an important role in the regulation of energy
balance. Edens and W ade (1983) also have suggested that brown adipose
tissue might be involved in the regulation of energy balance in rats treated with
ovarian hormones.

A reduction in brown fat therm ogenesis is usually

accom panied by a reduction in energy expenditure, which in turn leads to a
positive energy balance. This hypothesis needs to be examined more carefully
before it is assum ed to be true in the aging female rat model.
T hese past studies do not provide evidence of human correlations and
have not been continued. The correlation to human health param eters n e ed s
to be addressed in future research.
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HORMONAL EFFECTS ON FOOD INTAKE IN
THE HUMAN FEMALE
Hormonal effects on food intake have not been extensively investigated
in the hum an female. Currently the only macronutirent body weight data are
reported in the younger cycling female model during reproductive years. The
effects of exogenous female sex horm ones in the postm enopausal wom an
taking hormone replacem ent therapy have not been
reported.

investigated

an d

It should be noted that endogenous and exogenous fem ale sex

horm ones may not be valid comparisons. Chemically, th ese are not the sam e,
the natural rhythm of secretion release, and

the binding of en d o g en o u s

horm ones h a s not been mimicked by exogenous treatment. The com parison
merely provides a point of departure for further investigations

in the

postm enopausal female taking hormone replacem ent therapy. It is likely that
th e two com parisons may not reflect parallel applicable information. With that
disclaimer the following information will be examined.
System atic shifts in energy intake, corresponding to different p h a se s of
the m enstrual cycle, have been described (Barr, Janelle, & Prior, 1995;
Lissner, Stevens, & Levitsky, 1988; Manocha, Choudhuri, & Tandon, 1986;
Oram, 1987; Dalvit-McPhillips, 1981, 1983; Abraham, Beaumont, Argali, &
Haywood, 1981; Gong, Garrel, & Calloway, 1989; Gallant, et. al., 1987; Pliner
& Fleming, 1983).

Several studies have shown that in the younger cycling

fem ale the m enstrual cycle affects caloric intake and energy expenditure,
however a s earlier stated, no such research studies are found in the literature
in postm enopausal women with intake of exogenous female sex horm ones.
O ne such well controlled trial of college ag e fem ales show s that wom en
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consum ed about 500 kcal more per day for the 10 days following ovulation
(luteal phase) than the 10 days preceding ovulation (follicular phase) (DalvitMcPhillips, 1981).
(1983)

and

This w as supported in later work by Dalvit-McPhillips

M anocha et al.

(1986);

both

observed

elevated

energy

consumption during the 10 days before menstruation (luteal phase) when
com pared with the 10 days after the onset of menstruation (follicular phase).
However, Abraham et al. (1981) found that energy intake w as at its minimum
level around the onset of menstruation (late luteal phase).

Several authors

have recom m ended additional research investigating wom en’s health by
examining in greater detail food selection or nutrient intake (Dalvit-McPhillips,
1983; Tomelleri & Grunewald, 1987). Pliner and Fleming (1983) found that
both body weight and reported food intake were significantly higher during the
luteal p h ase than during the follicular phase in menstruating women. They
further report that caloric intake from sw eetness (sucrose) preferences
declined in the luteal phase when (progesterone levels were elevated) with an
ab sen ce of such a decline in the follicular phase. Som e have suggested that
a better understanding of the food intake patterns and body weight gain in
wom en may aid in understanding related d iseases and illnesses affected by
obesity (Bush, 1990).
Smith and S auder (1969) stated that in collecting their human data,
85% of those who craved chocolates also included them selves in the group
that craved sw eets.

In a report by G.E. Abraham (1984), a prem enstrual

tension syndrom e subgroup reported cravings for sw eets, “mainly chocolate."
B ecause many chocolate foods are high in both sugar and fat content, one
cannot conclude that women in previous studies were necessarily craving
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sw eets. They may have also been craving fatty foods or they may have been
craving a combination of sweet/fatty foods.

It is also possible that som e

subjects may experience a craving for chocolate flavor interacting with the
su g ar and/or fat content of the food.

Others may experience cravings for

chocolate independent of the sugar and fat content. Therefore, the present
investigation w as designed so that phase III of the study would m easu re
various fat and sugar levels of chocolate in the female rat model.
Caloric intake can be largely determined by the taste or palatability of
food, and many highly palatable foods (including most chocolate foods) are
high in sugar and fat content (Weiffenbach, 1977; Rodin, 1980).

O bese

hum ans find oral stimuli with a higher fat content (Drewnowski, et al., 1985) or
a higher sugar content (Rodin, Moskowitz, & Bray, 1976) more palatable than
do normal-weight subjects.

Increased taste responsivity to sw eets and oral

responsivity to fats have often been cited a s important factors in overeating
and in the development and m aintenance of obesity.
The ways in which foods may increase willingness to eat or to satisfy
the desire for further food is also an issue of great theoretical significance.
Products in which palatability has been

raised

in order to prom ote

consumption may have the potential for causing overnutrition.

In addition to

the new types of foods, additives are injected into the food supply on a regular
basis. Little is known about the effects of th ese additives on appetite. It could
be of great value to have tables showing the energy-satiety ratio of all the
common foods to indicate their potential for causing overnutrition (Heaton,
1981). The study of the m echanism s of appetite is another dimension of this
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a re a of research which is beyond the scope of this paper. But it is of profound
interest and applicability to this study and future research.
As earlier stated, to extrapolate data shown in the younger fem ale
during ovulatory menstrual cycles to the effects of exogenous female sex
horm ones in the postm enopausal female may not be accurate. However, it
d o es provide a view of the implications of energy intakes in the luteal a s
opposed to the follicular phase in younger cycling females. Specifically, Barr,
Janelle, and Prior (1995) com pared energy and macronutrient intakes across
the m enstrual cycle in 42 regularly cycling vegetarians and nonvegetarians.
Tem perature records were quantitatively analyzed to determine w hether
cycles were ovulatory, and if so, the date the luteal phase began.

Analysis

w as based on diet records matched with tem perature analysis results. Higher
caloric intake w as observed during the luteal phase. The contribution m ade
in this data suggests that 30% of the cycles may be anovulatory or have a
short luteal phase, and that energy intake of women differ betw een m enstrual
cycle p h a se s when the menstrual cycle is normally ovulatory.

They

recom mend that in cross-sectional studies, failure to consider menstrual cycle
p h ase could have important implications, especially if small num bers of
subjects are studied. They further recommend that the time of ovulation must
therefore be docum ented b ecause energy intake differs only when cycles are
ovulatory.

It should be noted that this study may provide evidence of the

conflicting reports seen in earlier literature such a s Abraham and his
colleague’s (1981) who reported energy intake at a minimum just before
menstruation.
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To exam ine estrogen and progesterone effects separately is not
possible in the younger human model.

Progesterone levels are elevated

during the luteal phase but not to the exclusion of estradiol (Becker, et al.,
1990). Animal work provides the strongest body of evidence, which indicates
greater caloric intake and body weight gain when progesterone levels alone
are elevated (Wade & Schneider, 1992). Evidence from recent reports
indicates a greater caloric intake, snack food consumption, and body weight
during several prem enstrual days com pared with the postm enstrual period
(Barr, Janelle, & Prior, 1995; Dalvitt-McPhillips, 1981; Dalvitt-McPhillips, 1983;
Pliner & Flemming, 1983; Lissner, Stevens, & Levitsky, 1988; Lyons, et al.,
1989; Gong, et. al., 1989) in contrast to the follicular phase when estrogen
levels are elevated. T hese studies provide interesting information to those
interested in investigating the effects of exogenous female sex horm ones,
estrogen and progesterone in the postm enopausal female. Hormonal effects
on food intake, body weight and the set point surrounding the timing of th ese
biological

processes

should

be

investigated

further

in

the

hum an

postm enopausal model. New information is appropriate on this growing
segm ent of the population which has previously not been studied.
HORMONAL EFFECTS ON APPETITE. TASTE AND PALATABILITY
Positive hedonic judgment or p leasantness of food taste such a s
sw eetn ess in chocolate can lead to a preference for consumption and
increased intake of a particular food group (Drenowski, et al., 1985). Appetite
and ta ste s may be influenced by both endogenous and exogenous female sex
horm ones. The timing and sequence of events leading to subsequent food
consumption and body weight increase has not been determined (Friedman,
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1990). Further, the impact of hormonal effect on food choice to the exclusion
of other more nutrient dense foods and subsequent effects on total health in
the female should be critically examined.
The question of increased palatability influencing food choice in the
face of a deprivation of essential vitamins and minerals necessary to maintain
bone density in m enopause could provide additional research questions in the
aging female. Do eating patterns in aging cau se the physiological m arkers of
degeneration with subsequent disease states and high cost health care in the
aging segm ent of the population?

If the answ er is yes, then (a) what is

causing the alterations in appetite and (b) what can be done to improve the
health status and correct nutrition related disease implications. Again, that is
beyond the scope of this paper but could ultimately affect future research and
the preventive medicine and wellness picture a s m anaged health care is
implemented.

Scientists involved in brain research a s it controls system ic

resp o nses are providing the most interesting current results.
However, knowledge of the m echanism s which control food intake and
body weight has been surprisingly meager. Recent work at the University of
North Carolina School of Medicine in this are a h as shown that the surface of
the gastrointestinal tract may be more than the site of absorption of nutrients; it
may be a preabsorptive reservoir of signals which would be released by
contact with ingested food (Whitehead, personal communication, 1995).
T hese preabsorptive signals would then act to control meal size, regulate
length of meal intervals or both.

This concept has been strengthened by

continuing chemical discoveries of neural and hormonal gastrointestinal
peptides which might serve a s satiety signals. The fact that many of th ese
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sam e peptides and their receptors are also present in brain tissue h as
generated acceptance of the idea that brain stores of certain peptides might
exert direct actions of feeding behavior, unrelated to any peripheral effects.
The classic small intestinal hormone cholescystokinin (CCK) when
administered systematically can cau se a reduction in food intake in rats.
When it is released by food ingestion,

it functions a s a negative feedback

signal to limit meal size. This inhibitory action has been observed in many
animal species, including sub-hum an primates, across a wide variety of test
conditions (Gibbs, Young, & Smith, 1973). The action is strongly dose-related
and is behaviorally specific. Although a large amount of evidence h as been
established, the fact that exogenous CCK reduces short-term food intake is
evident. The m echanism s of endogenous CCK for the normal termination of
eating have not been clearly determined but the CCK hypothesis is em erging
a s an established finding.
The horm one-releasing action of CCK is believed to elicit satiety. This
conclusion w as drawn from surgical and chemical lesion studies which have
dem onstrated that afferent, capsaicin-sensitive neurons of the abdom inal
vagus are required for the satiety action of CCK injected peripherally. The
entry into the brain through afferent neurons of the vagus have their first
synaptic relay in the hindbrain (Gibbs & Smith, 1982).

Brain sites and

pathways involved in processing food intake signals is the specific research
focus of many scientists investigating ingestive behavior.

Clearly, all the

answ ers are not in place. The following is a summary of m echanism s relating
to ultimate food choice.
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Pancreatic glucagon w as the first peptide tested for a possible effect of
food intake signals. Intravenous dosages of glucagon small enough to mimic
the rise in plasm a glucagon normally seen within twenty minutes after the
completion of a meal were shown to reduce test meal size by about 20%.
Geary and Smith (1982) reported the efficacy of systematically adm inistered
glucagon in producing satiety in a wide variety of animal and avian species.
Like exogenous CCK, exogenous glucagon is strongly dose-related, rapid in
onset, and transient.

Unlike CCK, the effect of glucagon ap p ears quite

sensitive to environmental conditions, deprivation
rhythms.

states and circadian

Mildly deprived or nondeprived rats are refractory to the satiety

influence of glucagon around the time of dark onset, but quite responsive two
or three hours later, or during the mid-light period (Martin & Novin, 1977).
The liver is the major target organ for metabolic actions of glucagon.
Novin and his colleagues tested the effects of infusions directly into the hepatic
portal vein (Martin, Novin, & VanderW eele, 1978).

By this route, glucagon

produced a rapid and dose-related reduction in food intake.

It appears that

afferent fibers of the hepatic vagus are the key elem ent supporting this
behavioral effect. T hese results constitute persuasive evidence that circulating
glucagon has a physiological role in controlling food intake.
Bombesin is known to be distributed in mammalian gastrointestinal tract
and brain.

Intraperitoneal injections of bombesin produced large, dose-

related reductions of food intake in rats. Several studies suggested that the
inhibition of food intake reflected a true satiety effect of the peptide which w as
not simply secondary to m alaise or generalized discomfort (Murrahainen,
Kissileff, & Thornton, 1983). As with CCK, the satiety effect of peripherally-
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adm inistered bom besin produced a significant inhibition of food intake at test
m eals without producing significant side effects.
Insulin, administered peripherally in large doses, h as long been known
to provoke feeding in animals and elicit reports of hunger (Lovett & Booth,
1970). In 1980 VanderW eele suggested that smaller doses of insulin closer to
the physiological range would reduce food intake when delivered chronically
to rats (VanderWeele, Pi-Sunyer, & Novin, 1980). Chronic reduction of insulin
w as shown to be due to a decrease in individual meal size. W oods and Porte
(1977) have suggested that insulin may play an important inhibitory role in
feeding behavior by acting directly on the brain. This places insulin not in the
short-term control of individual meal size, but rather a s a long term monitor of
the adipose tissue stores of the body. This hypothesis rests on several strong
supports: (1) plasm a insulin is well known to vary with the fat m ass; (2) in turn,
insulin levels in cerebrospinal fluid vary after a lag period, with plasm a insulin
(Woods & Porte, 1977), (3) insulin and insulin receptors can be found within
the brain, (4) infusions of small am ounts of insulin

directly into the

cerebrospinal fluid of rats and primates reduces daily food intake and body
weight, without raising plasm a insulin levels, and (5) although plasm a insulin
levels

are

elevated

in obesity,

th ese

investigators

have

found

that

cerebrospinal levels of insulin, brain levels of insulin and brain insulin binding
are all low in rodent m odels of obesity, suggesting that the insulin signal from
the adipose tissue m ass is not reaching its target sites in the brain (Baskin,
Stein, & Ikeda, 1985).
It is of interest that this hypothetical m echanism for the regulation of
long-term food intake and body weight ap p ears to interact with at least one of
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the putative short-term satiety signals. Although the administration of a very
small amount of insulin into the cerebral ventricles failed to affect food intake
by itself in rats and in primates, it potentiated a sub-threshold dose of CCK,
and the combination inhibited food intake (Woods & Gibbs ,1989).
Somatostatin, found in the gastrointestinal tract and brain appears to act
a s an inhibitor of multiple pancreatic and gut functions. Administered
intraperitoneally to rats and baboons, it produced a dose-dependent and
behaviorally specific inhibition of food intake (Lotter, Krinsky, & McKay, 1981).
Oxytocin,

which

is

synthesized

in

cell

bodies

of

intra-

and

extrahypothalamic neurons, also has binding sites widely distributed in the
brain tissue. D oses required to reduce feeding after peripheral administration
were massive;

intracerebroventricular administration of 10 ng/rat produced a

m arked suppression of food intake, accom panied by increased grooming.
This effect w as totally reversed by an oxytocin antagonist (Olson, et. al, 1989).
Calcitonin, which is released postprandially into the circulation, reduced
food intake in rats and rhesus monkeys following subcutaneous administration
and in rats after intracerebroventricular administration.

Maximal inhibition

occurred several hours following peripheral injection in rats, suggesting that
the peptide is not directly involved in the regulation of meal size (Krahn, et. al,
1986).
Corticotropin-releasing factor, a 41-residue peptide which stim ulates
pituitary ACTH and p endorphin release, also reduce food intake after injection
into cerebral ventricles and the paraventricular nucleus of the hypothalam us
(Krahn, Gosnell, & Levine,1984).
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Circulating pancreatic polypeptide levels rise dramatically at m eals, and
this peptide has been shown to reduce food intake and body weight after
peripheral

administration

in

lean

and

obese

mice

(M alaisse-Legae,

Carpentier, & Patel, 1977). It failed to reduce food intake in rats (Gibbs, Gray,
& Martin, 1980) and h as not been tested in other species.
Secretin and gastrin, two classical gastrointestinal peptide horm ones,
had no effect on food intake in rats, even when large doses were em ployed
(Gibbs, Young ,& Smith, 1973).
Progress in uncovering the physiological m echanism s of food intake
and body weight over the years is evident. The major elem ent in this progress
is the discovery of the key role of a small group of peptides which link the
gastrointestinal tract and the brain. Enterostatin and Neuropeptide Y are two of
the new est peptides reported to impact neural m echanism s of appetite and
food choice (Bray, et al, 1990). Leptin (Halass, et al., 1995), is the most recent
discovery and holds much promise in genetic implications of obesity research.
The review of the entire scope of all the current investigations is beyond the
scope of this paper.
In summary, certain appetite mechanism patterns seem to be em erging.
It ap p ears that several peptides have their initial action peripherally. Second,
this initial action is relayed centrally by afferent nerves. A major role is played
by the abdominal vagus. Third, the dorsal hindbrain is required for the full
expression of meal cessation.
The recent development of highly potent and highly specific receptor
antagonists and antibodies for several of th ese peptides h as provided an
indispensable tool for assessin g the physiological m eaning of effects on food
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intake produced by the agonists. The m echanism s of food intake and the
safety of th ese biologically potent agents when given chronically are unknown
and must be established (Bray et. al, 1990). The uncertainty of the health
status of the female taking exogenous female sex horm ones (which were not
utilized exogenously for centuries) leaves many questions to be answ ered.
However, it behooves the scientific community to address th ese relevant
questions when such a large segm ent of the population is potentially affected.
The m echanism s reviewed and the way in which the m echanism s
influence food choice and metabolic implications have currently not b een
correlated

to the effects of endogenous female sex hormones. Hormonal

effects on appetite, taste, and palatability in the human and the correlation to
an animal model should be evaluated. To date, the most reliable systemic
specific macronutrient food intake research has been conducted in animal
models. The following is a report of current and past work which may ultimately
lead to the answ ers affecting knowledge surrounding hormonal influences on
food intake and body weight.

Reports from both animal and human studies

will be included to provide a s much information a s is currently available in a
concise form.
W hen receiving exogenous

estrogen, the female rat show s an

increased sugar preference and a decreased fat preference.

Also, su g ar

preference increases with increasing levels of estradiol. Geiselman, Martin,
VanderW eele and Novin (1981) showed that when rats w ere behaviorally
responsive to their elevated endogenous estradiol levels they not only showed
a significant increase in sugar intake, but they also show ed a significant
d e crea se in fat consumption.
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In a similar human study, Aaron (1975) reported greater p leasan tn ess
of the sw eet taste in the follicular phase which lowered during the luteal p h a se
when progesterone levels were higher and estradiol and estrone were lower.
In an additional study across the menstrual cycle, Bowen and Grunberg (1990)
reported increased sw eet food consumption with higher preference ratings
during the luteal phase, when progesterone levels are generally elevated.
However, it should be noted that their “sw eet” foods included combinations of
fat and sw eet such a s chocolate, coffee cake, and gum drops analyzed
together.

Pliner and Fleming (1983) found that negative alliesthesia i.e., a

d ecrease in sucrose preference typically reported from before to after a
glucose load, occurs during the luteal phase but not the follicular phase. The
importance of studying not only sugar preference but also fat preference in a
controlled female rat model is further suggested by data showing that w hen
endogenous estrogen levels are lower and progesterone is elevated, rats
chose significantly more dietary fat (Geiselman, et al., 1981).

There are only

a few anecdotal reports in the human literature of changes in fat preference
across the menstrual cycle, with

no

evidence

in the

aging

rat or

postm enopausal female. It is important to understand the hedonics of specific
appetites a s affected by female sex hormones.
It is therefore important in this study to systematically exam ine both
sugar and fat content in food choices a s se en in separate food cups containing
nutritionally balanced sources of nutrients.

This study w as designed to

specifically identify and quantify the effects of exogenous
horm ones

(estrogen,

estrogen/progesterone,

and

fem ale sex

progesterone)

on

macronutrient preferences, sw eets, fats and chocolate in the ovariectom ized
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retired breeder female rat to provide information and preliminary data for future
hum an studies.

Based on the physiological param eters currently being

investigated in this specific study, the female Sprague-Dawley rat se em s to be
an appropriate animal model.
The animal literature primarily reflecting data collected in the S pragu eDawley rat strongly implicates female sex horm ones in the control of appetite,
food intake, and body weight.

When female rats are ovariectomized, food

intake and body weight both increase (Schemmel, et al, 1982).

However,

administration of small doses of estradiol reverses the body weight gain and
returns food intake to normal (Wade, et al, 1985). A significant d e crea se of
food intake when estrogen is high with a significant increase in food
consumption when estrogen is low w as seen in the cyclic secretion of
estrogen during the estrus cycle of the rat (Tarttelin and Gorski, 1971).
Later work by Tarttelin and Gorski (1973) with ovariectomized rats
show ed an increase in food intake and body weight which plateaued roughly
one month after surgery. Daily injections of 1.5 fig estradiol benzoate initiated
at that time significantly reduced both the food intake and body weight. When
estrogen treatm ent is initiated at the time of ovariectomy, the increase in food
intake and body weight is prevented. No influence of progesterone injection
(either with estradiol benzoate or alone) w as detected. T hese results suggest
that estrogen, but not progesterone, is the ovarian hormone active in the
regulation of intake param eters and body weight in the female rat (Tarttelin &
Gorski, 1973). Fantino and Brinnel (1986) have shown a direct fluctuation of
the body weight setpoint with the ovarian cycle. The implications of this work
have direct application to the concept of hoarding behavior a s a m easure of
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increased body fat stores and increased body weight in the ovarian cycle of
the female rat. Hoarding has been shown to be a direct correlate to increased
body rat stores. Proestrus and diestrus m easures were taken. The diestrus
period is equated to the luteal phase in the female when progesterone levels
are elevated.

Higher progesterone levels initiated increased

hoarding

behavior in the m ature Sprague-Dawley female rat.
Another study in rats (Mandour, et al., 1977) dem onstrated that 17 p
estradiol had a marked suppressive effect on the alpha cells of the p an creas
and a minimal effect on plasm a insulin release a s m easured in the portal vein.
The invasive nature of this study is not appropriate in humans. However, if the
data are extrapolated to the clinical situation, it could explain som e of the
observed biochemical changes seen in women on estrogen therapy, a s
evidenced by lowered fasting blood glucose levels (because of relative fasting
hyperinsulinemia) and elevated triglycerides (Bush, 1990).
Short-term therapy with progestogens (less than 6 months) is not
associated with alterations in glucose or insulin metabolism (Spellacy, et al.,
1970). However, later work by Notelovitz (1982) show s that time is a strong
indicator of effects and that early findings in the first 6 months may change with
time. Therefore, the early appetite changes seen when hormone replacem ent
therapy is initiated may not be long term. This fact should be explained to the
postm enopausal female by her physician. Such information could affect the
decision to begin hormone replacement therapy and the future level of
commitment and compliance.

However, that information is not currently

available. That is a contribution that this scientist hopes to make in the future
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in cooperative research with Dr. Notelovitz (Dr. Morris Notelovitz, personal
communication, 1995).
Currently the most reliable research in a mammalian model h as been
conducted in the primate at Bowman Gray School of Medicine (Dr. Thom as
Clarkson, personal communication, 1995). Observations of rhesus monkey
fem ales indicate a systematic relationship between levels of food intake and
endogenous estrogen and progesterone levels.

A positive correlation h as

been noted betw een the incidence of food rejection and levels of circulating
estrogens (Czaja and Roy, 1975). Gilbert and Gillman (1956) show ed a sharp
decline in primate food intake during the first 6 to 11 days and continued low
intake throughout the follicular phase followed by a consistent and m aintained
rise after ovulation with a peak of caloric intake being recorded betw een 2 and
7 days before menstruation.

Dr. Thomas Clarkson at the Bowman Gray

School of Medicine, Department of Comparative Pathology, is currently
m easuring food intake involving phytoestrogens from soybean and the effects
on body weight and cardiovascular disease in the primate.

His earlier work

provided the basis for the research design for the PEPI trial.

R esearch in

appetite, macronutrient intake and body weight with hormonal effects is
needed (Clarkson, personal communication, 1994).
EATING BEHAVIOR: ENERGY BALANCE MECHANISMS
Aside from all the uncertainty surrounding m echanism s and biological
mysteries, the body is a marvelous organism with built in hom eostatic
m echanism s.

Body weight and food intake are carefully regulated in most

laboratory animals, and hum ans by a variety of physiological and behavioral
control m echanism s (Balagura, et al, 1981; Code, 1967; Hervey, 1969;
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Morgan, 1965). Although short-term errors do occur in this regulation, long
term regulation is amazingly accurate, and adults of most mammalian sp ecies
gain weight only very slowly with age (Hervey, 1969).
However, although weight is carefully regulated, it should be noted that
body weight setpoint is not immune to physiological and environm ental
fluctuations. A variety of factors, including diet palatability (Corbit & Stellar,
1964), environmental tem perature (Brobeck, et al, 1947), relative levels of
various metabolic horm ones (Woods and Porte, 1977), and the opportunity to
exercise in running wheels (Leshner and Collier, 1973) affect body weight
level in rats. Additionally, neurological dam age may also raise or lower body
weight setpoint (Hoebel & Teitelbaum, 1962; Powley and Morton, 1976). Of
interest in this research, and increasingly more relevant are the effects of
exogenous female sex horm ones on caloric regulation.

T hese fem ale sex

horm ones should be added to the list of factors affecting behavioral and
physiological regulation of body weight.
We have summarized what is known about the effects of ovarian
steroids on energy balance and caloric conversion in younger rat models, and
earlier human studies. This information and the principles derived from this
earlier research have provided the basis to exam ine this hypothesis in
postbreeder female rats.

Eating behavior patterns in the ovariectom ized

postbreeder female rat may provide the model to investigate the effects of
exogenous female sex horm ones on food intake and body weight in the
mature female of other species. Fem ale sex horm ones have important effects
on behavioral and physiological controls of energy balance in a wide range of
mammalian species. Work with laboratory animals reveals that fluctuations in
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circulating estradiol and progesterone levels produce coordinated changes in
ingestion, metabolism, storage, and expenditure of metabolic fuels. In rats,
estradiol can act directly in the brain to alter food intake and voluntary
exercise.

Subsequent neuroendocrine m essag es are then translated into

actions in the adipose tissue, muscle, and liver to influence metabolism and
the storage of metabolic fuels. The effects of estradiol on food intake are due,
at least in part, to direct hormone actions in the brain (Wade and Schneider,
1992). Early work using intracerebral hormone implants suggested that
estradiol acted in the ventromedial nucleus of the hypothalam us (VMH) to
d ecrease food intake (Beatty, et. al., 1975; Jandowiak & Stem, 1974; Nunez, et
al., 1980; W ade & Zucker, 1970). However, more recent work indicates that
the paraventricular nucleus (PVN) of the hypothalamus, rather than the VMH,
is the principle regulator of estradiol on food intake (Butera & Beikirch, 1989;
Czaja, Butera, & MacCaffrey, 1983; King & Cox, 1973; Butera, 1995, personal
communication).

T hese data seem to indicate that estradiol can act to

d ecrease food intake in rats, and that it plays an essential role in the effects of
estradiol on food intake.

Little else is known about the m echanism s of

estradiol and other female sex horm ones on food intake.

The estrogen

receptor may hold the answ er in future investigations.
Very little is known about the effects of ovarian steroids on energy
balance in women, although food intake and metabolism are known to vary
with reproductive condition, including menstrual cycles, and m enopause.
Virtually nothing is known about the macronutrient choices a s affected by
exogenous female sex horm ones on energy balance and su b seq u en t
physiological outcom es in postm enopausal women. With recent evidence that
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hormone replacem ent therapy is cardioprotective in the postm enopausal
female (The PEPI Writing Group, 1995), information regarding body weight
param eters which could affect the rate of compliance is needed. Fluctuations
in body weight over a thirty day period represent hormonal influences on
setpoint a s Fantino and Brinnel (1986) have shown. Short term perceptions of
luteal phase or progestin initiated body weight gain may not be related to total
body weight over the life span but may be indicative of macronutrient choices
with varying caloric conversion rates. The implications may be short term or
long term depending on an array of variables yet unm easured.

The

investigation seeking th ese answ ers will be a continuing dimension to future
research related to disease states.
SUMMARY OF THE IMPLICATIONS OF THIS RESEARCH
The num ber of fem ales in this country taking daily exogenous female
sex horm ones has increased for the past 30 years and is currently at an all
time high (Notelovitz and Tonnessen, 1993; Wallis, 1995). The num bers are
increasing

daily

as

postm enopausal

baby-boom ers

choose

horm one

replacem ent therapy during m enopause. In earlier days of medical practice,
hormone replacem ent therapy w as simply called estrogen
therapy.

replacem ent

When research revealed the predisposition to cancer in those

fem ales who were taking “unprotected” estrogen, progesterone w as added to
the daily or monthly oral intake of exogenous hormones. "Currently, the variety
of prescriptions used to treat m enopausal symptoms has expanded to include:
continuous

low

levels

of

both

estrogen

and

progesterone

taken

simultaneously; and cyclical, whereby estrogen is taken for the first 10 to 14
days of the month and then progesterone is added for the last 14 days.

In
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addition to an array of patches, implants and injections, oral doses of
Premarin® (estrogen) and Provera® (progesterone) are the most widely
prescribed forms of hormone replacem ent therapy a s earlier stated. The
earlier levels of progesterone varied from 2.5 mg to 10 mg. Higher levels of
progesterone have been

shown to create prem enstrual

syndrome-like

symptoms which often deter continuance and compliance. The evidence of
this potential noncompliance may be initiated by nuisance side effects (such
a s edem a, breast tenderness, memory loss, mood swings, and food cravings)
(Gambrell, 1995). The question that must be addressed by the physician and
the fem ale patient is: what levels of exogenous female sex horm ones are
cardioprotective and osteoporosis protective without negative prem enstrual
tension syndrome-like side effects? The physician need s scientific information
b ased on peer reviewed research to prepare the patient, offer solutions, and
help to put potential problems in proper perspective.
The most current research findings involving exogenous fem ale sex
horm ones in the postm enopausal female do not provide th ese answ ers. The
results of the first efforts to examine cardiovascular health implications of
hormone replacem ent therapy were revealed at the Fall 1994 meeting of the
American Heart Association. This first female clinical trial investigating
hormonal

effects

on

cardiovascular

disease

in

the

Postm enopausal

Estrogen/Progestin Investigation (PEPI), reveals that estrogen only, or in
combination

with a progestin,

improves lipoprotein

ratios and

lowers

fibrinogen levels without detectable effects on insulin and blood pressure.
U nopposed estrogen is the optimal regimen for elevation of high density
lipoprotein cholesterol (HDL-C), but the study reveals that a high rate of
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endometrial hyperplasia restricts the use of estrogen alone by women with a
uterus. The design of the PEPI study w as changed after 12 months of testing
when endometrial biopsies revealed a precancerous state in the uteri of a
small percentage of the fem ales taking estrogen only. The research did not
focus on the effects of exogenous female sex horm ones on caloric intake,
body weight and subsequent affect on health status and longevity. The Block
Questionnaire (Block, et al, 1986) w as used to a s s e s s food intake patterns but
w as only collected three times during the three year study.

No direct

m easures in changes of exercise patterns in the subjects were m easured. The
further analysis of the existing PEPI data b ase will provide only a brief
indication of metabolic param eters affecting hormone replacem ent therapy
(Dr. Trudy L. Bush, personal communication, 1995).
The current study which seek s to answ er som e of th ese questions, is
aim ed at the interrelationships between exogenous female sex horm ones,
dietary intake, and specific food preferences (especially a s it relates to sw eets,
fats, and chocolate) in the control of appetite, eating and body weight. The
ovariectomized retired breeder female rat is used a s a model to provide
preliminary d ata and serve a s a guide for future studies m easuring the sam e
or similar param eters

in postm enopausal

women.

This study allows

identification of dietary and physiologic factors that vary with hormonal levels.
It is expected that the factors identified in this project will lead to a better
understanding of dietary and physiological implications involved in

caloric

regulation in the postm enopausal female taking exogenous fem ale sex
horm ones.

CH A PTER 3:

MATERIALS AND M ETH O D S

EXPERIMENTAL CONDITIONS
In order to establish hormone levels in a postm enopausal model,
postbreeder female rats which were ovariectomized and then implanted with
exogenous female sex hormones, were chosen for this study. Retired b reed er
Sprague-D aw ley female rats (Harlan Sprague Dawley, Madison, Wisconsin)
weighing 268.1g ± 3.1 g, which had been ovariectomized in Wisconsin before
shipment, were housed individually in stainless steel hanging wire c a g e s
maintained on a 12:12 lighting schedule (lights on at 0700 hr, off at 1900 hr).
A control group of sham surgically treated (ovaries were left intact) rats w ere
observed to document food intake and body weight of animals at this aging
status who were not manipulated by exogenous female sex horm ones or
novel food choices. A control group of ovariectomized rats of the sam e ag e
reflected the normal body weight and food selections of this model with no
hormone implants. (An additional group, sham receiving all food choices w as
originally included in the research design but a high death rate early in the
study eliminated this group.) Three other ovariectomized groups w ere treated
with exogenous female sex horm ones which were packed into silastic tubing
and implanted subcutaneously (Richard, 1986; Geary, et al, 1994; Butera and
Beikirch, 1989; Richard, 1995, personal communication). The source of
horm one w as chosen to most closely replicate endogenous levels in rats and
a s a reflection of the bioactivity of exogenous female sex horm ones in the
human.

The rats were randomized so that each treatm ent group would

contain a m ean body weight of 268.1g ± 3.1. This experimental design
resulted in the following treatm ent groups:
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GROUP A Sham:

Placebo (empty silastic tubing)

GROUP B OV:

Placebo (empty silastic tubing)

GROUP C OV:

17(3-estradiol crystalline (15mg)

GROUP D OV:

17p-estradiol (15 mg) and progesterone
(200 mg) crystalline

GROUP E OV:

Progesterone (200 mg) crystalline
ANIMALS

Sprague-Dawley female postbreeder rats which w ere 10 months old
and had given birth to 10 litters of pups were chosen for the study. The rats
were ordered four months prior to the study so that a hom ogenous group of
fem ales could be procured. Due to the stress of the two surgeries, the heat, or
the age of the animals, five died prior to data collection. The anim als w ere
transported to the LSU laboratories by air-conditioned plane and truck.
In summary all materials and m ethods were designed to answ er
questions posed in chapter I to test the stated hypotheses. The female rat
model w as chosen because the controlled laboratory environment allows
more accurate m easures of body weight and food intake m easurem ents than
can be obtained in free living subjects keeping dietary records.

The

application of animal data to human implications is som etim es questioned
(Wade & Schneider, 1992).

However, the rat model chosen for this study

reflects many of the param eters shown in the literature to directly parallel the
human female. The rats were ovariectomized for two reasons: a) to remove
endogenous hormone production so that controlled levels could be implanted
and docum ented, and b) to mimic the m enopausal state in an animal model.
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SURGERY
The ovariectomy or sham surgery w as performed by Sprague-D aw ley
prior to shipment. Sham surgery is typically used in research to induce the
stre ss experienced by the other research anim als but ovaries are left intact.
Rats w ere anesthetized with ketamine (100 mg/ml) + xylazine, (20 mg/ml) 3
parts ketamine to I part xylazine at 0.1 ml/100 g BW.

The incision w as on the

upper hind quarter along the back and w as secured by metal clam ps until
recovery. After an adjustm ent period the rats were weighed and assigned to
treatm ent groups according to body weight. The second surgery to implant the
horm ones w as performed 48 hours after arrival. After an incision w as m ade
behind the neck, implants packed with crystalline female sex horm ones from
Sigma w ere inserted and the incision was secured with silk thread.
HORMONE IMPLANTS
Silastic tubing m ade by Dow-Corning w as cut into single 15mm lengths
for the estradiol and into two, 40 mm lengths to accom m odate the
progesterone. Silastic capsules were prepared from medical grade silicone
tubing (1.5 mm i.d., 3.2 mm o.d.). The crystalline form of the steroids 17 13estradiol or progesterone (Sigma Laboratories), w as packed into the silastic
tubing. The ends of the silicone tubing w ere sealed with a wooden plug
followed by Medical Adhesive (Silicone Type A, Dow-Coming, Midland, Ml) to
prevent dispensation through the cut ends. The tubing w as then soaked in a
w ater bath overnight to begin the dispensation process. Thus, released
horm one into the animal began immediately upon implantation. The osmotic
flow through the walls of the silastic tubing has been shown to provide a
reliable method of administering female sex horm ones (Richard, 1986).
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Each rat received three implants: Sham and OV received a single 15
mm placebo, plus two 40 mm placebo empty tubes.
15mm estradiol and two empty

tubes,

E received a single

E&P received a single 15 mm of

estradiol and two 40 mm tubes containing active progesterone. P received a
single empty 15 mm and two 40 mm tubing filled with progesterone. Rats were
allowed 2 days recovery time from the surgery before food intake d ata w as
collected. When the rats were sacrificed, the tubes were extracted from the
neck are a to confirm that no tube w as totally depleted of the hormone source
(Richard, personal communication, 1995). Results confirmed that no tube was
totally empty.
CONFIRMATION OF HORMONE DOSAGES
Previous research has shown th ese 15 mg of estradiol and 200 mg. of
progesterone in silastic tubing provides blood levels of estradiol within the
normal physiological range. Dispensation of the horm ones from silastic tubing
w as confirmed at conclusion of study with radioimm unoassay of estradiol and
progesterone in serum and bioactivity w as verified by uterine weights
(Abraham, 1977; Judd & Korenman, 1982).
WATER AND FOOD CUPS
Tap w ater w as placed in inverted water bottles with stoppers and metal
drinking spouts and dispensed ad libitum. Food cups were small glass jars
which adequately provided e asy acc ess to the three food cups in phase I, four
food cups in phase II (three for S) and the eight food cups in phase III (three for
S). Food cups w ere secured with metal bracing to d ecrease the likelihood of
spillage. P h ase I food choices are seen in Table 3.1, P h ase II, Table 3.2 and
P h ase III, Table 3.3. Spills were collected in small plastic medicine cups and

TABLE 3.1 PH A SE I - TEN (10) DAYS
M A CR O N U TRIEN T C H O IC E S , S E P A R A T E FO O D C U P S O F
P R O T E IN , FAT AND C A R B O H Y D R A T E S
Group A

Group B

Group C

Group D

Group E

12 Rats

10 Rats

12 Rats

11 Rats

10 Rats

Sham
Surgery
Control
Treatm ent

Ovariecto
mized Surgery
Control
Treatment

Ovariecto
mized Surgery
Estradiol
Treatment

Ovariecto
mized Surgery
Progesterone
Treatment

Protein
Food Choice
Fat
Food Choice
C arbohydrate
Food Choice

Protein
Food Choice
Fat
Food Choice
Carbohydrate
Food Choice

Protein
Food Choice
Fat
Food Choice
Carbohydrate
Food Choice

Ovariecto
mized Surgery
Estradiol/
Progesterone
Treatment
Protein
Food Choice
Fat
Food Choice
Carbohydrate
Food Choice

Protein
Food Choice
Fat
Food Choice
C arbohydrate
Food Choice

TA BLE 3 .2 PH A SE II - TEN (10) DAYS
CA R B O H Y D R A TE A NALYSIS S W E E T V S N O N SW E E T
Group A

Group B

Group C

Group D

Group E

12 Rats

10 Rats

12 Rats

11 Rats

10 Rats

S ham
Surgery
Control
Treatm ent

Ovariectomized
Surgery
Control
Treatment

Ovariectomized
Surgery
Estradiol
Treatment

Ovariectomized
Surgery
Progesterone
Treatm ent

Protein
Food Choice
Fat
Food Choice
C arbohydrate
Food Choice

Protein
Food Choice
Fat
Food Choice
(a) Sw eet

Protein
Food Choice
Fat
Food Choice
(a) Sw eet

Ovariectomized
Surgery
Estradiol/
Progesterone
Treatment
Protein
Food Choice
Fat
Food Choice
(a) Sweet

(b) Nonsweet

(b) Nonsweet

(b) Nonsweet

(b) Nonsweet

Protein
Food Choice
Fat
Food Choice
(a) Sw eet

TA BLE 3 .3 PH A SE III - TEN (10) DAYS SW E E T FAT
AND CH O CO LA TE PR O FIL E WITH FO U R
C A LO R IC LEVELS O F CH O C O LA TE
Group A

Group B

Group C

Group D

Group E

12 Rats

10 Rats

12 Rats

11 Rats

10 Rats

S h am
Surgery
Control
Treatm ent

Ovariecto
mized Surgery
Control
Treatment

Ovariecto
mized Surgery
Estadiol
(15 mg)
Treatment

Protein
Food Choice
Fat
Food Choice
C arbohydrate
Food Choice

C hocolate

Ovariecto
mized Surgery
Estradiol &
Progesterone
15mg/200mg
Treatment
Protein
Protein
Protein
Food Choice
Food Choice
Food Choice
Fat
Fat
Fat
Food Choice
Food Choice
Food Choice
CHO
CHO
CHO
Food Choice
Food Choice
Food Choice
(a) Sw eet
(a) Sw eet
(a) Sw eet
Food Choice
Food Choice
Food Choice
(b) Nonsweet (b) Nonsweet
(b) Nonsweet
Food Choice
Food Choice
Food Choice
(a) Choc HF/HS (a) Choc
(a) Choc
HF/HS
HF/HS
(b) Choc HF/LS (b) Choc
(b) Choc
HF/LS
HF/LS
© Choc LF/HS © Choc LF/HS © Choc LF/HS

Ovariecto
mized Surgery
Progesterone
200 mg
Treatm ent
Protein
Food Choice
Fat
Food Choice
CHO
Food Choice
(a) Sw eet
Food Choice
(b) Nonsweet
Food Choice
(a) Choc
HF/HS
(b) Choc
HF/HS
© Choc LF/HS

(d) Choc LF/LS (d) Choc LF/LS (d) Choc LF/LS (d) Choc LF/LS
Chocolate:
(a) High Fat/High Sugar
(b) High Fat/Low Sugar
(c) Low Fat/High Sugar
(d) Low Fat/Low Sugar
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TA BLE 3 .4

M ACRONUTRIENT SEL E C T IO N D IETS

Protein

SW-CHO

Nonsweet CHO Fat

gm

% kcal gm

% kcal gm

% kcal gm

% kcal

Protein

84.8

89.7

4.9

5.1

4.9

5.1

8.8

5.1

Carbohy
drate
Fat

4.8

5.1

84.5

89.7

84.5

89.7

8.7

5.1

2.1

5.1

2.1

5.1

2.1

5.1

67.4

89.7

100.0

91.6

100.0 91.6

100.0

84.9

100.0

kcal/gm

91.1
3.72

3.77

3.77

Ingredient

gm

kcal

gm

kcal

gm

kcal

gm

kcal

3500

50

200

50

200

50

200

0

0.75

0

0.75

0

0.75

0

80

199.6g

692

559

2168

20

80

0

186

600

Total

C asein, 80 875
Mesh
13.1
DLMethionine
Corn Starch 20
Maltodextrin
10
S u crose
20

0

6.76

0

80

665.4g

2768

120

692

20

80

Cellulose,
50
BW200
Soybean Oil 22.2

0

50

0

50

0

50

0

199.8

22.2

199.8 22.2

199.8

22.2

199.8

Crisco

0

0

0

0

0

0366.7 3300.3

Mineral AIN
Salt Mix
S10001
Vitamin Mix
V10001
Choline
Bitartrate
FD&C Red
Dye #40
FD&C Blue
Dye #1
FD&C Yel
low Dye #5
Total

35

0

35

0

35

0

35

0

10

40

10

40

10

40

10

40

2

0

2

0

2

0

2

0

0

0

0

0

0.1

0

0.1

0

0

0

0.1

0

0

0

0.1

0

0.1

0

0

0

0

0

0

0

1047.4 3899.8 1035.05 3899.8 1035.05 3899.8 576.85 3900.1

Formulated by E.A. Ulman, Ph.D., R esearch Diets, Inc, 3/3/94
Chocolate selections are from powdered hot chocolate mix of 4 caloric levels
of varying fat and sugar.
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weighed back daily to achieve a more precise record of food consum ed. The
color coding of the powdered diets helped identify the source of spills.
DIETS
The formulas (Table 3.4) for individual macronutrient food cups which
were nutritionaliy balanced were developed in the laboratories of Cornell
University (Ulman, personal communication, 1994). T hese formulations of
balanced essential nutrients are used in standard diets for ingestive behavior
studies in animal models and have been analyzed for caloric value by bomb
calorimetry (Ulman, 1994).

The macronutrient choices were individually

balanced with vitamin and mineral com ponents so that rats could sustain life if
only one food cup source w as chosen. The diets were mixed at LSU with
standard ICN Biochemical ingredients.
The materials and m ethods regarding diet selections in each p h a se
w ere designed to m easure hormonal effects on caloric regulation and food
choice.

Therefore, in phase I the three macronutrient food choices, FAT,

carbohydrate (CHO) and protein (PRO) were nutritionally balanced for
essential vitamins and minerals (Table 3.1). In phase II the investigation of
sw eet com pared to nonsw eet choices of carbohydrate sources (Table 3.2) w as
divided into sw eet AIN-76 which w as four times higher in sucrose levels in the
non sw eet AIN-93 (Reeves, Nielsen, & Fahey, 1993). The sw eet food choice
w as designed to represent simple carbohydrates with a higher sucrose level.
The nonsw eet food choice w as designed to represent complex carbohydrates
with the addition of cornstarch, maltodextrin and cellulose (Table 3.4).

In

p h ase III the additional m easure of chocolate choices w as added to the fat,
protein, carbohydrate (sweet and nonsweet). The food cups contained
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chocolate sources of four caloric levels: High Fat/ High Sugar (HF/
HS), High Fat/ Low Sugar (HF/LS), Low Fat/ High Sugar (LF/LS), Low Fat/
Low Sugar (LF/LS) (Table 3.3). Chocolate sources were four caloric levels of
Carnation®

Hot

Chocolate

mix which

were

mixed

with

additional

hydrogenated shortening and water to provide a non-spill consistency. Low
Fat versions, which contained water were calculated for evaporation rates by
weighing separate food cups kept on a shelf in the sam e room. The food cups
with chocolate choices did not contain the essential vitamins and minerals that
w ere included in the other macronutrient food cups.

The HF/HS

w as

designed to be equivalent to a typical chocolate bar with 33% fat.

Carnation

Hot Chocolate Powder Mix w as used a s chocolate source.

The Rich

Chocolate (HF/HS) w as mixed with fat to constitute 5.56 calories per gram.
The Sugar Free(HF/LS) w as mixed with fat which and w as 5.17 calories per
gram. The 70 Calorie Mix(HS/LF) w as combined with water to form a paste to
yield 2.65 calories per gram. Diet Hot Chocolate mix (LF/LS) w as mixed with
w ater to yield 1.19 calories per gram. Statistical data w as reported in calories
not grams.
The diets were mixed in bulk and stored in the freezer until use during
the 30 day study. The powdered diets were color coded to more easily detect
the source of spills for maximum accuracy in food intake data collection.
Liquid food coloring w as blended with small am ounts of the diet and then
incorporated into the bulk mixture. The acceptability of the diet consistency
and formulation and four different forms of chocolate were tested in a pilot
study.
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DATA COLLECTION
Body weight gain w as determined daily, and, percentages of body
weight were calculated over the 30 day study.

Body weight gain and

percentage of body weight gain were calculated within p h ases to show effects
of macronutrient choice effects. Food cups were weighed and calculated for
m ean caloric intake daily, over each 10 day phase and at the conclusion of the
30 day study. Data were collected on an Excel spread sheet with Balance Link
by Mettler.
Data collection began in phase I (Day 1) with diets of carbohydrate, fat
and protein sources (Table 3.1) available ad libitum in sep arate food
containers, with 10-12 animals per hormone treatm ent group.

In phase II

(Table 3.2) all groups of rats except the sham group were allowed continuous
ad libitum a c c e ss to four macronutrient choices, protein, fat and carbohydrates
(sweet and nonsweet). Food intake w as m easured to the nearest g betw een
1000 am and 1100 am daily by weighing food dishes: spillage w as caught on
paper towels and weighed. In phase III (Table 3.3) the rats, except the sham
group, were given four caloric levels of chocolate in addition to the four
macronutrient choices (protein, fat, carbohydrate- sw eet and nonsweet).
BLOOD SAMPLES
Feeding param eters were followed for a total of 30 days, ten days for
each diet phase. Over the next 5 days the rats were fasted 24 hours and then
rem oved from their cag es one at a time and sacrificed. Three rats per day
w ere randomly selected from each hormone treatm ent group to en su re that
rats from all groups were randomly sacrificed throughout the entire time
period, a total of fifteen rats per day. Rats were anesthetized with ketamine +
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xylazine, 3:1 (100 mg/ml, 20 mg/ml), 0.1 ml/100g body weight. Blood sam ples
were taken by cardiac puncture and blood volume recorded.

Blood w as

allowed to clot at room temperature. Sam ple tubes were spun in centrifuge
tubes to separate the serum, which w as then pipetted into labeled Eppendorf
tubes and immersed in ice for later storage at 4° C or -80° C.
Blood sam ples

were analyzed

using

radioim m unoassay

for 125l

estradiol, 125l progesterone and 125l testosterone using Diagnostic Products
Corporation Coat-a-Count tubes and reagents (Sitteri & Febres, 1979). The
purpose of this analysis w as to verify serum hormone levels for docum entation
of bioactivity. The procedure is based on the competitive inhibition of binding
radioactively labeled horm ones to a specific antibody.

Concentrations of

horm ones in the 10 - 1 2 picogram range can be m easured by this technique.
Cholesterol and HDL cholesterol
Sigma

m easurem ents were determ ined using

Kits for colorimetric m ethods (Perkin-Eimer Lamba

1 UV Vis

spectrophotom eter) ( Friedewald, et al, 1972).
CARCASS COMPOSITION
At the conclusion of the study the rats were sacrificed according to the
protocol of the animal care committee

(LSU

Internal

Review

Board

Regulations, 1986). The hearts, livers and uteri were harvested, weighed and
frozen for further analysis.
C arcass composition of the five treatment groups w as determined and
reported in term s of percentage of carcass weight of lipid, protein, and w ater
(Maggio, et al., 1984). Eviscerated carcasses, autoclaved under pressure, and
hom ogenized using the Brinkman polytron/3500.

Aliquots of the c arca ss

hom ogenates were analyzed for the determination of nitrogen according to the
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micro-Kjeldahl method, lipid according to the ether extraction method and
moisture by drying to a constant weight at 100 degrees C.

Weights and

composition of the excised sam ples were used in the final calculations.
Additionally, fat extraction procedures were used to analyze fatty contents of
the livers using the sam e method described in total body composition analysis.
The Soctex Instrument m ade by the Tecator Subsidy of the A Pow erstep
Analytical Co. Indianapolis, Indiana w as used in the fat extraction analysis.
Moisture analysis w as conducted in a drying oven
Corporation, Sussex, England.

m ade

by Sanyo

Micro-Kjeldahl m easures for protein w ere

conducted on the autoanalyzer model BD-20 (Technicon Instruments Corp.)
according to procedure 976.06 in the Official Methods of Analysis of the
Association of Official Analytical Chemists, (1990).
STATISTICAL METHODOLOGY
Prior to implantation, rats were randomly divided into five groups. There
were no significant differences in starting body weights between rats assigned
to the five treatm ent groups and no significant difference betw een groups.
Hormone implants were surgically implanted in random order.

The m ean

body weight of the group of 55 rats w as 268.1 ±3.1 on the day the data
collection began. However, groups did not weigh the sam e after the two day
recovery period when the first body weight and food intake data were collected
and recorded. On day one of the data collection the beginning m ean body
weights were:

S: 272±8.2, OV: 266±7.7, E: 258±5.9, E&P: 266.2±6.5, P:

277±3.5.
For analyses of food intake (caloric, macronutrient and chocolate), the
experiment w as divided into three, ten day periods of each diet protocol for a
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total of 30 days. The food intake and body weight data were divided into three
p h ases. For each of th ese periods, one-way analyses of variance were used
to determine hormone treatment effects on food intake and body weight data.
One-way analysis of variance w as also used to determine hormonal effects on
different

caloric

macronutrient

intake.

Scheffd’s

multiple

com parison

procedure w as used to determine the differences among the treatm ents.
Additionally, linear group contrasts were used to determine the differences
betw een the four ovariectomized groups (E, E&P, and P) vs nonhormone (OV),
betw een

estrogen

(E, E&P) vs

nonestrogen

(OV,

P)

and

betw een

progesterone (E&P, P) vs nonprogesterone (OV, E) in clusters of treatm ents.
P h ase I and phase II differed only by the inclusion of the sw eet/nonsw eet
investigation of the carbohydrate macronutrient group.
In P h ase III, 4 caloric levels of chocolate were added to the food
choices. In the analysis of caloric intake,

foods were first converted from

weight consum ed (in grams) to caloric value. From those calculations,
conversion ratios (CR) of body weight gained per 1000 calories consum ed
w ere determ ined (CR = gram s of body weight increase divided by caloric
intake X 1000). Conversion ratios were calculated for each phase and over the
30 day period.
One way analysis of variance w as utilized to determine the effects of
horm one treatm ents on total body weight gain, % body weight gain, total
caloric intake, % of caloric intake from individual macronutrients and total
individual macronutrient intake, food intake (macronutrient and chocolate
choices), body composition, cholesterol, serum hormone levels, liver, heart
and uterine weights, weight to length ratios, fat content of livers, and caloric
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conversion ratios.

Data were collected with the use of Microsoft Excel

sp re ad sh ee ts and analyzed with Superanova Statistical software, A bacus
C oncepts (Gagnon, 1989). One way ANOVA with contrasts and ANOVA
factorial analysis with two independent variables (level of estrogen and
progesterone) were used. ANOVA percentages were used to statistically
com pare the data obtained a s percentages. P hase I analysis w as conducted
on all five groups since they received the sam e food choices. P h ase II and III
w ere analyzed by including the four ovariectomized groups receiving all food
choices. Data for the total study reflected all three p h ases in combined and
sep arate analysis. Both four and five group treatm ents (S for comparison)
w ere included in statistical analysis.
PILOT STUDY
A pilot study w as conducted to test macronutrient mixtures and
chocolate (chocolate syrup, chocolate chips, chocolate bars and chocolate
paste m ade from hot chocolate mix) for palatabiiity and form of presentation to
minimize spillage and loss (Ulman, personal communication, 1994).

The

chocolate paste w as found to be the most acceptable form to the rats. The
surgical administration of the hormone by silastic tubing implant w as also
piloted (Richard, 1986). This procedure provided continuous hormone release
without injections (Smith and Walsh, 1976).

All laboratory procedures and

statistical modeling were examined and evaluated during the pilot testing
period and by consulting scientists directly involved in endocrinology and
eating behavior research.

CH A PTER 4

R ESU LTS AND D ISC U S SIO N

In this section, specific p values for statistical com parisons will be found
in tables or appendixes (denoted by page number). Statistical techniques
used for data mentioned in the text will also be denoted in parentheses. In
P h ase I, data in the tables are based on ANOVA with five treatm ent groups
and five group ANOVA percentages. Analyses other than five treatm ent group
ANOVA are shown in the appendixes, for exam ple four group ANOVA,
percentages, group contrasts and factorial analysis. P hase II and III are b ased
on 4 group ANOVA, excluding the sham. The sham treatm ent group should be
judged a s a comparison

group which w as maintained

m acronutrients throughout the study.

on the three

Abbreviations for treatm ents are a s

follows: ovaries left in tact (sham), S; ovariectomy with no hormone treatment,
OV; estradiol, E; estradiol and progesterone, E&P; progesterone, P; all
endogenous (S) and exogenous hormone treatm ents, H. All summary figures
ap p ear in Appendix F (p208-224).

Any statem ent of significance (reported in

3 digits) m ade in the text m eans that p w as less than 0.05. Actual com puter
generated num bers in tables are reported (p=) for the purpose of conversion to
relative risk ratio calculations for use in future medical and physiological
publications.
RESULTS OF PHASE I: OVERVIEW
In P h ase I, three choices of macronutrients were presented: fat,
carbohydrate and protein in all five treatm ent groups.
BODY WEIGHT
Body weight gain (total & %) among groups w as affected by horm one
treatm ent but caloric intakes were not (Table 4.1 A, Figure 1.0 p208 and 4
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TA BLE 4.1 A PH A SE I - BODY W EIGHT GAIN
AND TOTAL CA LO RIC INTAKE
Treatm ent

Sham

Ovariec- O V +17B OV -+* 1713 OV +
tomized Estradiol Estradiol Proges+ Proges terone
terone
11
10
12
10

Number of 12
Animals
(n=)
Original
Weight of
Animals
264
258
272»
20.7± 3.1 24.4± 2.3 6.4±2.0
Total
Weight
(b)
(a)
(a)
Gain (g)
% of gain
Total
Caloric
Intake

ANOVA
p value

p=.388
271
275
14.7± 2.7 27.6± 5.0 p=.001
(a,b)
(a)

7.8% (a) 9.2% (a) 2.6% (b) 5.5%(a,b) 10.0%(a) p=.001
831 ±
898 ±
883 ±
773 ±
831 ±
p=.314
42.0
35.5
40.2
47.8
50.5

38.7%
32.1%
31.0%
% of total
Caloric
24.6±3.5 27.8±2.8 8.8±2.8
Conversion (a)
(a)
(b)
Ratio*

32.2%
31.4%
17.0±2.9 29.8±4.5 p=.001
(a.b)
(a)

• Initial m ean body weight of the five groups on day one of data collection w as
268.1.
Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffd’s S procedure for posthoc com parisons.
% of gain is for this 10 day period
% of total caloric intake shows percent of caloric total (phase I, II, III) consum ed
in phase I
* Caloric conversion ratio formula (CR): Gram s of body weight increase
divided by caloric intake X 1000.
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ANOVA p192). OV treated animals implanted with E gained less weight than
the S, OV, and P {total & % Table 4.1 A). The progesterone treated anim als
were the only hormone group significantly higher than the estrogen group
(total & % Table 4.1 A), initial body weight differences w ere exam ined by
ANOVA at the beginning of the study. There were no significant differences
(Table 4.1A ANOVA initial body weight p 193). Group contrasts show ed that
OV animals gained more weight (total & %) than the hormone treated anim als
and E w as significantly lower by 59% than NonE (4 group ANOVA p192 total
& % Table 4.1B). The estrogen effect on decreased body weight gain(4 group
ANOVA factorial p193) w as greater than E&P or P.
CALORIC INTAKE
There w as a trend (p=0.052) for decreased caloric intake for the E
anim als com pared to Non E animals (Total Table 4.1 B). A trend (p=.054) w as
also shown (4 group ANOVA factorial p193) with four group analysis.
CALORIC CONVERSION RATIO
The conversion of calories consum ed into body weight gain w as
significantly lower for the E group compared to S, OV and P (Total Table 4.1A
Total 4 group ANOVA p193, 4 group ANOVA factorial p194). Hormone
treatm ents significantly lowered caloric conversion ratios com pared to the OV
anim als with no hormone in group contrasts and E significantly lowered caloric
conversion ratios compared to Non E (4 group ANOVA p194).
TOTAL FAT
When the distribution of macronutrients consum ed

(Table 4.1C) w as

exam ined there were no significant among treatm ent differences in
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TA BLE 4.1 B PH A SE I - G R O U P C O N T R A ST S TOTAL
W EIG HT GAIN AND TOTAL FO O D INTAKE
Tmt

n

Total
Weight
Gain*
9

S
vs
H

p value
% 9
Wt. %

Total Caloric p value Caloric
p value
Intake (kcal)*
Conversion
Ratio
%
kcal

E
vs
Non
E

12 20.7
±3.1
33 15.8
±3.3
10 24.4
±2.3
33 15.8
±3.3
23 10.7
±1.9
20 26.0
±2.7

7.8 p=.211
±1.3
5.9 %p=.191
±.9
9.2 p=.035
±.8
5.9 %p=,029
±.9
4.1 p=.001
±.7
9.6 %p=.001
±1.

831.0
±42.0
827.6
±42.1
898.0
±47.8
827.6
±42.1
803.5
±31.3
890.7
±30.4

37.9 p=.971 24.6
±1.2
±3.5
31.4
18.4
±.6
±3.4
32.2 p=.194 27.8
±.9
±8.9
31.4
18.5
±.6
±3.4
31.1 p=.052 12.9
±.7
±2.8
32.2
28.8
±.7
±3.7

P
vs
Non
P

22 20.5
±3.0
21 15.0
±2.5

7.5 p=.077
±1.1
5.7 %p=.071
±.9

854.9
±32.8
832.8
±31.8

31.6 p=.632 23.4
±.8
±3.7
31.6
18.3
±.7
±2.8

OV
vs
H

Sham = S
Hormones = E, P, E&P
Ovariectomized = OV, no hormones
Estrogen = E, E&P
Non Estrogen = OV, P
Progesterone = P, E&P
Non progesterone = OV, E

p=.756

p=.025

p=.001

p=.267
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TA BLE 4.1 C PH A SE I - M ACRONUTRIENT
FOOD C H O IC E S IN KCAL
Treatment Sham

n
Total
Intake of
C arbo
hydrate
(Calories)

Ovariec- OV +17(3
tomized Estradiol

12
368.6 ±
43.1

10
542.2 ±
55.4

(a.b)

(a)

11
372.1 ±
40.6
(a,b)

OV +17(3
Estradiol
and Pro
gesterone
12
314.8 ±
36.2

OV +
P roges
terone

ANOVA
p value

<b)

10
413.2 ±
33.6
(a.b)

38.0%
(b)
132 ±
16.1
(b)

47.8%
(a.b)
66.3 ±
16.8
(a.b)

p=.027

p=.007

% of total 45.5%
(a,b)
Total
34.4± 6.2
Intake of
Protein
(a)
(Calories)

59.4%
84.6 ±
22.8
(a.b)

47.5%
(a.b)
87.8
± 17.5
(a.b)

% of total 4.2%
(a)
Total
428.0 ±
Intake of 58.6
Fat
(Calories)

9.3%
(a,b)
271.5 ±
41.8

11.7%
(a.b)
313.3 ±
35.5

16.2%
(b)
384.4 ±
41.6

7.6%
(a.b)
403.6 ±
57.5

p=.001

% of total 50.3%

31.3%

40.8%

45.8%

44.7%

p=.117

(a)

p=.001

p=.144

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc com parisons (p=.05)
% is for this 10 day period
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calories from fat. However, a P effect w as observed on total fat intake
com pared to NonP (Total Table 4.1 D). Additionally, when fat % group
contrasts (Table 4.1 D) were conducted, all hormone treatm ents significantly
increased, fat intake com pared to OV which did not receive horm ones (Figure
2.0, 3.0 page 209-210). T hese findings were confirmed by factorial analysis
(ANOVA factorial p194). A significant P effect on FAT consumption was
evident which m eans that P alone had a greater effect on FAT intake than E
alone or E combined with P.
TOTAL PROTEIN
E&P treated animals consum ed three times a s much protein a s the S
anim als (Total & % Table 4.1C). In both total and percent group contrasts, S
consum ed significantly less protein than H, and E consum ed significantly more
protein than NonE (Table 4.1 D).
TOTAL CARBOHYDRATE
E&P treatm ent consum ed less CHO compared to the OV group in both
total and percent (Table 4.1 C). Similarly, hormone treatm ents also d ecrea se d
the total intake of CHO in rats a s contrasted with ovariectomized anim als not
receiving horm ones (Total & % Table 4.1 D). Significant differences were also
observed in E vs. NonE and P vs NonP (Total & %). Also, factorial analysis
provides evidence that both estrogen and progesterone significantly affect
CHO intake (4 group ANOVA factorial p195).
DISCUSSION OF PHASE I
In phase I, the effect of estrogen on decreased body weight gain w as
evident with all statistical m ethods of analysis. The question of the effects of
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TA BLE 4.1 D P H A S E I - G R O U P C O N T R A ST S FO R
TO TA L C A R BO H Y D RA TE, PR O TEIN AND FAT
Treat n
m ent

S
vs
H
OV
vs
H

12
33
10
33

E
23
vs
Non 20
E
P
vs

22

Non 21
P

Carbohydrate p value
*
9
369.0
±43.1
363.7
±36.8
542.0
±55.4
363.7
±36.8
342.2
±27.1
478.0
±34.8
359.6
±26.6
453.1
±38.1

9
%%
45.5 p=.970
±5.3
4.1 %p=.890
±2.4
59.4 p=.001
±4.0
14.0 %p=.006
±2.4
42.5 p=.03
±2.9
53.6 %p=.019
±14.1
42.4 p - 03
±3.2
53.2 %p=.022
±2.9

Protein tc

9
34.4
±6.23
97.4
±16.8
84.6
±22.8
97.4
±16.8
110.9
±12.5
75.5
±13.9
102.2
±3.4
86.2
±13.9

Sham = S
Hormones = E, P, E&P
Ovariectomized = OV, no horm ones
Estrogen = E, E&P
Non Estrogen = OV, P
Progesterone = P E&P
Non progesterone = OV, E

p value

9
%%
4.3 p=.015
±.8
12.1 %p=.001
±1.3
9.3 p=.583
±2.4
12.1 %p=.496
±1.3
14.0 p=.042
±1.6
8.4 %p=.008
±6.5
12.3 p=.434
±1.6
10.5 %p=.396
±7.8

Fat*

p value

9
428.0
±58.6
367.0
±44.9

9
% %
50.3 p=.263
±5.3
43.8 %p=.197
±2.7

272.0
±41.8
367.0
±44.9

31.3 p=.104
±5.2
43.8 %p=.044
±2.7

350.0
±28.0
338.0
±37.8
393.0
±33.8
293.0
±26.9

43.4
±3.3
38.0
±3.9
45.3
±3.5
36.3
±3.5

p=.818
%p=,719
p=.043
% p-.057
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exogenous fem ale sex horm ones on additional body weight w as answ ered.
Estrogen replacem ent curbed the body weight gain which occurred a s the
result of the ovariectomy. The significant differences in body weight were not
b ased on caloric intake although a trend for an estrogen effect w as observed.
This raised the question of cau se and effect which led to the calculation of
caloric conversion ratios. Estrogen appeared to cau se a decrease in the
efficiency rate at which calories are converted into body weight which is
supported by Stem et. at. (1974), and Storlein et al., (1979) OV converted
calories more readily into body weight than all hormone treatm ents. Non E
treated anim als converted more efficiently than those implanted with estrogen.
Hormones may also affect the choice of macronutrients.

Animals

implanted with P consum ed significantly more FAT than Non P implanted
animals.

When grouped together, H treated animals consum ed more FAT

than anim als in the OV treatment group which received no hormones. This
supports the hypothesis that FAT intake is higher in the luteal p h ase of the
normally cycling female when P levels are elevated. The combination of E&P
ap p eared to motivate PRO consumption when com pared to S, which a g re e s
with Wurtman, et al. (1992). Factorial analysis revealed that E in the p resen ce
of P is more effective in stimulating PRO consumption than either horm one
individually. With group contrasts, hormonally treated anim als and those
implanted specifically with E chose more P than S and Non E treatm ents. The
com pensation or preference for calories from another macronutrient group by
the OV animals, w as from CHO. They chose more CHO than the E&P treated
animals. In both total and percent in group contrasts, H, E and P su p p ressed
CHO consumption to a greater degree than

OV, Non E and Non P
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respectively. T hese data imply that hormone replacem ent may su p p ress the
craving for highly refined carbohydrate snack foods.
ft has been known for years that exogenous estrogens exert anorectic
effects in rodents (Wade, 1976; Wade, Gray, & Bartness, 1985). Reduced food
intake h as been observed following the preovulatory surge of estradiol in
younger anim als that occurs either at proestrus or at the end of the follicular
phase, depending on the species.

In addition, the anorectic effects of

estrogens (Kemnitz, et al. 1989; Haarbo, et al, 1991; Geary et al, 1994) have
also

been

em phasized

in ovariectomized

animals

in which

estrogen

replacem ent therapies reduce the effect of removal of the ovaries. In rats,
generally estradiol d e creases the intake and increases the expenditure of
energy, which results in decreased body fat stores in the younger rat models.
Progesterone reverses nearly all of these effects of estradiol and thus,
prom otes fat storage in rats (Poucher, Tobin, 1985).

In a series of

experiments, Gray & W ade, (1981) reported increased food intake, body
weight, and carcass adiposity in OV rats treated with progesterone but not in
OV rats treated with estradiol benzoate.

However, it must be noted that in

P h a se I in the present study, the group without ovariectomy and no exogenous
horm ones (S) responded similarly to the progesterone group. The above
studies agree with the findings of the present study in the postbreeder rat in
body weight but not in caloric intake and adiposity. No significant differences
were observed in body composition in the present study in the older models.
The young female Sprague-Dawley

rat model

has been

used

extensively in much of the previously reported work on gonadal female sex
horm ones. In earlier studies in younger rats (Gray & Greenwood, 1984) the
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injection of progesterone alone, to OV had no additional effect on food intake
or body weight beyond that observed in OV only (Blaustein & W ade, 1977;
W ade & Gray, 1979). This ag rees with the present study. Additionally, in his
review of effects of gonadal hormones, W ade & Schneider (1992) reported
that administration of progesterone to either estrogen-primed or gonadally
intact adult rats led to increased food intake and an increased rate of body
weight gain. This could parallel the luteal phase in the normally cycling female
(Dalvitt-McPhillips,

1983).

Estrogen

alone

or estrogen

progesterone a s shown in the follicular phase

combined

with

in the cycling fem ale

su p p ressed body weight gain. An increased level of maturity combined with
hormonal status may provide the differences observed in the present study.
Additional research should be conducted on the aging model to exam ine what
h as earlier been implicated a s a reflection of gonadal influence of food intake
and body weight.
Fluctuations in the rate of conversion of caloric intake into body weight
may be seen under the influence of exogenous female sex horm ones both in
the rodent and the human female and in future studies. The Sprague-D aw ley
rat ap p ears to be a valuable model in preliminary work to show trends and
param eters not scientifically m easurable in the human.

Other aging strains

and species of animals should also be tested.
Galletti and Klopper (1964) found that when mature female rats w ere
given 3.14 mg of progesterone daily for 20 days they showed a greater body
weight gain than controls. C arcass analysis revealed this extra weight to be
due to an increased fat deposition.

Immature fem ales did not gain weight

faster than controls and showed no enhanced fat deposition. They reported

76

that when adult female rats were castrated they gained weight faster than
intact anim als but treating such castrated animals with progesterone did not
cau se an additional weight increase beyond the OV effect The average daily
weight gain in the P treated animals w as 2.33g daily com pared to the intact
controls which gained 1.56g body weight per day. The additional body weight
in the postbreeder OV and P treated animals in the present study reveal the
sam e results for body weight; however, no significant differences in adiposity
were observed.
Differences have also been examined in lean com pared to o b ese rats.
Gray and Greenwood (1984) injected 5 pg of estradiol benzoate (EB) in OV
rats for five days, which resulted in decreases in the rate of body weight gain in
both lean and obese Zucker rats. Additionally, EB administration resulted in
significant induction of progestin binding sites in both neural and adipose
tissues.

However, EB treatment significantly decreased lipoprotein lipase

activity in adipose tissue from lean but not obese Zucker rats. Their research
show s that the presence of receptor sites for estrogens and the receptivity of
the sites for progestins can be dem onstrated in both adipose and

uterine

tissues. This suggests that the enzymatic changes that are observed in th ese
tissues following hormone administration may be receptor m ediated and that
the original state of lean compared to obese may reveal very different results.
T hese m echanism s may also help to explain the results of the present study
with regard to differences observed in E and P treatm ents.
The effects of estrogenic stimulation (not progesterone)

on diet

selection were examined by B adness & Waldbillig (1984) on intact, OV and E
treated animals. The FAT, PRO and CHO levels of laboratory chow w ere
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manipulated. OV treatm ent w as associated with the nearly exclusive choice of
higher caloric intake which w as decreased in the E treated animals.

Total

caloric intake and body weight did not vary across the estrus (follicular) cycle.
However diet selection did vary. Fat intake increased; CHO and to a lesser
extent, protein intake decreased during estrus when estrogen levels are
elevated. An opposite diet selection occurred during diestrus (luteal).

OV

treated animals (no endogenous E & P ) chose progressive increases in CHO
and protein intake, with concurrent d ecrea se s in fat consumption.

The E

treated anim als partially reversed this diet selection profile dem onstrating
estrogenic reduction in CHO intake with standard high-CHO commercial diets.
In addition, an increase in fat intake during estrogenic stimulation w as found.
This supports the results of the present study with regard to food intake and
body weight patterns in the OV and E treatm ents a s a reflection of estrus.
The mechanistic effects of cyclic estradiol replacem ent on satiety and
choiecystokinin (CCK-8) with subsequent

resulting body weight gain in

ovariectomized rats (Geary, et. al, 1994) were recently reported.

Estradiol

significantly increased CCK-8’s inhibitory effect on sucrose intake. In contrast,
progesterone alone or in combination with estradiol did not consistently
influence the satiating potency of CCK-8. Potentiation of the satiating effect of
CCK released from the small intestine by ingested food may be one of the
m echanism s by which food intake decreases during the period of high
estrogen concentration in the estrus cycle. During the 10 week study the
ovariectomized rats treated only with the sesam e oil vehicle gained about 60 g
more than the estradiol-treated rats. T hese results are supported by treatm ent
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and body weight data found in P hase I of the present study and may help to
explain estrogen mechanism s.
The physiological phenom ena which affected the outcom es in the aging
female rat in phase I of this study with no significant differences in caloric
intake (Figure 3.0) are not currently known. In P hase I, all anim als received the
sam e three macronutrient food choices.

Estrogen

replacem ent c au se d

reduced weight gain, however, progesterone failed to suppress body weight
gain com pared to E treated animals. Additionally, ovariectomy and horm one
treatm ents significantly altered preferences for macronutrient food choices.
Contrary to previously reported studies (Wade, 1976; W ade & Gray
1979), the increase in body weight in the present study w as not accom panied
by additional caloric intake in P hase I.

However a trend w as observed

(p=.052) for lower caloric intake in the E treatment. Progesterone, which did
not significantly increase body weight and food intake in the intact fem ale rat
(W ade & Gray, 1979) w as found to increase body weight in the aging model in
p h ase I when com pared to estradiol treated animals. This supports the
conclusions of other previous studies in the younger model (Hervey & Hervey,
1967) which suggests that both ovariectomy and progesterone increase food
intake and body weight. Galleti and Klopper (1964) reported that progesterone
ap p ears to lead to the laying down of fat, and that this can come about in on e
of three ways. Either the animals take in more food, or m ake more body fat out
of the sam e amount of food by more efficient use of foodstuffs or else energy
output is reduced by the sedative effect of progesterone. This view (of
progesterone effects) in immature animals is supported by the fact that a
progesterone effect w as also observed in mature animals in P h ase I and Total
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Study analysis in the present research. Possibly the effect of progesterone on
weight gain in P h ase I in adult female animals arises from the suppression of
estrus at which time the animals are very active.
The obvious question becom es, w as increased caloric expenditure a
factor? Although the effects of female sex horm ones on body weight in young
rats are rather well docum ented (Hervey & Hervey, 1967; Wade, 1976; W ade
& Gray, 1979), there is little information in the literature detailing the
m echanism s through which th ese horm ones act on the regulation of energy
balance.

According

to

previous

reports,

estradiol

increases

energy

expenditure by playing a role in increasing physical activity (Rodier, 1971;
W ade & Gray, 1979). Richard (1986) has suggested that when food intake is
kept constant, ovarian horm ones affect energy balance by altering energy
expenditure. In the current study, exercise w as not m easured.

However,

empirical observations indicate that an increase in body weight gain may be
due to decreased activity, lack of endogenous horm ones or hormone induced
lethargy. A pronounced lethargy and hostility were observed in P treated
animals. Voluntary exercise in the aging female rat should be m easured in
future research studies.
The m echanism s responsible for hormonally induced increases in food
intake in ovariectomized rodents are also poorly understood. Tarttelin (1973)
h as shown that the effect of the ovariectomy diminishes after 4 weeks. This
provides evidence of a potential existing m echanism that results in altered
caloric conversion ratios shown in the present study. The reported increase in
food intake observed after ovariectomy (Hervey & Hervey, 1967) is probably
due to the removal of the circulating estrogens which are known to have an
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anorectic effect. The most interesting concepts surround a m essenger system
which sen d s information from the digestive system to the brain.

Neural

m essengers and the m echanism s involved are currently under investigation to
determine hormonal effects on food intake regulation in the female rat
influenced by exogenous female sex horm ones (Geary, et al, 1994; Butera,
1995 personal communication). No conclusive evidence has been published.
The significant differences in caloric conversion ratios in the present study
suggest that there may be metabolic alterations stimulated by exogenou s
female sex horm ones yet unreported.
In a review of known or hypothesized potential mechanism s, W ade and
Schneider (1992) reported that a transience could be related to estradiolinduced shifts in a hypothetical weight set-point.

C hanges in food intake

would in this c a se persist only until body weight is brought into line with a new
regulated level (Harris, 1990). A more useful working hypothesis may be that
ovarian steroids act centrally or peripherally to perturb the balance betw een
the storage and mobilization of metabolic fuels (e.g., via changes in autonom ic
activity,

insulin

and

counter-regulatory

activities, hepatic fuel metabolism, etc.).

hormones,

adiopocyte

enzym e

Food intake could change in

response to changes in fuel availability that result from th ese alterations in fuel
partitioning. O nce a new equilibrium is established, body fuel stores would
then stabilize at a new level, and fuel availability (and, consequently, food
intake) would revert to the previous values. The questions must then be, is this
phenom enon inevitable in mid life or following an ovariectomy? Can or should
it be m anipulated?

Perhaps the current practice of injecting replacem ent

hormone into fem ales immediately following the hysterectomy helps to prevent
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this added body weight in the human female. That investigation in the hum an
h as not been reported (Hayes, personal communication, 1995).
Ovarian

steroids

affect

other

food-related

behaviors

in

rats.

Ovariectomy c au ses a transient increase in the hoarding of food, an d
treatm ent with estradiol su p p resses food hoarding in ovariectimized rats
(Coling & Herberg, 1982). Various laboratories have used different protocols
and different macronutrient sources, generally presented with sucrose in w ater
bottles.

It is conceivable that ovarian steroids primarily affect hedonic

resp onses of rats to taste stimuli, affecting the animals’ response to differences
in the relative palatability of the available macronutrients.

Indeed, ovarian

steroids have significant effects on rats’ preferences for nonnutritive sw eet and
bitter tastes, and on electrophysiological responses to tastes in the brain stem
which is a major relay for taste information. Experimental manipulations of
circulating gonadal steroid levels indicate that many of th ese changes in
energy balance with reproductive status are due to the actions of th ese
horm ones, both in the brain and on nonneural peripheral tissues (DiLorenzo &
Monroe, 1989; W ade & Zucker, 1969, 1970; Zucker, 1969).

Little else is

known about the neural circuitry mediating the actions of estradiol on food
intake (Butera, personal communication, 1995).
There are num erous interconnected neural structures which contain
estrogen receptors and which: 1) receive the chem o-sensory and visceral
inputs; 2) integrate this information with other sensory cues; and 3) m odulate
the autonomic, hormonal, and behavioral responses to this information (Wade
& Schneider, 1992).

T hese structures within the brain include the are a

postrem a and the nucleus of the solitary tracts, the mid brain central gray, the
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lateral parabrachial nucleus, the central nucleus of the amygdala, the bed
nucleus of the stria terminallis, the lateral hypothalamus, the paraventricular
nucleus, and the ventromedial hypothalamus (Loewy, 1990; Pfaff & Keiner,
1973; Simerly, et al, 1990).
Psychologists, physiologists, biochemists and molecular biologists are
attempting to m easure and report these mechanisms. W ade (1987) stated that
one strategy would be to manipulate energy balance with estradiol treatm ents
and m easure ch an g es in neuronal function, such a s c-fos activity, in brain
regions known to be associated with regulation of feeding and body weight.
Indeed, estradiol treatm ent has been shown to alter c-fos expression in rat
brain (Hoffman, et al, 1990; Insel, 1990).

An obvious problem with this

approach is that ovarian steroids act in the brain to affect a wide variety of
behaviors and physiological responses, not just those affecting energy
balance.

In addition, there is substantial anatomical overlap of the neural

system s controlling energy balance and other horm one-sensitive functions,
making it difficult to relate hormone-induced

neuronal changes to any

particular behavior or physiological endpoint (Wade & Blaustein, 1978).
However, it might be possible to avoid, or at least minimize, this problem by
using

nonsteroidal

antiestrogens.

T hese

com pounds

(e.g.,

tamoxifen,

nafoxidine, MER-25) block most of the neuroendocrine actions of estradiol,
including running wheel activity, estrus behavior, maternal behavior, and
gonadotrophin secretion (Andieh, et al, 1987; Bowman, et al, 1983; Gerall, et
al, 1973; Komisaruk& Beyer, 1972; Labhsetwar, 1970; Roy, et al, 1979; Roy &
W ade, 1975, 1977; W ade & Blaustein, 1978). On the other hand, nonsteroidal
antiestrogens mimic the actions of estradiol and reduce food intake and body
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weight in ovariectomized rats; they are completely devoid of antagonistic
activity on th ese m easures (Bowman, et al, 1981, 1982; Donohoe & Stevens,
1982; Gray & W ade, 1981; Roy & Wade, 1977; W ade & Blaustein, 1978).
Although estradiol-induced d ecrea se s in food intake undoubtedly
contribute to the observed

decreased

body weight gain,

pair-feeding

experim ents indicate that behavioral changes are neither necessary nor
sufficient to cau se weight loss. Estradiol-treated rats fail to gain weight even if
they do not undereat (Kennedy, 1953; Thomas, et al, 1986; W ade, 1974;
Zucker, 1972).

However, in another study the hypophagia normally se e n

during estradiol treatm ent w as not sufficient to cau se weight losses in vehicletreated, ovariectomized rats (Wade and Gray, 1979).

Finally, the majority of

the studies reported confirm that ovarictomized rats gain weight and fatten
w hether or not they are permitted to overeat (Bartness & Waldbillig, 1984;
Landau & Zucker, 1976; Mook, et al, 1972; Roy & W ade, 1977; Thomas, et al,
1986). Thus, it is clear that estradiol and ovariectomy both have significant
effects on the postingestive handling and utilization of metabolic fuels. In the
present study, significant differences in treatment effects of caloric conversions
ratios are evidence of th ese phenom onen in the aging rat model.
Earlier research reported on younger animals by Wade, Gray and
B artness (1985) indicated that exogenous female sex horm ones, in addition to
the well-known actions on reproductive physiology and behavior, have been
reported to affect a wide variety of nonreproductive functions, including the
metabolic p ro cesses that regulate energy balance, body weight, and body
composition. They have reported that among female rats there are significant
fluctuations in behavioral and physiological controls of energy balance with
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ch an g es in reproductive conditions such a s puberty, ovulatory cycles,
pregnancy, lactation, and reproductive state.

In addition, they have shown

with experimental manipulations of circulating gonadal horm ones that many of
th ese chan g es in energy balance with reproductive status are due to the
actions of female sex hormones, both in the brain and on non-neural
peripheral tissues. This work in the mature rat model remains to be done.
The following are som e exam ples of how ovarian steroids act in som e
metabolically important organs, such a s liver and adipose tissue, to adjust the
metabolism and partitioning of calories. After food is absorbed from the gut,
most of it enters the splanchnic circulation and is carried to the liver.
S ubstrates from other sources (e.g., fatty acids and glycerol from adipose
tissue, amino acids from muscle) are also carried to the liver. T hese fuels may
simply p a ss through the liver on their way to other organs or they can be
oxidized,

stored

as

glycogen,

or

converted

to

other

forms

(e.g.,

gluconeogenesis, lipogenesis, ketogenesis).
Ovarian steroids have a num ber of important effects on hepatic
handling of metabolic fuels.

For example, ovariectomy increases hepatic

gluconeogenesis and reduces tissue glycogen content, and th ese ch an g es
are reversed by treatm ent with estradiol alone (Ahmed-Sorour & Bailey, 1981;
Matute & Kalkhoff, 1973; Sladek, 1974). T hese effects in both human and rats
could be due to direct hepatic actions of estradiol, b ecau se the liver is known
to be a target tissue for estrogens (Aten, et al, 1980; Eisenfled, et al, 1977). In
addition, estradiol could act indirectly by modulating hepatic responsiveness
to glucoregulatory hormones, or by altering the secretion of th ese horm ones
via direct or indirect actions on the pancreas (Ahmed-Sorour & Bailey, 1980;
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Bailey & Ahmed-Sorour, 1980; Faure, et al, 1979; Mandour, et al, 1977;
Storlien, et al, 1979; Tesone, et al, 1979; Thomas, et al, 1986).
Manipulations of ovarian steroid

levels also affect hepatic

lipid

metabolism. Ovariectomy decreased hepatic lipogenesis and triglyceride and
lipoprotein production; sustained estradiol replacem ent therapy reverses
th ese changes.

However, careful examination of the tim e-course of th ese

effects also indicates that estradiol treatment had biphasic effects on hepatic
lipid metabolism (Edens & Wade, 1983).

In the short term, estradiol inhibits

hepatic lipogenesis and triglyceride release, but with longer treatm ent times,
th ese functions are stimulated (Eisenfeld, et al, 1977; Gray & Greenwood,
1982; Kenagy, et al, 1981; Kim & Kalkhoff, 1975, 1978; Ramirez, 1980).
Therefore, it is not really clear from the existing literature, how the relatively
rapid (day-to-day, hour-to-hour) changes in circulating levels of ovarian
steroids that are seen across ovulatory cycles affect hepatic lipid m etabolism
in rats. Clearly cholesterol, LDL, and HDL were affected in the PEPI subjects
who were postm enopausal fem ales taking exogenous female sex horm ones
(PEPI Writing Group, 1995).
Ovarian steroids have striking effects on the storage of calories in
adipose tissue. They do this by altering the activities of the enzym es that
control both the uptake and release of metabolic fuels by adipocytes. In rats,
ovariectomy has been shown to increase body fat stores w hereas treatm ent of
ovarictomized animals with estradiol d e crea se s body weight and fat content
(Leshner & Collier, 1973; W ade, Gray, and Bartness, 1985; W ade & Gray,
1979). Percentage of body composition is not indicated, but should be
reported in future studies.
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Estradiol probably acts both centrally and peripherally to alter ad ip o se
tissue fuel metabolism.

Rat adipose tissues contain steroid-specific, high-

affinity, limited capacity receptors for both estrogens and progestins that are
similar to the receptors in other steroid target tissues (Gray, et al, 1981; Gray &
W ade, 1979; Pedersen, et al, 1991; W ade & Gray, 1979). T hese findings
support the possibility that estradiol could act directly on adipocytes to alter
enzym e activities (Wade & Schneider, 1992).
It is conceivable that estradiol might act on other peripheral tissues,
such a s the liver, to alter adipose tissue enzym e activities indirectly (W ade &
Gray, 1979). For example, estradiol can act directly on the liver to m odulate
the production and release of certain apoproteins which act a s cofactors for
adipose tissue lipoprotein lipase (Kim & Kalkhoff, 1978).
The m echanism s in the brain have been more extensively exam ined.
Estradiol may act in the brain to modulate adipose tissue metabolism via either
hormonal (W ade & Schneider, 1992) or autonomic outputs.

Cutting the

sympathetic nerves to retroperitoneal white adipose tissue

significantly

attenuates the estradiol-induced fat pad weight loss (Lazzarini & W ade, 1988
a).

This reduction of fat pad responsiveness to estradiol is not due to a

d ecrease in estrogen receptor concentration.

Instead estradiol se em s to

increase the activity of the sympathetic nerves to the retroperitoneal fat pads,
but not those to the heart (Lazzarini & Wade, 1988b). An estradiol-induced
increase in release of catecholam ines from sympathetic terminals would
stimulate lipolysis.

It is likely that estradiol acts centrally to stimulate

sym pathetic activity, since many of the neural a re as that control autonom ic
activity are also target sites for estradiol (Lowey, 1990; Pfaff & Keiner, 1973;
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Simerly, 1990). Thus, it appears that estradiol enhances lipolysis by acting
both in the brain to stimulate sympathetic activity (and consequently
norepinepherine release in adipose tissue) and in adipose tissue to increase
lipolytic sensitivity to catecholam ines (Benoit, et ai, 1982; Hansen, et al, 1980;
Lacasa, et al, 1991; Lazzarini & Wade, 1988a).
Estradiol may affect adipose tissue physiology indirectly, via the actions
of other hormones.

Estradiol alters the secretion of hormones, which may

have important effects on metabolism and adipose tissue (Faure, et al, 1983;
Storlien, et al, 1979; W ade & Gray, 1979). It is unlikely that estradiol-induced
ch an ges in insulin secretion play a critical role in the effects of estradiol on
energy balance. Estradiol treatm ent increases circulating levels of insulin, but
this should increase, rather than decrease body fat stores. In addition, the
actions of ovariectomy and estradiol replacem ent on body weight are not
impaired in streptozotocin-diabetic rats given controlled am ounts of insulin
(Faure & Sutter-Dub, 1979; Faure, et al, 1983; Mandour, et al, 1977; Storlien,
et al, 1979; Thomas, et al, 1986).
Estradiol increases the expenditure of metabolic energy via ch an g es in
both regulatory behaviors and metabolic processes. Ovariectomy d e c re a se s
and estradiol treatm ent increases metabolic rate and therm ogenesis in rats.
This estradiol-induced increase in heat production is accom panied by a rise in
dry heat loss, so that changes in core tem perature are absorbed, or at least
inconsistent. That is, the extra heat is dissipated a s fast a s it is generated, and
estradiol increases

heat flux without affecting the

substantially (Wade & Schneider, 1992).

body

tem perature
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Although thermoregulatory m echanism s often signal the beginning of
m enopause, very little is known about the effects of ovarian steroids on energy
balance in mature women.

Food intake and metabolism are known to vary

with reproductive condition, including menstrual cycles, pregnancy and
m enopause (Wade & Schneider, 1992). Virtually nothing is known about the
effects of exogenous human female sex horm ones on energy balance.

We

know only that in women of a wide variance of a g es who are taking
exogenous female sex hormones, body weight changes occur. More research
clearly n e ed s to be conducted.
During hormonal shifts throughout the life cycle, fem ales are often
aw are of changes which can be felt physiologically in feelings of fullness, due
to edem a and perceived

perm anent additional

weight gain

(personal

communication, Hayes, 1993). W hether this is a temporary state or a metabolic
alteration is not known. This study sought to m easure body weight shifts a s
influenced by female sex hormones.

The female rat model w as chosen

b e ca u se the controlled environment allows more accurate m easures of body
weight and food intake m easurem ents than can be obtained in free living
subjects keeping dietary records. The application of animal data to hum an
physiology is often questioned. However, the rat model chosen for this study
reflects many of the param eters shown in the literature to directly parallel the
hum an female a s suggested by W ade & Schneider (1992). The present study
also show s a strong correlation of the rat to the human. The results of the PEPI
study should relate additional information on the hormonal effects on hum an
body weight when it is released in 1996 (The PEPI Writing Group, 1995).
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RESULTS OF PHASE II: OVERVIEW
The availability of sw eet and nonsw eet CHO sources allowed for the
additional investigation of hormonal effects.

Body weight differences in

hormonal treatm ents between P hase I and P h ase II utilizing the sam e anim als
provided new information with regard to the effects of progesterone and
provided evidence of regulatory m echanism s. Four food cups containing three
macronutrient food choices were presented to the four OV groups. The sham
rats which were used for comparison, continued with the three foods cups. The
CHO source w as divided into sw eet and nonsweet components. The caloric
content of the sw eet food choice w as 4 times higher in simple sugars than the
nonsw eet. The nonsw eet carbohydrate sources were maltodextrin, cornstarch
and cellulose which are classified a s complex carbohydrate food choices
(carbohydrate formulations Table 3.4). Protein and fat sources were the sam e
formulation a s in phase I. The sham group w as not included in the following
tables reported in this chapter. The tables which indicate 5 group contrasts
and percentages along ANOVA factorials, and 5 group summary graphs can
be found in the appendix.
BODY WEIGHT
Body weight gain in both absolute and relative m easures (total and %)
w as greater (Table 4.2A, 5 group ANOVA p196, Figure 5.0 p212) in the OV
anim als than the E&P and P. Ovariectomized animals gained more body
weight than hormone treated animals (Table 4.2 B total & % 4 group ANOVA
contrasts 5 group ANOVA p196). P treated animals gained less than Non P
(total & % 5 group p196, factorial, 197).
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TA BLE 4.2A
Treatment

PH A SE II - BODY W EIGHT GAIN AND TOTAL
CA LO RIC INTAKE
Ovariectomized

Number of 10
Animals
<n=)
15.3±3.4
Total
Weight
(a)
Gain (g)
% gain
Total
Caloric
Intake

5.3%(a)
953.5 ±
66.4

% of total 34.1%
Caloric
15.6±3.2
Conversion (a)
Ratio

OV + 176 OV + 17B
Estradiol Estradiol
and Pro
gesterone
11
12

OV +
P roges
terone

7.3 ±2.1
(a.b)

4.2 ± 2 .7
(b)

p=0.009

2.8%(a,b) 1,7%(b)
822.7 ±
838.1 ±
23.6
44.8

1.4%(b)
871.7 ±
39.2

p=0.013
p=0.188

33.0%
7.9±2.1
(a,b)

31.8%
4.3±3.1
(b)

p=.016

4.6 ± 1.4
(b)

31.6%
5.5±1.7
(a.b)

ANOVA
p value

10

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc com parisons
% of gain is for this 10 day period
% of total caloric intake shows total for phase
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TA BLE 4 .2 B PH A S E II - G R O U P C O N T R A ST S FO R TOTAL
BODY W EIG HT GAIN AND TOTAL CA LO RIC INTAKE
Treat n
ment

Total Weight p value
Gain*

Total Calorie p value
Intake*

g
% %

g
OV
vs
H

10 15.3
±3.4
33 5.3
±2.1
E
23 5.9
vs
±1.2
Non 20 9.7
E
±2.5
P
22 4.4
vs
±1.4
Non 21 11.1
P
±2.1

5.3
±1.2
2.0
±.4
2.3
±.5
3.3
±.8
1.5
±.5
4.0
±.7

Caloric
p value
Conversion
Ratios

g
g

p=.001

% %

954.0 34.0 p=.045 15.6±3.2
±66.4 ±1.2
%p=.002 843.1 32.2 %p=.059 5.9±2.3
±35.9 ±.6
p=.122 831.0 32.3 p=.073 7.9±2.1
±24.2 ±.7
%p=.127 913.0 32.9 %p=.81 9.9±3.2
±38.7 ±.8
p=.007 853.8 31.9 p=.473 4.3±3.1
±21.7 ±.6
%p=.006 884.0 33.4 %p=.486 11.8±2.6
±41.1 ±.8

*Mean ± SEM, a.0 5
Hormones = E, P, E&P
Ovariectomized = OV, no hormones
Estrogen = E, E&P
Non Estrogen = OV, P
Progesterone = P E&P
Non progesterone = OV, E

p=.0024

p=.173

p=.010
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CALORIC INTAKE
There were no differences in of total caloric intake across the treatm ents
(Table 4.2A, 4 group ANOVA factorial p196). However, in total caloric group
contrasts, OV with no hormone consum ed higher levels of calories than
hormonally treated animals (Total Table 4.2B, 5 group p197).
CALORIC CONVERSION
Caloric conversion ratio (Figure 7.0 p214) w as less in the P treated
anim als com pared to OV animals (Total Table 4.2A). In group contrasts, OV
conversion of calories into body weight w as higher than in H treated animals,
and P w as lower than Non P (Total Table 4.2B). A progesterone effect on
caloric conversion ratio w as also shown with factorial analysis (4 group
ANOVA factorial p197).
FAT
No main effects were observed for fat intake (total & %) among the
treatm ent groups (Table 4.2 C). However, hormonally treated anim als ate a
greater percentage of fat than OV a s revealed by group contrasts and E
implanted rats consum ed a higher % of fat than Non E {% Table 4.2D). Total
calories comparing FAT, CHO, and PRO are shown in Figure 6.0 p213.
PROTEIN
Total protein consumption (Figure 6.0 p213) w as higher in the OV and
E&P than in P treated anim als (Total & % Table 4.2C). Group contrasts also
revealed that protein intake w as higher with the OV than the hormonally
treated anim als (Total Tabie 4.2D). A E&P effect w as shown on increased
protein consumption (4 group ANOVA factorial p197).
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T A BLE 4 .2 C P H A S E II - M ACRONUTRIENT
FO O D C H O IC E S IN KCAL
Treatm ent Ovariectomized

OV +1713
Estradiol

OV + 178
Estradiol and
Pro
gesterone
12

OV +
P roges
terone

37.0%
85.0 ± 10.5

47.6%
33.9 ± 3.0
(b)

ANOVA
p value

Num ber 10
11
10
of
Animals
(n=)
Total In 524.2 ± 48.9 324.1 ± 4 5 .4 310.4 ± 3 3 .3 395.9±51.8 p=.007
take of
(a.b)
(a)
(b)
(b)
C arbo
hydrate
(Calories)
% of total 56.5%
Total
78.3 ± 9.4
Intake of (a)
Protein
(Calories)

39.8%
49.6 ± 9.5
(a.b)

(a)

p=.054
p=.001

10.1%(a)
4.0%(b)
% of total 8.6%(a,b)
6.2%(a,b)
p=.004
Total
351.0 ± 75.7 448.0 ± 60.7 443.5 ± 37.7 441.8± 83.8 p=.683
Intake of
Fat
(Calories)
% of total 34.9%

53.9%

53.0%

48.4%

p=.084

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc com parisons
% of gain is for this 10 day period
% of total caloric intake show s total for phase
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TA BLE 4.2D PH A SE II - G R O U P C O N T R A S T S FO R
TO TA L C A R BO H Y D RA TE, PR O TEIN AND FAT
Treat n
m ent

C arbo
hydrate

p value

Protein

p value

g
OV
vs
H

10
33

E
23
vs
Non 20
E
P
22
vs
Non 21
P

9
524.0
±48.9
340.9
±43.5
317.0
±27.2
460.0
±37.6
349.3
±30.4
419.4
±39.4

%
56.5
±5.4
41.1
±3.0
38.3
±3.2
52.0
±4.3
41.7
±3.7
47.8
±4.2

%
p=.001

g

78.3
±9.4
%p=.020 57.7
±7.7
p=.003
68.0
±7.9
%p=.013 56.1
±7.0
p=.120
61.8
±8.0
%p=.153 63.3
±7.3

Hormones = E, P, E&P
Ovariectomized = OV, no hormones
Estrogen = E, E&P
Non Estrogen = OV, P
Progesterone = P E&P
Non progesterone = OV, E

%
8.6
±1.2
7.0
±.7
8.3
±.9
6.3
±.8
7.3
±1.0
7.4
±.9

Fat

p value

g

%
p=.042

g
g

351.0
±75.7
%p=.058 445.0
±60.7
p=,216 446.0
±34.2
%p=.278 397.0
±55.9
p=.616 443.0
±42.1
%p=.581 402.0
±48.1

%
34.9
±5.1
51.9
±3.2
53.4
±3.6
41.7
±4.5
50.9
±3.9
44.9
±4.4

%
p=.228
%p=.015
p=.450
%p=.042
p=.508
%p=,418
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TA BLE 4 .2 E P H A S E II - CA LO RIC INTAKE O F S W E E T AND
N O NSW EET CARBOHYDRATE
Treatm ent

Ovariectomized

Number of
10
Animals (n)
SW vs. Non/SW
277 ± 26
S w eet
C arbohydrate

OV + 17fB
Estradiol

11

OV+ 1713 OV + Pro ANOVA
Estradiol gesterone p value
and Pro
gesterone
12
10

167 ± 21

♦
226 ± 30

164 ± 2 9

p=.017

%

29.2%

21.1%

26.6%

19.9%

p=.1678

N onsw eet
C arbohydrate

247 ± 55
(a)

158 ± 3 9
(a >b)

85 ± 1 4
(b)

232 ±4
(a,b)

p=.015

%

27.3%

18.7%

10.3%

27.6%

p=.022

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc com parisons.
♦ E&P intake w as significantly different in SW/CHO vs. NON/SW CHO p=.001.
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T A B L E 4 .2 F P H A S E II - G R O U P C O N T R A S T S CA LO RIC
INTAKE O F S W E E T AND N O N SW E E T C A R B O H Y D R A T E S
Treat n
ment

OV
vs
H
E
vs

10
33
23

Non 20
E
22
P
vs
Non 21
P

SW Carbo-hydrate p value
9
SEM
277.2
±25.8
185.6
±26.7
166.5
±27.2
220.7
±27.5
164.4
±29.8
221.8
±47.1

%
29.2
±2.5
22.6
±3.0
21.1
±3.2
24.6
±3.2
19.9
±3.9
25.7
±2.9

9
%
p=.127
%p=.120

NSW
Carbohydrate

g
247.1
±54.7
157.9
±30.9

%

p value

g

%
27.8 p=.0552
±6.3
18.8 % p=.058
±3.6

p -,2 5 3

157.5
±39.4

%p=. 189

202.3
±47.2

18.7 p=,004
±4.4
27.5 % p=.006
±5.3

p=.264

231.6
±8.0
202.3
±94.2

27.6 p=.616
±4.7
22.9 %p=,581
±5.4

%p=.301

Hormones = E, P, E&P
Ovariectomized = OV, no hormones
Estrogen = E, E&P
Non Estrogen = OV, P
Progesterone = P E&P
Non progesterone = OV, E
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CARBOHYDRATE
Macronutrient analysis in phase II (Table 4.2 C-E Figure 6.0 p213), a s in
p h ase I, revealed that both E and E&P treatm ents decreased total CHO intake
com pared to OV (Total Table 4.2C). CHO intake w as higher in the OV than in
hormonally treated anim als when using group contrasts (Total & % Table
4.2D). Estrogen implanted animals consum ed less CHO than Non E treated
anim als (Total & % Table 4.2D). E combined with P had a greater effect than
either separately (4 group ANOVA factorial p198).
SWEET & NONSWEET CARBOHYDRATE
Sw eet vs. Nonsweet CHO w as significantly different in E&P treated
anim als (Table 4.2E).

Sw eet carbohydrate consumption w as significantly

higher in the OV than the H treated animals in group contrasts (Total Table 4.2
F). There w as an E&P effect which m eans that E&P combined stimulated more
SW/CHO intake than E or P separately (4 group ANOVA factorial p198).
E&P treatm ent group had an intake of nonsw eet CHO which w as one
third of the level consum ed by the OV animals (Total & % Table 4.2E).
Estrogen treatm ent group had a significantly lower intake of nonsw eet CHO
than the Non E treated anim als (Table 4.2F). An E effect w as observed (4
group ANOVA factorial p 198).
DISCUSSION OF PHASE II
The purpose of phase II w as to continue to examine hormonal effects for
another ten days on body weight, macronutrients and especially “te a se out”
the type of carbohydrate intake, sweet or nonsweet, a s affected by exogenou s
female horm ones. The effect of estrogen, continued a s observed in P h ase I,
but all the other groups and especially the progesterone treated anim als
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adapted and did not continue to gain weight the sam e (Figure 17.0) a s in
P h ase I. This is important information b ecause currently progesterone is
perceived to cau se body weight gain and this can be a major reason fem ales
do not comply with HRT prescriptions given by the physician (Lemer, 1995).
E&P represents the typical hormone treatm ent therapy

prescribed

by

physicians. In HRT, the progesterone is added to d ecrease the likelihood of
reproductive cancer.
When P hase II is compared to P h ase I, body weight in four group
analysis with both total and % analysis revealed increased body weight in the
OV anim als com pared to P. OV gained 3 times more body weight than the P
treated animals. Progesterone treated animals gained an average of only .4 g
of body weight per day compared to 1.5 g in the OV treatment. Group contrasts
confirmed th ese effects with higher body weight in OV com pared to H, and
Non P com pared to P.
In P hase II a s in P hase I, no significant differences were observed in
caloric intake. The only caloric consumption differences were observed in OV
anim als which w as significantly higher than H when group contrasts w ere
examined. With the significant differences in body weight and the a b sen ce of
significant differences in caloric intake am ong the treatm ent groups,

the

evidence in P hase II showing hormonal effects on caloric conversion ratios
w as strengthened. OV animals required fewer calories to gain a gram of body
weight than did the P treated animals. When grouped, OV body weights w ere
higher than H and Non P were higher than P.

This provides evidence that

hormone treatm ent suppresses the additional body weight gain of the OV and
that specifically progesterone in P hase II suppressed body weight gain,
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contrary to the results observed in P h ase I. It should also be noted that the S
group responded similarly to the P group in P hase II with dramatically different
caloric conversion ratios contrasted to P h ase I. This slowing of body weight
gain may be a natural response to elevated body weight gain following
surgery in P h ase I.
Hormones also continued to affect food choices with significant
differences in macronutrient consumption in P hase II. Macronutrient choices
revealed that the percent of fat intake w as higher in the H and E than in the OV
and NonE treatm ents. This agrees with the hypothesis that FAT consum ption
is higher during the luteal phase. Protein intake w as higher in OV and E&P
com pared to H and P, confirming an estrogen effect on PRO consumption.
Total CHO intake w as higher in the OV than in the E&P and P with an estrogen
effect revealed by factorial analysis.

In group contrasts OV consum ed more

total CHO than H and NonE consum ed more total CHO than E. With regard to
consumption patterns for SW/CHO, E&P had a greater effect when com bined
than either hormone had separately. OV consum ed more SW/CHO than

H.

More NSW/CHO w as consum ed by NonE than E.

Additionally, E&P

consum ed significantly more SW/CHO than NSW/CHO.

However, the rats

were clearly able to discriminate and combine both SW and NSW.
The examination of the hypothesis of hormonal effects on food intake
and body weight revealed a different and unexpected result in p h ase II. The
reason for the d ecrease in body weight gain in phase II in the female w as
further examined.

One reason may be due to the regulation m echanism

term ed “set point”, which serves a s a therm ostat or regulator around which
upper and lower limits of body weight are maintained reported by Fantino &
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Brinnel (1986). This set point regulation m echanism has also been observed
in the human female (Harris, 1990).
Calories appear to be converted into body weight at a higher rate in OV
anim als (postm enopausal model) compared to the S anim als (prem enopausal
model) with intact ovaries. Differences were observed in caloric intake am ong
the five groups (Figure 6.0). Com parisons

of the percentages

of fat

consumption of the four groups show s fat consumption to be lower in the OV
com pared to H and higher in the E treated animals when com pared to NonE in
agreem ent to G eiselm an's et al. findings (1981). The high caloric conversion
ratio of the OV group is evident in Figure 7.0. This study provides evidence that
the high CHO intake of the OV group may have contributed to increased body
weight gain. This information agrees with a recent report from the Center for
Genetics, Nutrition, and Health in Washington, D.C.,

(Simopoulos, 1994)

which show s that a high carbohydrate diet or conversely a low fat diet can be
fattening, which also supports the research conducted by Tarttelin and Gorski
(1973).
The unexplained weight gain in 25 to 30 % of the aging population
(Leibel, 1995) is a subject widely discussed in the popular and professional
press. Insulin resistance may provide a further explanation of increased body
weight with high carbohydrate consumption in phase II (Simopolous, 1994).
Abnormalities in carbohydrate
hyperinsulinemia have been

and

lipid

metabolism

investigated by Reaven (1988).

evident

in

He h a s

concluded that the possibility exists that resistance to insulin-stimulated
glucose uptake and hyperinsulinemia are involved in the etiology and clinical
course of three major related diseases; non-insulin dependent diabetes,
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hypertension and coronary disease. In addition to th ese conditions, obesity,
particularly truncal obesity, has been shown to be associated with insulin
resistance and hyperinsulinemia, increased very-low density lipoprotein
triglyceride, decreased high-density lipoprotein triglyceride, d ecreased highdensity lipoprotein cholesterol and hypertension.

Reaven h a s term ed this

state a s “syndrom e X". The current hypothesis, however, is that syndrome X
and obesity, whether genetically determined or acquired, might act through
insulin resistance to cau se metabolic abnormalities (Reaven, 1988).

From a

physiological standpoint, it is important to know if insulin resistance is the first
abnormality from which the others follow. Other factors that modulate insulin
action should also be studied.
The increased body weight with high CHO consumption may be due to
an increase in insulin resistance in the OV animals.

Treatment with

exogenous horm ones (E and E&P) in the present study resulted in an altered
rate of weight gain, variation in the intake % of calories consum ed a s CHO and
the subsequent impact on the caloric conversion ratio. This comparison is also
indicative of the important role of E and P in the above processes a s it relates
to macronutrient selection.

It should be mentioned that this research by no

m eans dem onstrates that insulin resistance w as confirmed in the OV anim als
or that E and P are the only horm ones involved, a s many other factors are
changed with the ovariectomy.
Simopoulos, (1994a) recent research reveals that insulin resistance
can occur in the preobese state. Typically insulin is not m easured a s an
indication of irregular body weight gain in the human, neither w as it m easured
a s an indicator of body weight changes in this study.

However, a growing
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body of evidence has recently reported that with aging, adult onset diabetes is
increasing and that 25 to 30 % of the population may suffer from insulin
resistance (Leibel, 1995).

This figure also parallels the percentage of the

population known to be obese (Atkinson, 1990). Ovariectomy may affect
insulin resistance and possibly the greater consumption of CHO. The concepts
of metabolic param eters in obesity correlated to insulin resistance should be
exam ined in greater detail in future research.
The environment also has an impact on insulin resistance in the form of
stress, drugs, smoking, alcohol, diet and inactivity.

The effects of th ese

environmental factors have been investigated and results indicate that in the
predisposed individual, saturated fats decrease insulin sensitivity and that
alcohol raises blood pressure and triglycerides. W hereas regular physical
exercise improves insulin sensitivity (decreases insulin resistance),

reduces

blood sugar and lipid levels, lowers blood pressure, reduces body fat, and
leads to weight loss. Subgroups of individuals at high risk in whom m arkers of
the predisposition exist, should be identified (Reaven, 1988) by m easuring
insulin resistance. Som e genotypes may be more sensitive to environm ental
influences than others. B ased on a cardiovascular d isease study by Borkman
et al. (1993) and assum ing that dietary fatty acid intake influences the
composition

of

muscle

m em brane

phospholipids,

the

highly

refined

carbohydrate current food supply provides the perfect environmental influence
in which genetically predisposed individuals gain excess body weight. The
relationship to insulin resistance is indicated but not currently proven.
Results of the food choice and caloric regulation data in the present
study may be highly relevant for the human condition.

For example, low fat
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cookies are perceived to be a low calorie food choice, but they truly are not
low in calories. T hese food choices are high in calories in the form of simple
sugars. With this perception and a CHO appetite an entire box of diet cookies
can be consum ed by a postm enopausal woman with high caloric intake and
increased body weight. Even if excess calories are not consum ed, a diet high
in simple sugars could theoretically lead to obesity (Reaven, 1988), contrary to
recent perceptions.

In phase II surprisingly, a higher fat intake w as observed

with lower body weight in the E&P treated rats. A recent report (Allred, 1995)
states “A low fat or low-calorie food is low in neither if multiple servings are
consum ed and excess caloric intake occurs."
In the past, cyclical variations in food intake and body weight in females,
synchronous with the ovarian cycle, have been well docum ented.

T hese

findings are reflected in research in hum ans (Pliner & Flemming, 1983), in
monkeys (Rosenblatt, et.al., 1980), and in num erous rodents such a s the rat
(Brobeck, W heatland, & Strominger, 1947; W ade and Gray, 1979), ham ster
(Miceli & Fleming, 1983; Morin & Flemming, 1978) and guinea pig (Czaja,
Butera, & McCaffrey, 1983; Czaja & Roy, 1975).

In all th ese species food

intake and body weight are minimal at estrus, increase, reaching a maximum
during diestrus, and then decrease until the next diestrus. The dependence of
th e se cycles on female sex horm ones is attested to by their disap p earan ce
after ovariectomy and their restoration by appropriate hormonal treatment.
Ovariectomy in younger female rats (Landau & Zucker, 1976; W ade, 1974),
mice (Blaustein, Gentry, Roy, & Wade, 1976) and ham sters (Miceli & Fleming,
1983) increases food intake and perm anent body weight increase.

C arcass

analyses have indicated that body weight changes represent changes in fat
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m ass within age and treatment groups (Galleti & Klopper, 1964; Gray & Wade,
1981; Leshner & Collier, 1973; Pallier, Aubert, & Lemonnier, 1980; W ade,
1976), total protein, and water content (Gavin, Gray, & Johnson, 1983). Data
reflecting original percent body composition are needed in future research at
the beginning and end of each phase.
The fluctuation in body weight observed in p h ase II n e ed s further
investigation.

The addition to the literature of the progesterone effect on

lowered body weight in the aging model is a new contribution.
RESULTS OF PHASE III: OVERVIEW
The objective in phase III was to determine hormonal effects on
chocolate choices and the subsequent impact on caloric regulation and body
weight beyond the observations in phase II by adding 4 caloric levels of
chocolate to the existing macronutrient choices. This gave the animals 8 food
cups from which to choose: the four macronutrients from phase II plus the four
choices of chocolate. Chocolate choices included: high fat/ high sugar; high
fat/ low sugar; low fat/ high sugar; and low fat/ low sugar. Hormonal effects on
chocolate choices and macronutrient preferences were observed. The weight
gain w as not significantly different in this phase among

OV, E, P, and E&P

which received the chocolate food choices however body weight w as
significantly different from S which received the 3 macronutrient choices
throughout the entire study. The addition of another group,

S receiving all

food choices, would have allowed the investigation of surgery vs. food choices
but due to death rates early in the study, this group w as eliminated.. Statistical
analysis of the 4 groups compared to 5 groups yielded different results.
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An interesting finding of phase III w as that caloric intake w as chosen
from the nutrient deficient chocolate choice to the exclusion of the more
nutrient dense FAT, CHO, and PRO food cups, which were complete diet
choices that included all the macronutrients in the recom m ended amounts.
Results also revealed that the sw eet/nonsweet carbohydrate food choices
were ignored in preference to the chocolate flavored choices. Caloric intake
from macronutrients FAT, PRO, and CHO w as calculated both separately and
with those found in the chocolate food cups for comparative analysis.
BODY WEIGHT
No significant differences were observed in total body weight gain when
excluding the S groups for the statistical analysis (Table 4.3A). The S group
continued to gain weight at a rate similar to phase II, while not being given the
chocolate choices (5 group % S vs H p199). There were no group contrast
differences in body weight (Table 4.3B). Body weight gain increased across all
treatm ents in phase III compared to phase II for ovariectomized rats regardless
of the type of hormone replacement. Weight gain among the treatm ent groups
in this phase w as not significantly different. Four group ANOVA is shown in the
tables in the text. Five group analyses, percentages, and factorials ap p ear in
the appendix. Body weight w as significantly different when S w as included
(Total & % 5 group ANOVA p 199).
TOTAL CALORIC INTAKE
No significant differences were observed in total caloric intake am ong
treatm ents a s affected by exogenous female sex horm ones (Total Table 4.3A).
There were no total contrast differences in caloric intake (Table 4.3B). Total
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TA BLE 4 .3 A
Treatm ent

PH A SE III - BODY W EIGHT GAIN AND TOTAL
C A LO R IC INTAKE

Ovariec- OV +1713 OV+17IB
tomized Estradiol Estradiol
and Progesteron
e
10
11
12

Number of
Animals(n)
Total Weight 21.7 ±
Gain (g)
2.6

26.2 ±
3.1

% gain
7.1%
9.6%
Total Caloric 942± 56 898±30
Intake

25.3 ±
2.7

OV +
ANOVA
P roges p value
terone

10
25.9 ±
3.5

p=.708

8.8%
8.5%
p=.351
977± 44 988± 57 p=.516

% of total
36.0%
33.7%
36.8%
36.0%
22.7±2.0 29.2±3.2 25.3±2.1 26.2±3.7 p=.450
Caloric
Conversion
Ratio
Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc com parisons
% of gain is for this 10 day period
% of total caloric intake show s total for phase (including chocolate)
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TA BLE 4 .3 B PH A SE III - G R O U P C O N T R A ST S FO R BODY
W EIGHT GAIN AND TOTAL CA LO RIC INTAKE
Treat n
m ent

OV
vs
H

Body Weight Gain* p value

9
10 21.7
±2.6
33 25.8
±3.1

g
% %
7.1 p=.251
±.7
9.0 %p=.268
±.6

E
23 25.8
vs
±2.0
Non E 20 23.8
±2.2

7.8 %p=.526
±.7

22 25.6
±2.1
Non P 21 24.0
±2.1

8.6 p=.577
±.7
8.4 %p=.563
±.7

P
vs

9.2 p=.515
±.7

*Mean ± SEM, a.05
Hormone = E, P, E&P
Ovariectomized = OV, no hormone
Estrogen = E, E&P
Non Estrogen = OV, P
Progesterone = P, E&P
Non progesterone = OV, E

Total Calorie
Intake*
kcai
942.1
±56.0
955.0
±25.0
940.0
±27.6
965.2
±39.4
983.4
±34.3
919.1
±30.5

p value
g
% %
33.8
±1.1
36.4
±.6
36.6
±.6
34.9
±.9
36.5
±.8
35.0
±.7

p=.815
%p=.794
p=.578
%p=.457
p=.184
%p=.145
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calories reflect intake from all sources. Caloric intake w as significantly different
when S w as included (Total & 5 group ANOVA p 199).
CALORIC CONVERSION RATIO
No significant differences were observed among OV treated anim als,
with or without exogenous hormone replacement treatm ent (Total Table 4.3A).
Caloric conversion ratios were not significantly different when S w as included.
TOTAL FAT
No significant differences were observed in % or total fat am ong the
groups (Table 4.3C). There were no group contrast differences in fat intake
(Table 4.3D). However, it should be noted that high fat, high sugar chocolate
intake contributed the major portion of high fat intake

in the caloric

consumption profile (Total & % Table 4.3E ). No significant differences w ere
observed in 5 group analysis.
TOTAL PROTEIN
No significant differences were observed in protein intake (Table 4.3C).
Factorial analysis revealed an interaction effect of E&P which m eans that with
regard to protein intake, the presence of E with P had a greater effect than
either alone (4 group ANOVA factorial p200).
TOTAL CARBOHYDRATE
For the first time in the thirty day study there were no significant
differences in total CHO intake for both total and % (Table 4.3C). There were
no differences in CHO in group contrasts analysis (Table 4.3D). In this p h a se
of the study neither the estrogen nor progesterone treatm ents affected the
carbohydrate consumption. No significant differences were observed in N/SW
CHO or in SW/CHO.
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T A BLE 4 .3 C P H A S E III - M ACRONUTRIENT
FO O D C H O IC E S AND C H O C O L A T E
Treatm ent Ovariectomized

OV+1713
Estradioi

Number of 10
Animals
(n)
Intake of 432.7
C arbohy ±37.0
d rates
(Calories)

OV + Pro ANOVA
g esterone p value

11

OV +176
Estradiol
and Pro
gesterone
12

441.9
±38.1

389.7
±23.8

431.9
±58.9

p=.814

% of total 46.8%
Intake of 72.1
±16.9
Protein
(Calories)

43.8%
34.2
±7.7

45.3%
74.2
±10.8

44.1%
49.2
±11.5

]D=.965
p=.062

% of total 7.5%
Intake of 437.3
Fat
±51.2
(Calories)

4.0%
474.3
±59.1

8.1%
463.2
±37.5

4.8%
507.0
±72.8

p=.087
p=.858

45.7%

52.1%

46.6%

51.1%

p=.708

% of total

10

Values are m eans ± SE.
% of gain is for this 10 day period
% of total caloric intake show s total for phase (includes chocolate)
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TA BLE 4.3D PH A S E III - G R O U P C O N T R A ST S FO R
CA R BO H Y D RA TE, PR O TEIN AND FAT
Treat n
ment

CHO
Intake
kcal

%
9
OV 10 432.7
46.8
vs
±37.7
±4.2
H
33 420.0
44.5
±42.9
±2.5
E
23 416.9
44.6
vs
±25.3
±2.6
45.5
Non 20 432.3
E
±3.4
±34.0
P
22 437.4
44.8
vs
±28.9
±2.7
Non 21 410.2
45.2
P
±29.8
±3.3
*Mean ± SEM, a.05

p Value

PRO
Intake
kcal

9
%
p=.819

9
72.1
±16.9
%p=.716 53.3
±10.0
p=.698 54.2
±7.8
%p=.647 60.6
±10.3
p=.547 62.2
±8.2
%p=.562 53.1
±19.7

Hormone - E, P, E&P
Ovariectomized = OV, no hormone
Estrogen = E, E&P
Non E = OV, P
Progesterone = P, E&P
Non progesterone = OV, E

p Value

9
%%
7.5 p=.174
±1.7
5.7 %p=.153
±.7
6.2 p=.592
±1.0
6.1 % p=.479
±1.0
6.6 p=.477
±1.0
5.7 %p=.424
±1.0

Fat
Intake
kcal
9
437.3
±51.2
480.2
±56.5
468.5
±35.6
472.2
±44.1
483.1
±38.2
456.7
±38.6

P
Value
'

%
45.7
±4.3
49.8
±2.7
49.2
±2.9
48.4
±3.6
48.6
±2.9
49.1
±3.6

9.
%
p=.612
% p=.596
p=.994
%p=.972
P -.69 8
% p=.629
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TA BLE 4 .3 E P H A S E III - M A CRO NU TRIENT FO O D
C H O IC E S C O N T R A S T S O F C H O C O L A T E C H O IC E S*
Treatment Ovariectomized

OV+1713
Estradiol

OV + 178
Estradiol +
P roges
terone
High Fat/ 330.0 ± 65.4 271.9 ± 38.3 400.4 ± 4 1 .8
High
(48.9g)
Sugar
(71.9g)
(599)
C hoco
late cal.
%
31.3 ±5.2
33.9±5.5
40.8±3.9
High Fat/ 32.1 ± 8 .7
13.9 ±3.9
53.3±12.1
(a,b)
Low
(a)
(b)
Sugar
C hocolate (6.2g)
(2.7g)
(10.3g)
cal.
3.2±0.7
1.5±.4
%
5.3±1.1
Low Fat/ 54.9 ± 2 1 .4
42.2 ± 8.5
46.6 ± 12.1
High
(20.7g)
(15.9g)
(17.6g)
Sugar
C hocolate
cal.
%
4.6±0.9
6.2±2.6
4.6±1.1
27.1 ±5.3
20.7 ± 2.8
Low Fat/ 22.8 ± 4.7
Low
(19.2g)
S u g ar
(22.8g)
(17.4g)
C hocolate
cal.
2.6±0.6
3.0±0.5
2.2±0.3
%
*AII chocolate combined:
Total kcal
439.8.
355.1
% Total kcal 46.7%
39.5%

521.0
53.3%

OV +
Progesterone

p value

346.3 ± 49.1 p=.302
(62.2g)
34.7±3.4
41.3± 10.9
(a,b)

p=.483
p=.036

(8.0g)
p=.024
4.3±1.1
33.7 ± 10.0 p=.757
(12.7g)
3.7±1.1
27.0 ± 5.5

p=.729
p=.757

(22.7g)
3.0±0.7

p=.675

448.4
45.4%

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc com parisons
% of gain is for this 10 day period
% of total caloric intake show s total for phase (chocolate only)
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TOTAL CHOCOLATE
All groups that were given chocolate dem onstrated a preference for
High Fat/ High sugar chocolate, consuming from 272 to 400 kcal of this food
choice. All other chocolate choices were ingested in sm aller amounts. E&P
consum ed higher levels of HF/LS than E (Total & % Table 4.3E). P consum ed
higher levels of the HF/LS than the Non P (Total & % ). The effect of P w as a
greater than E or E&P on HF/LS chocolate intake (4 group ANOVA factorial
p200).

During this phase, 40 - 53% of calories consum ed cam e from the

chocolate food choices.
DISCUSSION OF PHASE III
The overriding effect of chocolate on food choice, body weight gain and
caloric regulation in P hase III w as a new contribution in this research.

The

paste form w as similar to the consistency of bonbons. Much higher levels of
chocolate consumption than previously expected were recorded.

Careful

observation of the data revealed that the rats increased their preference for the
chocolate food cups across all treatm ent groups, and did so to the exclusion of
the more macronutrient dense selections, FAT, CHO and PRO. T hese three
macronutrient food choices had been carefully planned and balanced to
provide all essential vitamins and minerals but were dramatically excluded in
preference to chocolate. The S group did not receive the chocolate choices
but served a s a comparison group of endogenous hormonal effects on FAT,
CHO, and PRO in the normally cycling rat of the sam e age. When the S group
w as included for comparison, the following significant differences w ere
observed: body weight, caloric intake, and caloric conversion ratio differences.
Therefore, not surprisingly, in group contrasts, S w as significantly different
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than H. Figures 8.0 through 10.0 (pp 215-217) give the reader a review of the
five group comparisons. The tables and analyses in this section for P h ase III
reflect four group com parisons in total and percent. Body weight, caloric
intake, and caloric conversion ratios in the four groups were not significantly
different.
Macronutrient choices a s influenced by horm ones were evident but no
differences were observed in the SW/NSW CHO profile in the analyses in
phase III. Factorial analysis provided additional information with regard to the
E&P effect of protein consumption.

This indicates that the combination of

horm ones h as a more powerful influence on protein consumption than when
estrogen and progesterone are administered separately. To parallel the
evidence from the current study with the human female; estrus com pares to the
follicular phase when estrogen levels are endogenously higher and diestrus
com pares to the luteal phase when progesterone levels are elevated.

The

reader will recall that E&P is typically prescribed for women with a uterus and
E alone to those who have had a hysterectomy.
The question: do horm ones affect chocolate consumption w as clearly
answ ered. The overriding effect of HF/HS chocolate on macronutrient choices
in the OV retired breeder female rat w as quite evident. The suppressing effect
of estrogen on body weight in P hase I and the suppressing effect of
progesterone on body weight in phase II w as “wiped out” in phase III when
chocolate w as presented a s a food choice. The only significant differences in
chocolate consumption in phase III were the preferences for HF/LS in the E&P
vs E treatm ents and the group contrasts in P vs. NonP. In this case, the fat in
the chocolate (HF/LS) seem ed to be a greater attraction than the sucrose to
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the E&P group. When E and P effects (for HF/LS) were com pared in factorial
analysis the P effect w as greater than either the E&P combined or the E alone.
In a broader sen se, this may indicate that fem ales on a continuous com bined
regimen

of estrogen

(Premarin®)

and

progesterone

(Provera®)

may

experience a greater attraction to chocolate, regardless of sw eet flavor
sources. And that when P levels are higher (in the luteal p h ase or w hen
cyclical hormone replacem ent is prescribed, E for 12 days and E&P for 12
days), FAT and chocolate are more important than sucrose. Chocolate and fat
may be craved (in contrast to sugar) when both E and P are elevated (in
diestrus in the rat) (luteal phase in the cycling female) and when progesterone
is taken in hormone replacement therapy.
This indicates that the progesterone effect relates more to fat choice
than to sucrose preference. This progesterone effect w as further em phasized
in group analysis in both total and percent. P treated animals preferred the
HF/LS in significantly greater quantities than Non P treated animals. This
show s that the rat can discriminate between sw eet flavors when they are
combined with chocolate and FAT. This potential parallel to the human a d d s
merit to the use of the Sprague-Dawley rat in this type of

research.

The

hum an literature strongly reports the progesterone effect of chocolate and FAT
choices in the luteal phase when progesterone levels are high. This may help
explain the hypothesis of preferred (craved) fat and chocolate intake just prior
to menstruation.
The increase in total chocolate calories em phasizes the attraction to
chocolate com pared to the more nutrient dense foods. They w ere clearly
ignored in preference to chocolate.

It is presum ed that the S group would
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also have chosen chocolate had the choice been given and that chocolate
would also have increased

the S body weight. Further research should be

conducted to determine if the surgical effect of the removal of the ovaries
affected th ese food choices or altered metabolic conversion rates.
This evidence challenges the Bowen and Grunberg (1990) hypothesis
which reported

increased

sw eet preference

in the luteal

phase

with

docum ented progesterone levels. However, the reader will recall that their
sw eet choices also included fat and chocolate. This evidence ag rees with the
earlier work by Abraham (1984) who reported cravings for chocolate in the
luteal phase. Pliner and Fleming (1983) also found that both body weight and
food intake were significantly higher during the luteal phase than during the
follicular phase in menstruating women. In a later study (1983) they also
reported decreased sucrose preference both before and after a sucrose load
during the luteal p h ase but not in the follicular phase.
Aaron’s work (1975) which supports these findings reported greater
p leasan tn ess of the sw eet taste in the follicular phase which lowered during
the luteal phase when progesterone levels were higher and estradiol an d
estrone were lower. Without regard for the hormonal phase, Smith and Sauder
(1969) stated that 85% of those who craved chocolates also included
them selves in the group that craved sw eets. The current data clearly indicate
that eating behavior research should always reveal the stag e in the m enstrual
cycle or source of exogenous horm ones when reporting food intake data in the
future.
T hese results also em phasize the importance of studying not only su g ar
preference but also fat preference. When the evidence from the three p h a se s
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is combined, the ‘leasing out” of the sweet, fat and chocolate com ponents are
possible. In phase I , H (E and P) consum ed a significantly higher % of dietary
FAT than OV. And P treated animals consum ed significantly more total FAT
than NonP. Evidence from phase II clearly indicates a sw eet preference (3
tim es higher) in the E&P treated animals over nonsw eet carbohydrate. And in
P h ase III, the study show s that the high fat/low sugar chocolate is preferred by
the E&P animals in contrast to E. This indicates that in the aging fem ale rat,
FAT and chocolate may be preferentially chosen over the sw eet when both
estrogen and progesterone levels are elevated. This also provides evidence
of the value of using the sam e rats over the 30 day study under the influence of
the sam e horm ones with three different food choice patterns.

Through varying

the macronutrients in phase I we were able to discern hormonal effects on the
choice of FAT, CHO or PRO. In phase II we were able to further discriminate
betw een the sw eet and nonsweet. Then in phase III we were able to se p ara te
the hormonal effects further with the four caloric levels of chocolate by
separating high and low fat levels with saccharin and sucrose and observing
the P effect of FAT and chocolate over sucrose.
Flavor, palatability and the opioid effect of chocolate are

likely

contributing factors (Drenowski, 1985). Data on the preferred HF/HS type of
chocolate were also observed (Giraudo, et al., 1993). The rats chose the more
palatable chocolate choices a s is typically seen in the human population. No
definitive evidence in animals or hum ans w as reported to explain the
preference for chocolate.

Discriminatory palatability

differences

in the

Sprague-D aw ley rat have been shown in earlier taste tests in rats (Hamilton,
et al., 1995). Addition research is needed to investigate the excessively high
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levels {40-53% during the

10 day study) of chocolate

intake

in all

ovariectomized animals.
This paste form of chocolate in four caloric levels may be a new addition
to the eating behavior taste research arena. The paste form used w as quite
palatable, easy to m anage, and the most acceptable form of chocolate chosen
by rats in a pilot study when chocolate chips, chocolate bars, chocolate syrup
and the paste form were compared.
No female

rat studies comparing

chocolate

consumption

under

hormonal influence have been reported. However, earlier studies m easuring
other param eters have reported the use of chocolate in the Sprague-D aw ley
rat (Runyan et al, 1990, Richard et al, 1982). In one such study, cocoa pow der
w as fed to male and female Sprague-Dawley rats in a multi-generational study
to exam ine toxicity and carcinogenicity (likelihood of cancer). No evidence of
carcinogenicity w as reported in either gender (Tarka, et al., 1991).
Few recent human chocolate eating behavior studies have been
conducted which m easure hormonal influences. One human study m easuring
fat, carbohydrate and chocolate indicated increasing preferences for chocolate
a s body weight increased and obesity advanced over time (Drewnowski, et al.,
1985). Increased body weight w as positively correlated to food preferences
for fats, sw eets and chocolate. In another study, Hetherington & Macdiarmid
(1995) m easured responses to three different presentations of chocolate in
two groups of females: overeaters and m oderate eaters. Three conditions of
presentation were (a) a fixed amount of milk chocolate; (b) ad lib a cc ess to
milk chocolate; and (c) a self-selected amount of the individual's most
preferred form of chocolate. The results revealed that variables associated
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with the excitation of appetite were higher in overeaters and variables
associated with the inhibition of appetite were lower in the overeaters relative
to the controls. This study suggests that investigations of individuals who eat
certain foods to ex cess can help define normative and aberrant eating
behavior.

This is an important contribution in eating behavior research.

However,

actual

levels

of chocolate

intake

were

not

reported.

The

m easurem ent of hormonal profiles in future female studies should be
docum ented and correlated to food intake param eters.
Interestingly, in the present study with chocolate consumption in p h a se
III, rats increased caloric intake compared to phase II, and no significant
differences were observed in body weight gain and total caloric intake within
this 10 day period in the four groups receiving chocolate choices. Also, no
differences were observed in overall FAT, CHO, and PRO intake which
included the fat and carbohydrate from the chocolate choices.

The actual

intake of the nutrient rich FAT, CHO, and PRO food choices w as decreased a s
fat and carbohydrate were consum ed from the HF/HS chocolate choice.
Choices from the chocolate food cups which w ere consum ed in large
quantities (40-53% of caloric intake) were nutrient deficient. This m eans that
the rats were not consum ing a nutritionally balanced diet. With respect
micronutrients,

they

were

getting

about

one-half

the

daily

to

NRC

recom m endations (R eeves et al, 1993). While this is not critical for a ten day
study period, on a long term basis the animals may becom e seriously
deficient, depending on individual requirements. Aging human fem ales may
also choose nutrient deficient snack foods to the exclusion of more nutrient
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dense foods that could help combat osteoporosis, B-vitamin deficiencies and
other nutrient related diseases.
Often in the human, the additional chocolate is eaten for dessert. To
date we do not have conclusive evidence in the aging female a s to w hether
this is added a s ex cess caloric intake or is chosen a s the major portion of the
diet in preference to nutrient dense foods a s w as observed with the female rat.
However, the rats did increase total caloric intake by 9.24% from phase II to
phase III when the caloric preference included chocolate. Both the rat and the
hum an female may choose chocolate in preference to more nutrient d e n se
foods when the choice in available with subsequent body weight increase and
negative health benefits.
RESULTS: ACROSS ALL PHASES
The following results are reported for both five and four group analysis.
Data in tables are based on 5 group ANOVA. All percentages, contrasts an d
factorials are in the appendixes. There are limitations in the interpretation of
th ese data across all phases. One w eakness is that the sam e anim als w ere
used throughout the 3 p h ases in the 30 day study. Ideally animals would have
been sacrificed at the conclusion of each phase.
BODY WEIGHT
Five Group Analysis: Total body weight w as higher in the OV and P
anim als com pared to the S over the 3 p h ases in both total and %(Table
4.4A).Group contrasts revealed that in averages over the 30 days, S w as lower
than H, OV w as higher than H, E w as lower than Non E (Total & % Table 4.4B).
Four Group Analysis: The total body weight w as higher in the OV
anim als com pared to H and E w as significantly lower than Non E (4 group
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Total & % ANOVA contrasts p 201). An estrogen effect w as observed (4 group
ANOVA factorial p202) which m eans that E had a greater effect on d e creased
body weight than E&P or P alone.
TOTAL CALORIES
Five Group Analysis: The average in total caloric intake over the three
p h a se s for S w as lower than the averages for E, E&P, P, and OV (Total & %
Table 4.4A). S w as lower than H (total) and E revealed a trend of a lower
average caloric intake than Non E in group contrasts (Table 4.4B).
Four Group Analysis: ANOVA showed no significant differences in the
caloric intake across the phases (4 group ANOVA).
CALORIC CONVERSION RATIO
Five Group Analysis: S w as lower than P and OV (Total & % Table 4.4
A). S w as lower than H, and E w as lower than Non E (Total Table 4.4B) in
group contrasts. An effect w as observed in factorial analysis (p203).
Four Group Analysis: A trend, P..058, w as observed in 4 groups (p202).
E w as lower than Non E (Total 4 group ANOVA p202).
TOTAL FAT
Five Group Analysis: Total fat intake w as not significantly different
(Table 4.4C). OV w as lower in percentage (not total) of fat consum ed than H
across all p h ases (Table 4.4D) (Figure 14 & 16 p221-223).
Four Group Analysis: No differences were observed.
TOTAL PROTEIN
Five Group Analysis: S and P consum ed less protein than E&P (Total &
% Table 4.4C). S consum ed less protein than H (Total Table 4.4D).
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TA BLE 4.4A TOTAL STUDY - BODY W EIGHT GAIN AND
TO TA L CA LO R IC INTAKE AND C O N V ER SIO N R A T IO S
Treatment

S ham

Ovariectomized

OV +1713 OV + 1 7 6 OV + Pro
Estradiol Estradiol gesterone
and Pro
gesterone
11
12
10

ANOV
A

P

value

Number of 12
10
Ani-mals (n)
Total
27.3± 4.4 61.4 ± 6.5 39.9± 5.2 44.6 ± 3.2 57.7 ± 6.0 p=.001
Weight
(a ,b )
(a ,b )
(a)
(b )
(b )
Gain (g)

(a)

(b )

12.2 ±
1.8(a)

22.1 ± 2 .8 16.0±.2.0 16.8 ±1.1
(a,b)
(a,b)
(b )

(b )

(b )

o
o

16%(a,b) 16.7%(a,b) 21% (b)
10% (a) 23% (b)
2184±69 2794±144 2493 ±83 2650 ± 93 2743±100 p=.001
T3
II

% gain
Total
Caloric
intake (kcal)
Conversion
Ratio •

(b )

21.0 ± 2 .0 p=.003
(b )

Values are m eans ± SE. Means in the sam e row with the different superscripts
are significantly different from each other by Schefte’s S procedure for posthoc com parisons
• Conversion ratio is body weight increase divided by total caloric intake over
30 days x 1000 or g wt. gained/1000 kcal consum ed
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TA BLE 4 .4 B TOTAL STUDY - G R O U P C O N T R A S T S O F
BODY W EIGHT GAIN AND TOTAL CA LO RIC INTAKE
Treat n

Total Weight p value
Gain*
9
% %

9
12 27.3
10.4
S
±4.4
vs
±1.8
H
17.6
33 47.0
±1.1
±4.8
23.1
Ov
10 61.4
vs
±6.5
±2.4
H
17.6
33 47.0
±4.8
±1.1
E
16.2
23 42.3
vs
±2.8
±1.2
N oE 20 60.5
21.9
±4.4
±1.6
P
22 50.6
18.6
vs
±3.4
±1.2
19.2
N o P 21 50.1
±4.7
±1.8
*Mean ± SEM, a.05

p=.001

Total
p value Conversion p value
Calorie
Ratio
Intake*
kcal
Mean±SEM
Mean±SEM
2184 ± 7 0 p= .002 12.2±1.8
p=.008

%p=.001 2627 ± 47
p=.024

17.8±2.0

2794 ± 144 p - .165 22.1 ±2.3

%p=.024 2627 ± 47

17.8±2.0

2582 ± 61

p= .053 16.3±1.0

%p=.005 2769 ± 90

21.9±1.5

2692 ± 67

p= .599 18.7±1.1

%p=.998 2636 ± 86

18.9±1.6

p=.001

p=.917

Sham = S
Hormones = E, P, E&P
Ovariectomized = OV, no hormones
Estrogen = E, E&P
No Estrogen = OV, P
Progesterone = P E&P
No progesterone = OV, E

p=.063

p=.008

p=.920
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TA BLE 4 .4 C

TOTAL STUDY - M ACRO NU TRIENT
FO O D C H O IC E S IN KCAL

Treatm ent Sham

Ovariectomized

Number of 12
Animals

10

OV + 17B OV + 17fB
Estradiol Estradiol
and Pro
g esterone
12
11

OV +
P ro g es
terone

ANOVA
p value

10

(n)
Intake of 811 ±90
C arbohy (a)
drates
(Calories)

1499± 112 1086± 117 1067± 65 1241±131 p=.001
(a,b)
(a,b)
(a.b)
(b)

% of total 38.0%
118±17
Intake of
Protein
(a)
(Calories)

53.9%
235 ± 31
(a,b)

43.6%
172 ± 3 0
(a,b)

40.4%
291 ± 30
(b)

46.1%
149 ± 2 8

p=.082
p=.001

(a)

% of total 5.5%(b)
8.6%(a,b) 7.1%(a,b) 11.2%(a) 5.4%(b) p=.003
Intake of
1255±137 1060± 130 1236±142 1291 ±101 1352±197 p=.701
Fat
(Calories)
% of total

56.5%

37.5%

49.3%

48.3%

48.5%

p=.088

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheff6’s S procedure for posthoc com parisons
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TA BLE 4 .4 D G R O U P C O N T R A ST S O F TOTAL STUDY
M A CR O N U TRIEN T FO O D C H O IC E S INTAKE
Tmt

n Intake of
p value
Carbohydrate
★

total
S
12 811
vs
±90
H
33 1126
±104
OV
10 1499
vs
±112
H
33 1126
±104
E
23 1057
vs
±64
Non 20 1410
E
±84
P
22 1146
vs
±70
NonP 21 1283
±92

total
%%
38.0 p=.008
±4.7
43.2 %p=.057
±2.2
53.9 p=.004
±3.5
43.2 %p=.036
±2.2
42.0 p=.007
±2.4
50.0 p=.051
±3.1
43.0 p=.192
±2.7
48.5 %p=.212
±2.9

Intake of
Protein*
total
118
±17
208
±29
235
±31
208
±29
227
±24
199
±23
227
±27
202
±22

*Mean ± SEM, a.05
Sham = S
Hormones = E, P, E&P
Ovariectomized = OV, no hormones
Estrogen = E, E&P
Non Estrogen = OV, P
Progesterone = P, E&P
Non progesterone = OV, E

p value

%
5.5
±.8
8.1
±.8
8.6
±1.2
8.1
±.8
9.3
±1.1
7.0
±.8
8.6
±1.1
7.8
±.9

total
%
p=.007
%p=.061
p=.352
% p=.396
p=.164
%p=.194
p=.541
%p=.612

Intake of
Fat*
total
1255
±137
1291
±147
1060
±130
1291
±147
1298
±87
1161
±117
1319
±102
1152
±96

p value

total
% %
56.5 p=.812
±5.1
48.7 %p=.961
±2.5
37.5 p=.176
±3.8
48.7 %p=.046
±2.5
48.8 p=.692
±2.8
43.0 % p=.716
±3.6
48.4 p=.232
±3.0
43.7 %p=.295
±3.3
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Four Group Analysis: E&P animals consum ed more protein than both E
and P treatm ent groups (Total p203). An E&P effect w as observed (4 group
ANOVA factorial p 203).

This m eans that the presence of estrogen with

progesterone had a more significant impact on protein consumption than
estrogen or progesterone alone.
TOTAL CARBOHYDRATE
Five Group Analysis: Carbohydrate

intake w as lower in S than OV

(Total Table 4.4C). S consum ed less than H (total), OV consum ed more than
H (total & %), E consum ed less than Non E (total), (Table 4.4D).
Four Group Analysis: OV w as higher than H, and E w as lower than Non
E (Total 4 group ANOVA p203).

An estrogen effect w as shown on

carbohydrate intake (4 group ANOVA factorial p204).

This m eans that the

p resen ce of estrogen alone had a more significant impact on lowered CHO
intake than P or E&P.
POSTMORTEM ANALYSIS
TOTAL BODY COMPOSITION
Total body composition w as compared using a percentage basis to
correct for the larger and sm aller rats (Table 4.4E). No significant differences
for the percentage of body fat were observed by the ether extraction method.
No differences in percentage of moisture were determined in m easures of
carcass hom ogenate taken in a drying oven (Table 4.4E). Neither w ere there
percentage differences observed in total body composition from protein.
(Table 4.4E).
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CHOLESTEROL
Levels of serum cholesterol in the S treatm ent were lower (Table 4.4F)
than the H treated animals (5 group ANOVA group contrasts p226).
HDL CHOLESTEROL
Additionally levels of serum HDL Cholesterol were lower (Table 4.4F) in
S than H (5 group ANOVA group contrasts p228).
CHOLESTEROL-HDL RATIO
No significant differences in total cholesterol to HDL ratios w ere
observed am ong treatm ents (p225-226).
SERUM ESTROGEN
No significant differences in serum estrogen levels were observed
(Table 4.4G).
SERUM PROGESTERONE
A significant difference w as observed in serum progesterone (Total
Table 4.4G, and 4 group ANOVA p205).
SERUM TESTOSTERONE
No significant differences were observed in 5 group serum testosterone
levels (Table 4.4G, 4 group ANOVA p205). Group contrasts revealed
differences in 4 groups analysis. P vs. NonP revealed significant differences
in testosterone levels (Total 4 group ANOVA p205).
WEIGHT OF HEART
No significant differences in heart weight were observed among the
treatm ents (Table 4.4H).
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TA BLE 4 .4 E
Treatm ent Sham

TOTAL STUDY - BODY C O M PO SITIO N
Ovariectomized

O V +17B
Estradiol

Number of 12
8
10
Animals(n)
8.21± .37 8.22 ± .72 9.10 ± .7 8
Fat (%)
Protein (%) 9.77 ± .15 9.29 ± .25 10.07±.71

OV + 173
Estradiol
and Pro
gesterone
11

OV +
Proges
terone

ANOVA
p value

11

10.0± .48 8.95 ± .39 p=.141
9.3 ± .23 9.00 ± .1 9 p=.240

W ater (%) 80.30±.52 81.30±.58 79.60±1.42 79.20±.63 80.40±.22 p=.466
Values are m ean s ± SE.
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TA BLE 4 .4 F TOTAL STUDY - C H O L E ST E R O L AND HIGH
D EN SITY L IP O PR O T E IN C H O L E S T E R O L
Treatm ent

Sham

Number of 12
Animals (n)
Cholesterol 82.3
mg/dl
± 5.1
Group
(a )v
C ontrasts
HDL
71.8
Cholesterol ± 4 .5
mg/dl
Group
C ontrasts

a) V

Ovariectomized

10

OV + 1 7 0 OV +1713
Estradiol Estradiol
and Progesteron
e
11
12

105
± 5 .6

102.0
± 7 .6

110.0
± 7 .9

101.0
±11.7

p=.116

(b
80.8
± 5 .0

(b)*
87.7
± 7 .7

(b)*
93.6
± 7 .6

(b)*
84.4
+9.0

p=.014
p=.216

(b)*

(b)*

(b)*

(b)*

p=.034

r

OV + Pro- ANOV
gesteron A
e
p value

10

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc com parisons,
v * D enotes group contrasts.
Group m eans: CHOL: S: (82.3±5.1), OV (104.5±8.2)
HDL-C: S:(71.8±4.5), OV (86.6±7.3)
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TA BLE 4 .4 G HORM ONE LEVELS BY
R A D IO A M M U N O A SSA Y
Treatm ent

Sham

Number of
Animals (n)
Estradiol

12

Ovariec- OV +
OV +17R OV +
ANOVA
tomized 178
Estradiol P roges p value
Estradiol plus Pro terone
gesterone
11
11
10
11

141.0
± 4 6 .6

79.0
± 2 4 .7

142.0
± 2 1 .2

140.0
± 18.6

109.0
± 29.6

p=.521

Progesterone

10.1
± 2 .2

4.9
± 1.7

4.2
±.9

11.0
± 2 .8

18.7
± 6 .3

p=.033

T estosterone

.97 ± .46 .08 ± .08 .37 ± .29 .05 ± .03 .65 ± .32 p=.139

Group contrasts (a.b)

(b)

(b)

(a)

(a)

p=.050

Values are m eans ± SE. Means in the sam e row with the different superscripts
are significantly different from each other by Scheffe's S procedure for posthoc com parisons
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WEIGHT OF LIVER
S had lower liver weights than E&P and P (Total Table 4.4H). S and OV
also had lower liver weights than H (Table 4.4I).
WEIGHT OF UTERUS
Five Group Analysis: OV and P were lower than E&P, E, and S (Total
Table 4.4H). S w as higher than H, OV w as lower than H, E ( total Table 4.4I
p204).
Four Group Analysis: Both OV and P were lower than E&P and E (Total
p233). OV uterine weights were lower than H and E w as higher than Non E
(Total p206). An estrogen effect on uterine weights w as observed (4 group
ANOVA factorial p206).
FAT PERCENTAGE OF LIVER
Five Group Analysis: Percentage fat (% Table 4.4J ) in the E group w as
lower than Non E,
Four Group Analysis: An E effect w as observed in liver fat content (% 4
group ANOVA factorial, p207).
WEIGHT TO LENGTH RATIO
Five Group Analysis: E treated anim als had a lower (Total Table 4.4 K)
weight to length ratio than Non E.
Four Group Analysis: An E effect w as observed in weight to length ratios
(4 group ANOVA factorial, p 207).
DISCUSSION OF THE TOTAL STUDY
T hese data for the total study across all phases indicate that exogenou s
female sex horm ones affect caloric conversion ratios in retired breeder female
rats given novel food choices. And that over time the rats treated with
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TA BLE 4.4H TOTAL STUDY - W EIGHT O F O R G A N S
Treatm ent

Sham

Ovariecto- OV +1713 OV +1713
mized
Estradiol Estradiol
and
Progester
one
12
10
11

OV +
ANOVA
Progester p Value
on e

Number of 12
Animals (n)
Weight of
.74
Uterus (g) ± .0 5

.24
± .0 3

.62
± .05

.61
± .0 5

.40
± .0 4

p=.001

Weight of
Heart (g)

1.17
± .04

1.27
± .07

1.2
± .0 3

1.21
± .07

1.29
± .0 5

p -4 5 8

Weight of
Liver (g)

9.15
± .2 3

9.85
±.19

10.40
±.32

10.50
±.24

10.60
±.37

p=.002

10

Values are m eans ± SE. Means in the sam e row with different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc comparisons.
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TA BLE 4.41 TOTAL STUDY G R O U P
C O N T R A S T S F O R W EIG H T O F O R G A N S
Treat
ment

n

S vs

12

H

33

OV vs

10

H

33

E vs

23

Non E

20

P vs

22

Non P

21

Weight P
of
value
Uterus
Mean ±
SEM
.738 ± p=.001
.049
.545 ±
.046
.242 ± p=.001
.026
.545 ±
.046
.616 ± p=.001
.047
.322 ±
.035
.508 ± p=.091
.046
.430 ±
.037

Weight P
Weight P
of
value
value of
Heart
Liver
Mean ±
Mean ±
SEM
SEM
1.17 ± p=.254 9.15 ± p=.001
.04
.23
1.23 ±
10.50 ±
.31
.05
1.27 ± p=.625 9.85 ± p=.052
.07
.186
1.23 ±
10.50 ±
.05
.31
1.21 ± p=.174 10.50 ± p=.488
.28
.06
1.28 ±
10.20 ±
.28
.06
1.25 ± p=.713 10.60 ± p=.096
.31
.06
1.24 ±
10.10 ±
.05
.25

Sham = S
Hormones = E, P, E&P
Ovariectomized = OV, no horm ones
Estrogen = E, E&P
No Estrogen = OV, P
Progesterone = P E&P
No progesterone = OV, E

Weight
of
Bone
Mean ±
SEM
1.19 ±
.05
1.14 ±
.04
1.17 ±
.05
1.14 ±
.04
1.13 ±
.04
1.17 ±
.05
1.17 ±
.05
1.13 ±
.05

P
value

p=.355

p=.589

p=.431

p=.483
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TABLE 4.4J % FAT CONTENT OF THE LIVERS
Treatm ent

Sham

Number of 12
Animals (n)
Fat (%)
1.4±.2
Group
contrasts

ml

Ovariec- OV +17(3 OV+ 1713 OV +
tomized Estradiol Estradiol P roges
and Pro- terone
gesteron
e
10
10
11
12

ANOVA
p value

1.9 ± .3

1.3 ± .2

1,2± .1

2.1 ± .4

p=.086

w

<b)

w

w

p=.010

Values are m eans ± SE. M eans in the sam e row with the different superscripts
are significantly different from each other by Scheffe’s S procedure for posthoc comparisons. It should also be noted that factorial analysis show s
significant effects of estrogen at (p=.02).
Group m eans: E: (1.3± .5), lower than NonE (2.0 ± .4) in group contrasts.
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TA BLE 4 .4 K
Treatm ent

S ham

Number of 12
Animals (n)
Weight to
16.7
Length
± .4
Ratio g/cm
A
Group
C ontrasts

TOTAL STUDY - W EIGHT TO LENGTH
R A T IO S
Ovariectomized

OV +
ANOVA
P roges p value
terone

10

OV +1713 OV+ 1713
Estradiol Estradiol
and Pro
gesterone
11
12

18.3
± .5

16.8
±.4

17.2
± .4

18.3
± .4

(a)

(b)

(b)

10

___

p=.015

p=.004

Values are m eans ± SE. Means in the sam e row with the different
superscripts are significantly different from each other by Scheffe’s S
procedure for post-hoc com parisons
A Weight to length ratio is length in centim eters divided by weight in gram s
Group m eans: E: (17±.4) lower than NonE (18.3±.5).
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exogenous fem ale sex horm ones regulate body weight. Evidence of this
regulation phenom onen is the caloric conversion ratio for phase II which w as
lower than for phase I and phase III. In order to exam ine th ese param eters
separately in an aging model over time the combined effects of the 30 day
study also seem worthy of consideration. Eating behavior literature typically
reflects this type of data collection. Therefore, the following report relates the
statistical analysis of all three phases combined.
The carryover effect from phase to phase of the body weight param eter
and sub sequent effects on body composition should be noted. The effect can
be m oderated by considering the % weight gain and growth rates in the
animals. In future studies, the collection of body weight data from the day the
horm ones

were

implanted

is recommended.

Significant

body

weight

differences may also be due to growth rates (Figure 17.0) and interactions with
exogenous hormones.

A recent study addressing body weight changes,

indicates that children had significantly greater percentages in body weight
changes than their adult parents, which indicates that caloric conversion ratio
differences can be age related (Epstein et. al., 1995). Growth hormone which
h a s recently been approved by FDA for human use in this country could be
m easured in future studies. The future m easurem ent of insulin is also
r

recom m ended.

The observations within each phase have already been

presented. The results at the end of the study are a summary of the hormonal
effects for the 30 day period (Figures 1.0-17.0 pp 208-224).
The estrogen effect on body weight a s observed by W ade & S chneid er
(1992) w as found only by factorial analysis when the results were com bined
over the 30 day study. When Sham is removed for four group analysis E is
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significantly lower than the OV treatment. Body weight w as higher in the OV
and P treatm ents in both total and percent when com pared with the sham in
five group analysis. As previously stated, this may reflect chocolate choices not
allowed by the S group and E effects on suppressed body weight. Group
contrasts with five groups reveal H to be significantly higher than S, And in
both four and five group analysis OV w as higher than H and Non E higher than
E. The application to hormonal effects on body weight in the hum an forms a
nice parallel.

The endogenous

estrogen

pool

representative of the

prem enopausal female appears to keep body weight at lower levels.

Once

surgical or natural m enopause occurs, the natural endogenous source in
removed.

Exogenous estrogen appears to keep body weight gain lower

com pared to the increased body weight gain in the OV female with no
exogenous supplemental hormonal therapy.
The more interesting concept in the aging model is the evidence that
under hormonal influence, calories are converted into body weight at varying
d eg rees a s shown in significant differences in caloric conversion ratios. The
higher the caloric conversion ratio, the fewer kcal are required to gain a gram
of body weight. Calories in this c a se are more efficiently converted. Both OV
and P conversion ratios were significantly higher than S.

Factorial analysis

also revealed an estrogen effect on lower caloric conversion ratios. Group
contrasts confirmed the aging human model implications; ovariectom ized
anim als

given

hormone

conversion ratios than S.

supplem ents

had

significantly

higher

caloric

Non E conversion ratios were higher than E.

Estrogen would appear to suppress caloric conversion into body weight in
both the ovariectomized and normally cycling females.
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Macronutrient choices were significantly different but not in ways which
were expected. An interesting new concept w as that hormone treated anim als
ch o se higher percentage levels of FAT than OV with significantly lower body
weights. PRO w as chosen by the E&P group in significantly higher levels than
the S and P which w as confirmed by factorial analysis.

Group contrasts

identified higher levels of PRO intake in H treated animals com pared to S.
This may be of value if the PRO intake is chosen in the form of red m eat in the
bleeding postm enopausal female who may be deficient in hem e iron.
CHO w as consum ed in greater quantities in the OV animals com pared
to S. In this study higher levels of CHO in the OV anim als resulted in
significantly higher body weight gain. Estrogen had a greater influence alone
than P or combined E&P in suppressing CHO intake. When grouped, with
regard to CHO consumption, OV w as significantly higher than H, Non E higher
than E and H w as higher than S. The hormonally untreated postm enopausal
fem ale model may consum e higher quantities of highly refined carbohydrate
snack foods, convert calories into body weight more efficiently and ultimately
gain more body weight than those who receive exogenous female sex
horm ones.
The evidence of hormonal effects on body weight gain, macronutrient
food choices and caloric regulation w as observed early in the study, when
estrogen implanted animals gained significantly less body weight than the
progesterone and OV animals. Further, the additional body weight gain effects
of progesterone were of short duration, which may occur at the onset on
m enopause or immediately following surgical

removal of the ovaries.

Progesterone effects of increased fat and chocolate intake are often observed

138

in the younger female in the luteal phase followed by periods of fasting during
the m enses or follicular phase (Dalvitt-McPhillips, 1983). This adds strength to
the argum ent that the Sprague-Dawley female rat is a good model to study in
examining human pharmaceutical and physiological questions.

Earlier

studies in the intact female rat have shown greater caloric intake and body
weight in the diestrus phase when progesterone levels are elevated (Gray &
Greenwood, 1983). T hese data also agree with the estrogen effect observed in
younger rats in earlier studies which reflects decreased body weight gain and
the trend to lower caloric intake in estrus when estrogen is elevated (Wade,
1975, 1976). The more meaningful interpretation of th ese physiological
endocrine param eters to the aging female may be that the declining estrogen
pool seen during this period of life (Wing, 1992) may contribute to metabolic
alterations leading to the additional body weight observed in the aging rat
model in this study.
The rats in this study may have adapted a s evidenced by reduced body
weight possibly via a setpoint m echanism over time. In phase II, the second
ten day period, the rate of gain decreased for S, E&P and P when com pared to
the first 10 days of the study for phase I. Body weight increased again in
p h ase III when chocolate w as available. In this study, higher CHO both a s a
total and percentage of calories consum ed w as identified with ovariectomy
and increased caloric conversion to body weight gain. Increased fat intake
both a s a total and percentage of calories consum ed w as observed in
treatm ent groups with decreased
conversion ratios.

body weight gain and lower caloric

T hese concepts are clearly contradictory to current

hypotheses that low fat diets produce decreased body weight gain.

The
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evidence shown by the changes in caloric conversion ratios could indicate
physiological and metabolic m echanism s which should be investigated in
future research.
Before th ese conclusions can be considered for potential theoretical
change, the potential w eaknesses which could have affected in th ese results
should be discussed. Inclusion of the sham group in statistical analyses must
be ad d ressed b ecause the more palatable novel food choices were never
offered to this group. The sham group w as only offered the three nutrient
d en se food choices FAT, CHO and PRO throughout the study. This group
served a s a comparison and represented the normally cycling female. Future
studies should include a sham group which received all food choices. This
w as the original design of the study, but due to the high death rate following
the two surgeries early in the study, one group w as unfortunately eliminated.
Therefore the sam e three macronutrient food choices ingested throughout the
study could have affected the body weight data. There is a strong likelihood
that the sham group did not gain at the sam e rate due to the difference in food
choices. The other obvious factor is the difference in surgical processes which
left the ovaries in tact in the sham animals. Sham body weight w as less than
other treatm ents in all other p h ases except for p h ase I when all groups
received the sam e food choices. They did not receive the sam e SW/NSW
CHO and chocolate options in p h ases II and III, respectively,

a s the other

groups. This design and information may skew the results when the sham is
com pared to the other treatm ent groups.

The

other four groups

of

ovariectomized anim als who had acc ess to the more palatable choices
show ed clear preferences when the options were available in p h ase III. This
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h as marked implications for examining behavioral food choice m echanism s.
To extrapolate this evidence to the human model may indicate that when more
palatable food choices are available, th ese may be chosen to the exclusion of
other well balanced, nutrient dense foods that may not be a s delicious but are
nourishing and essential to good health. This concept ag rees with the work of
Rolls (1993) in the study of sensory specific satiety.
Caloric intake from the three macronutrient choices w as significantly
different in group contrasts between the sham and the horm one treated
anim als with a trend toward significance when estrogen and nonestrogen
were compared. No caloric intake differences were shown when only the four
treatm ent groups were individually compared. W hen macronutrient food
choices were observed and compared,

carbohydrate,

protein

and

fat

consumption were shown to be influenced by the hormone treatm ents. CHO
w as preferred by OV.

Protein choice w as almost twice a s high for E&P

com pared to the P, and a progesterone treatment effect on FAT consum ption
during the 30 day study period.
In the total study exogenous horm ones were clear indicators of body
weight differences between S and OV, with regard to caloric intake. Caloric
conversion for S w as lower than the for OV and P groups. Two additional
param eters that possibly played a role in this study which should be m easured
in future research are; the hormonal effects on increased voluntary exercise
and hormonally induced lethargy.
Due to the biases potentially created by the sham receiving the three
food choices throughout the study, the four OV groups should be discussed.
When the four OV groups were compared, E treatm ent resulted in lower caloric
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conversion of food intake into body weight than in the Non E treated animals.
Differences of caloric conversion ratio and body weight to length ratio both
revealed a trend between the OV and hormonally treated rats. The differences
in weight to length ratios may relate to the rate of growth in the rat model.
Exogenous female sex horm ones may alter length growth rates in rats.
Exogenous hormone treatm ents may increase involuntary activity, voluntary
exercise, or metabolic differences and should be exam ined in future research.
T h ese effects separately or combined may have influenced the data used to
calculate the rate at which calories are converted into body weight. Obviously,
in the four OV groups, ovariectomy results in the a b sen ce of end o g en o u s
estrogen influence. Exogenous estrogen prevented the increased body weight
which w as observed in the OV, P and S (endogenous) rats in phase I in this
study and in the OV and P in the total study (Galletti & Klopper, 1964; Gray &
Greenwood, 1984). Tracking the effects over longer periods of time in the
aging model may provide additional information.
At the conclusion of the study, animals were sacrificed and the post
mortem results were analyzed. The following could have affected the statistical
outcom es and should be mentioned. NonE treated animals w ere significantly
longer at the conclusion of the study than the E treated animals which could
affect body weight data. Liver weights were significantly higher in the E&P and
P treated anim als than S indicating the need for further analysis into the
hepatic markers related to exogenous female sex hormones.
The significantly different uterine weights confirm the bioactivity of the
exogenous

hormone

implants.

This

important

marker w as

shown

in

significantly different uterine weights with atrophy of the uterus clearly se e n in
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the OV group.

E and E&P implants were equally effective in approaching

m aintenance of pre-ovariectomy uterine weights. P alone could only partially
maintain uterine weight.

Thus estrogen w as the most critical hormone in

preventing atrophy of the uterus in the ovariectomized

rat.

The additional

biomarker used to a s s e s s the activity of the implants w as radioim m unoassay
of the serum to m easure progesterone, estradiol and testosterone. Serum
progesterone levels were significantly higher in the animals implanted with
progesterone. Testosterone levels were higher in animals with progesterone
implants.

Estradiol levels were not found to be significantly different.

Biological evidence of uterine weights clearly reveals that estradiol levels
were also different, however a more sensitive form of RIA analysis should be
used in the future to m easure this hormone.
Surprisingly, body fat distribution did not vary across the treatm ents. In
fact, total body composition (%) analysis revealed no significant differences in
fat, w ater and protein among the five treatm ent groups.

Mean

body

composition data, obtained upon sacrifice, show ed 9% of the total weight a s
fat, 11% a s protein, SO % a s body water. The rats consum ed almost half of
their caloric intake from fat, but deposited only 9% of it in body fat stores a s
shown in total body composition analysis. This information is contrary to earlier
reports by W ade and Gray (1979) in which adiposity w as m easured in term s of
lipoprotein lipase activity and correlated to increases in body fat storage. A
potential w eakness in the use of lipoprotein lipase a s a marker of changes on
body fat composition

is that lipoprotein

lipase

activity may

increase

proportionately a s body weight increases and may not necessarily reflect
differences in % body composition. Earlier studies reported lipoprotein lipase
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increased with increased body weight in the absence of m easures for protein
and w ater which were not m easured in proportional body composition.
Therefore the body fat composition (%) reported in W ade’s earlier studies may
not be different and therefore flawed in reporting. If increases in body fat a s a
percent of total body composition were reported by Wade, the results might
present a different picture. Similar results to those found in the present study
might be shown. Preliminary and concluding body composition data by DEXA
should be m easured in future studies but were not possible in the present
study. The m ethods of measuring total and % body fat increases should be
exam ined.
Body composition analysis w as questioned by Clark and Tarttelin
(1982). They report conflicting results from chemical analysis for exam ple,
comparing intact rats, to the weight of body fat in OV rats a s a percentage of
body weight. To examine the differences,

Sprague-Dawley

rats w ere

ovariectomized at three ages: 3 days, 4 weeks and 7 w eeks and w ere
subsequently sacrificed at four ages, 7, 9, 12 and 15 w eeks for chem ical
analysis of carcass and skin. Chemical compositions were analyzed at % wet
weight and

a s component weights by two-way analysis

of variance.

Ovariectomy increased overall body weight without causing obesity.

The

weight gain of the OV rat w as mainly due to true growth response. OV
treatm ent increased fat reserves but slowed the growth of other body
com ponents including the skeleton.

E treatment reversed this process.

Clearly body composition data must be examined with the sam e age, sp ecies
and treatm ent to provide com parable data. Earlier studies have reported
increased (Leshner & Collier, 1973; De Smet, 1953), d ecreased (Galleti &
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Kloper, 1964, Rebuffe-Scrive, 1987), and unchanged body fat end points
(Bogart, Lasley & Mayer, 1944; Holt, Keeton, and Vennesland, 1936; Nyda,
deMajo, & Lewis, 1948; Reed, Anderson, & Mendel, 1932).

Data in the

postbreeder female which h as been ovariectomized and implanted with
female sex horm ones were not evident in the literature.
Body composition can also be influenced by
calorically consistent food choices.

the availability of

It should also be noted that in earlier

studies (Wade & Gray, 1979; W ade & Schneider, 1992) animals w ere not
offered choices of macronutrients or food choices of sweet, nonsw eet and
chocolate. The food choices in their studies consisted of lab chow and sucrose
in water. Body weights were different and therefore body composition in the
younger rat could also have been affected. The present study indicates that
the aging female model changes in body weight but that the ratios in total
body composition analysis of fat to protein and body fluids remain consistent
across the treatm ents.
Total study caloric conversion ratios of food intake to body weight w ere
shown to be lower in the sham than the other treatm ent groups (Figure 12.0).
The effect of estrogen w as first seen in phase I in the E group.

T hese anim als

gained less weight per calorie than the other hormonal treatm ents.

This

evidence indicates that the OV and P implanted anim als convert calories into
body weight at a higher efficiency rate than the S and E treatm ent groups
(Figure 12.0). The significance shown in the sham group is clearly influenced
by the phase III data in which the S group w as not given chocolate choices.
There appeared to be differences in body weight, although calorie levels w ere
not significantly different. T hese differences can also be described a s the ratio
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at which feed is converted to body weight. The caloric conversion ratios
provide evidence that calories are converted into body weight at differing rates
possibly due to changes in basal metabolic rate, hormonally induced lethargy
or activity levels which were not m easured in the present study. This concept
requires further investigation.

The data leading to caloric conversion ratios

reported in this paper on the postbreeder female rat is not consistent with
evidence reported by W ade and Schneider (1992) in a review of gonadal
influence on body weight and adiposity. Their previously reported data from
younger rats implanted with female sex hormones, indicated that the research
contained in this report would constitute a valuable contribution in the body of
knowledge with regard to the aging female rat model (Wade, personal
communication, 1995). An earlier study (Roy & W ade, 1977) adds strength to
the findings of the current study, food intake had to be restricted to 80% of the
norm to keep weight stable in the estrogen deficient rats. This suggests that
th ese anim als may have had similar caloric conversion ratios to the anim als in
this research.
The current information suggests that when comparing research d ata
on different age animal models (e.g. neonatal vs 4 months vs 10 months), the
ag e and reproductive status may reflect different metabolic implications which
affect eating behavior and body weight. Similar results may be se en in studies
with other aging animal models. In the human, Wing (1992) h as reported that
additional weight gain occurs a s a result of

aging. The term “aging"

en co m p asses many biological alterations. Most param eters m easured in
younger rats compared to the postbreeder rat reveals a different profile. Wing’s
suggestions in the human female may be true in the aging female rat.
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The question of declining estrogen a s correlated to body weight gain
during the life span may becom e clearer when tests for estrogen are less
expensive and more commonly used. Currently LH and FSH are m easured a s
indicators of the m enopausal state. Additional research should be conducted
to m easure body composition changes a s body weight increases are
observed in the aging process.

Additionally, the percent body weight gain

shown a s adipose tissue compared to muscle tissue (% lean body m ass) in
the female taking hormone replacement needs further investigation.
In review, the impact of hormonal differences on the caloric intake and
body

weight gain for the total study can be viewed in Figure 11,

the

sub sequent resulting caloric conversion ratios in Figure 12. Figure 13
indicates different patterns of body weight gain over the three phases. Figure
14.0 reveals influence of hormonal treatm ents on the percent of total caloric
intake from FAT, CHO, and PRO. The higher total and % of fat intake is most
obvious in this chart. Total kcal intake from each of the three p h ases is shown
in Figure 15.0. Total caloric intake from all sources in Figure 16.0 clearly
dem onstrates the overwhelming effect of chocolate in phase III.

Figure 17

allows the reader to view a line graph of body weight over the 30 day study.
P h ase II begins on day 11 and P hase III in day 21.
»

In future studies the m easurem ent of pre and post markers of total body
composition (% fat, protein and water) would be of great value in m easuring
effects of exogenous female sex hormones. Differences have been observed
in the total body weight between treatm ents with no significant differences in %
body composition.

Differences have also observed hormonal effects in

macronutrient choices and different caloric conversion ratios. Total dietary fat
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w as high across all treatm ents (37.5 - 56.5%). Across all p h ases the OV group
(which consum ed the lowest percentage of calories from fat) gained the most
BW. The total percentage of fat in body composition analysis w as S 8.2%, OV
8.22%, E 9.46%, E&P 10%, P 8.64% (p=.0945).

Therefore, the higher

percentage of fat intake from macronutrient food choice w as not converted
proportionately into percentage of body fat stores.
Therefore the extensive body of research and current reports in the
popular press which indicate that the lowering of fat intake will result in
d ecreased body weight are not in evidence from this research.

This “low fat

concept” is so widespread that the higher fat intake a s seen in the sham
treatm ent group with lower body weight and the lower fat intake seen in the
ovariectomized animals with the greatest weight gain could easily have b een
thrown out a s false data.

However, this contribution to the literature is

meaningful and should be discussed.

The possibilities which explain this

phenom enon may include: (a) fat is a satiating macronutrient and therefore
su p p resses

the desire to consum e additional food, (b) gut motility of foods

containing higher levels of fat d ecrea se s the rate of digestion and provides a
longer period of absorption and assimilation, (c) high fat foods may create a
pleasure factor in eating behavior param eters that overrides other factors not
met by low fat food items, and, (d) the biochemistry of appetite through
systemic m essenger signals whether hepatic or neural or otherwise, may be
more or less efficient under the influence of certain hormones.
There is an extensive body of literature on the effects of estrogen on
feeding behavior, but the relevance of these studies to the control of energy
balance h as yet to be fully established.

According to W ade and S ch n eid er
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(1992) there is a complete absence of any unifying consensus a s to how
estrogen m odulates feeding behavior and body weight, although several
hypotheses have been proposed.

One hypothesis tested is that estrogen s

produce anorexia by directly affecting the m echanism s that normally term inate
m eals.

It has been suggested that estrogen promotes the effectiveness of

various peripheral short-term satiety signals by trigeminal (Beretter & Barker,
1976) pancreatic and/or gastrointestinal action (Bailey &

Matty, 1972;

Blaustein & W ade, 1977; Lichtenberger, Nance, & Gorski, 1976; Nance, 1983;
W ade & Gray , 1979), or direct action on the metabolism of adipocytes (W ade
& Gray, 1979).

The current study is in direct opposition to th ese reports

b e cau se there were clearly body weight differences when ANOVA of caloric
intake revealed no significant differences.
Additionally,

num erous

argum ents

speak

against

W ade

and

Schneider’s (1992) hypothesis (Geary, et al, 1994; Nance, 1983; Ramirez,
1980). Other authors have suggested that the effects of estrogen on feeding
behavior result from a horm one-dependent shift in the long-term control of the
energy balance, which fixes the level of regulated body weight or fat stores.
Redick et al. (1973) were the first to suggest that estradiol does not su p p re ss
food intake directly, but dictates a low level of body weight gain.

Such a

m echanism would correspond to a shift-down of the setpoint of body weight
regulation and, a s a consequence, feeding would be secondarily su p p re ssed
in animals which have excess weight a s a regulatory attempt to readjust body
weight to a lower regulated level. While this hypothesis h as been repeatedly
evaluated (Landau & Zucker, 1976; Nance, 1983; Fantino & Brinnel, 1986;
Leibel, et al, 1995) and strengthened by num erous experimental argum ents, it
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h as never been directly verified.

Indeed the very nature of body weight

setpoint is not known (Mrosovsky & Powley, 1977; Toates, 1983; W ade &
Zucker, 1970a), so hormone-induced variations have never been directly
appreciated.
Additionally, the elegantly designed method of evaluating the body
weight setpoint in rats through food hoarding behavior during a period of
reduced body weight (Fantino & Brinnel, 1986) provides strong evidence that
physiological m echanism s are strongly in place.

In the wild, hoarding

behavior is a specific response in rodents, occurring mainly in autumn, and
this response is useful in improving their long-term energy balance (Anderson
& Krebs, 1978; Launay, 1975). Fantino and Brinnel (1986) reported that in
fem ale rats a s well a s in male, the m ass of food hoarded during extended
three-hour experimental sessions increases when body weight d ecreases.
Fantino m easured body weight, food intake and food hoarding behavior in
fem ale rats fed ad lib and correlated th ese m easures with the ovarian cycle.
All three param eters fluctuated synchronously with the 4 day cycle with estrus
(two days prior to ovulation) and diestrus (two days following ovulation). But
he detected that the critical level of body weight for the onset of hoarding
behavior w as 13.2 g lower at estrus than at diestrus.

His research provides

direct evidence in the rat of the estrogen effect of fluctuation of the body weight
setpoint with the ovarian cycle under hormonal influence.
The question of additional body weight gain a s related to total body
composition in this model is of interest. The absence of percent change in
body fat stores may provide new information in the aging rat model and in the
future, help to explain shifts in body fat disposition in tine human. Women may
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comment, "I weigh the sam e at 50 a s I did at 30, but my clothes don’t fit the
sam e way.” Percentage of fat to lean muscle tissue and percent moisture may
actually not be different a s shown in the present experiment. Shifts in waist to
hip ratios, and upper body and lower body weight may occur (Haarbo, et al.,
1991). The shifts in location of body fat stores may be perceived a s body
weight gain if m easures are obtained by triceps skin folds in the upper body in
the aging model (Folsom, et al., 1989).

T hese m easures should not b e

com pared to the younger model to reflect body weight gain. Shifts to upper
body adiposity and waist to hip m easurem ents are evident in the aging hum an
female (Brezezinski & Wurtman, 1993; Armellini, et al., 1990; Peiris, et al.,
1989). Methods of m easuring the validity of th ese param eters are currently
under evaluation but have not yet been approved by FDA for hum an use in the
medical setting (Troisi, et al., 1995). Evaluation and m easurem ent of body
weight and body composition changes over time will be included in future
human research.
Exogenous female sex horm ones are among the highest selling
pharm aceutical agents in the industry (Wallis, 1995).

Postm enopausal

fem ales are currently choosing hormone replacem ent therapy to combat the
negative symptoms of m enopause and a s a protective therapy against
osteoporosis and cardiovascular disease. This is the reason that the two most
prevalent, estrogen (17 p estradiol) and progesterone were chosen for this
study to exam ine subsequent physiological effects (Richard, 1986; Butera &
Beikirich, 1989). The estrogen group w as chosen to reflect the follicular p h a se
in the normally cycling female, estrogen replacem ent therapy in the fem ale
who has had a hysterectomy or the estrogen phase in horm one replacem ent
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therapy. The estrogen and progesterone group w as chosen to reflect current
hormone replacem ent therapy and mid cycle hormonal profiles in the normally
cycling female. And the progesterone treatment group w as observed to show
exclusive effects of progesterone. Progesterone is often prescribed to com bat
uncontrolled

vaginal

bleeding,

prevent

miscarriages,

or

as

horm one

replacem ent for women w hose genetic patterns reflect a likelihood for
reproductive cancer (Notelovitz & T onnessen, 1993). D osages and reaso n s
physicians prescribe exogenous female sex horm ones vary.
Body weight and food intake are major concerns during this period in
the life of a female. Often the comment is heard, “I am eating the sam e am ount
but gaining additional weight.” This perception has not been addressed in
depth

by the

medical

community

but has

initiated

major

monetary

expenditures ($33 billion, [Atkinson, 1990] previously cited) in the population.
The o b ese are not the only ones who invest in weight loss programs. The
investment to lose an extra 10 to 20 pounds of additional body weight is an
expense incurred by a large segm ent of the weight conscious population. The
body weight fluctuations which result in either perm anent or temporary body
weight gain may be affected by female sex horm ones a s shown in this study.
Low fat food items are expensive and not effective in achieving the desired
result (Allred, 1995). When excess calories are consum ed in the form of simple
sugars, th ese
(Geiselman,

simple sugars may initiate additional

caloric ingestion.

et al., 1981; Simopoulos, 1994b). The data observed in the

current study (Figures 13 and 14) agrees with reports by Rolls (1992): that
caloric intake is more important in body weight gain than fat gram s consum ed.

152

In earlier research on rats, a high rate of weight gain se e n in the
ovariectomy has been prevented or reversed by injection of estradiol (Landau
& Zucker, 1976; W ade & Zucker, 1970b) or by unilateral implants of estradiol
benzoate in the ventromedial hypothalamus (Nunez, Gray, & W ade 1980;
W ade & Gray, 1979). The present study supports the information in th ese
reports.

In several younger species, endogenous a s well a s ex ogenou s

estrogens have revealed a suppressive effect on both body weight gain and
food intake (Czaja, Butera, & McCaffrey, 1983) which is not reflected in the
current study. The earlier reports and the current results can explain why body
weight is minimal at estrus, when circulating estradiol is maximal (Czaja,
Butera, & McCaffrey, 1983; Morin & Fleming, 1978) but does not explain the
non significant food intake results and subsequent differences in caloric
conversion ratios.
Accordingly, the simplistic concept which h as been reported in weight
loss program s that the ingestion of 3,500 additional calories will produce a
pound of body weight gain or that the deprivation of 3,500 calories will c a u se a
pound of d ecrease in body weight may not be true in all cases. There m ay be
metabolic effects of aging during the m enopausal years which can be directly
correlated to the decline in endogenous female sex horm ones such a s
r

estrogen with subsequent variations in the way calories are converted into
body weight. This research shows that in the aging female rat, the a b sen c e of
endogenous estrogen creates the condition whereby calories are converted
into body weight at a higher ratio.
Body weight has becom e an important consideration in the quality of life
in the female. Genetics and lifestyle changes currently seen in the population
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may contribute to differences observed in the human.

Undefined levels of

hormonal therapy designed to relieve the symptoms of m enopause (hot
flashes, vaginal dryness, night sw eats) may create problems. Currently,
laboratory documentation of endogenous levels prior to the prescribing of
exogenous levels is not the normal clinical procedure.

Perhaps this

assessm en t should be considered in the future in symptomatic individuals
before the decision is m ade on whether to prescribe 10 mg. or 2.5 mg of
Provera early in m enopause or immediately following surgery when body
weight se em s to be affected most by progesterone (eg. P h ase I). In addition
d o sag es of exogenous female sex horm ones may need to be individually
determined through laboratory analysis in the future. Currently, women are
prescribed levels of exogenous female sex horm ones in d o sag es which apply
to the larger population and often based on patterns established in Europe.
This protocol may not be appropriate for all women. Perhaps individual
analysis and cultural differences should be considered in future research.
Current discomforts and body weight gain may be dose related and affect
compliance problems (OB/GYN physicians, personal communication, 1995).
Recent reports reveal that the earlier indicated 8% lifetime compliance rate
may be declining.
The findings reported in this document in female postbreeder rats may
provide preliminary data to design research studies in the human. Clearly, the
human model is the best model for the study of the human.

Human fem ale

caloric conversion ratios should be exam ined in postm enopausal fem ales
taking various sources and d o sag es of hormone replacem ent therapy. There
are clearly body weight and caloric fluctuations in the ovariectomized post
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breeder ra t There may also be differences in the postm enopausal hum an
female. Exogenous female sex horm ones are probably here to stay, a s they
improve the quality of life in the postm enopausal female. More information is
needed, and additional research should be conducted.
The fluctuations shown in body weights observed in phase I and II of
this research reveal increased body weight gain with subsequent d ecrease in
the rate of gain a s w as reported by Fantino & Brinnel (1986). The complex
molecular m echanism s by which discrete ingestive behavior, continuous
energy expenditure, and dynamic energy storage in adipose tissue are
integrated remain unknown. The demonstration that "leptin” (Haalas, et. al.,
1995) can reduce food intake and body weight in o b ese and lean mice
provides further evidence for the hypothesis that a circulating protein-based
signal, generated in adipose tissue, acts on control neuronal networks and
plays an important role in the regulation of feeding behavior and energy
balance.

The failure to achieve these results in other genetic strains is

consistent with the hypothesis that a genetic defect in som e renders them
unable to appropriately respond.

Perhaps this may occur a s a result of a

defect in the receptor or postreceptor signaling pathway (Campfield, et. al.,
1995). Several lines of evidence argue for circulating signals that act in the
brain to regulate feeding behavior and energy balance.

Future research to

exam ine aging and gender differences will be needed to interface exogenous
female sex horm ones and the affects of leptin. The altered caloric conversion
ratios in the present study may be evidence that female sex horm ones play a
role and should be included in future investigations.

CH A PTE R 5: SUMMARY

C O N C L U S IO N S & IM PLICATIONS

The focus of this research w as the body weight implications of the
relationship between macronutrient food choices and exogenous female sex
horm ones. The body weight consequences of changes in physiological status
through the ovariectomy with and without hormone

replacem ent w ere

exam ined. C hanges in macronutrient preference, caloric conversion ratios,
and additionally the m easurem ent of body composition and post mortem
param eters were also examined.

Contempory models of the regulation of

energy balance investigate and em phasize the physiological signals that
control energy intake. T hese results reflect the outcom e of those signals.
The female rat model w as chosen to obtain data on body weight, caloric
regulation, and macronutrient choices in a controlled environment.
seq u en ce of studies using

This

the postbreeder rat model (to exam ine a

postm enopausal and normally cycling female) provided an arena in which to
exam ine questions that could otherwise not be investigated and answ ered in
free living human subjects. Following is a summary of the conclusions from
the present study:
PHASE I:
1. Exogenous estrogen in ovariectomized rats caused a significant
d ecrease in body weight gain without significant differences in
caloric intake (there w as a trend toward lower caloric intake in the
estrogen treated rats).
2. Caloric conversion ratios (grams of body weight gain divided by
caloric intake x 1000) revealed an estrogen effect and w ere lower for
H vs. OV (total) and E vs. Non E (total) among the groups.
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3. Exogenous female sex horm ones affect macronutrient choices with
statistical analysis a s group contrasts: (a) Higher levels of FAT (total)
w ere consum ed by P vs. NonP treated animals (confirmed by
factorial analysis) and H vs. OV (%), (b) Higher levels of PRO w ere
consum ed by H vs. S (total & %) and E vs. Non E (total & %), (c)
Higher levels of CHO were consum ed by OV vs. H (total & %), Non E
vs. E (total & %) and Non P vs. P (total & % ) (all CHO results
confirmed by factorial).
PHASE II:
1. There may be time related metabolic differences in the conversion of
calories into body weight after the ovariectomy. D ecreased body
weight gain in phase II com pared to phase I for the S and P groups
may indicate set point (age, gender) adjustm ents over time.
2. Caloric conversion ratios were lower for H than for OV and P vs. Non
P. The physiological effects of ovariectomy without supplem ental
horm ones may produce a carbohydrate appetite a s dem onstrated by
increased

caloric

intake

from

both

sw eet

and

nonsw eet

carbohydrate. E&P chose 3 times more SW than NSW.
3. Exogenous female sex horm ones affect macronutrient choices with
statistical analysis a s group contrasts: (a) More FAT w as consum ed
by H vs. Non H {%), and E vs. Non E (%), (b) More PRO w as
consum ed by OV vs. H (total & %), (c) More CHO w as consum ed by
OV vs. H (total & %), Non E vs. E (total & %, factorial E effect), (d)
More SW/CHO w as consum ed by OV vs. H (total), (e)

More
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NSW/CHO w as consum ed by Non E vs. E (total & %) (also factorial
E effect).
PHASE III
1. The chocolate novel food choices in phase III produced a higher rate
of body weight gain.

Access to chocolate eliminated both the

reduced rate of weight gain caused by exogenous estrogen in
P h ase I and P h ase II and the set point adjustment or adaptation with
subsequent reduced conversion of calories into body weight in the
progesterone group observed in phase II.
2. Caloric intake was significantly lower (total) in the Sham (which did
not receive chocolate) than the OV treatm ents (caloric conversion
ratios were not significantly different in 5 group compared to 4 group
analysis). A sham group receiving chocolate should be included in
future research.
3. Chocolate (a choice only in phase III) w as consum ed at 40% to 53%
of total caloric intake in ovariectomized anim als with or without HRT
to the exclusion of the nutrient dense macronutrient food choices. P
vs. NonP preferred higher levels of HF/LS chocolate which indicates
that in the luteal phase chocolate and FAT may be chosen in
preference to sucrose.
TOTAL STUDY:
1. Exogenous estrogen prevented the increased body weight which
w as observed in the OV, P and S rats in phase I in this study and in
the OV and P in the total study. Overall body weight gain for the 30
days w as greatest in animals with no estrogen, the OV and P
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treatm ents. The P group (as well a s the S) adjusted in p h ase II with
lower rate of body weight gain equal to that of the E group. In P h a se
III, the S group did not receive chocolate while the P group
increased body weight gain with chocolate a s a choice. Body weight
gain w as higher according to group contrasts in H than S (total & %),
OV w as higher than H (total & %) and Non E w as higher than E (total
& %). Ovariectomy without hormone replacem ent w as shown to be
the greatest indicator in increased body weight.

Therefore in

m enopause or with surgical removal of the ovaries, HRT is indicated
for suppression of increased body weight gain.
2.

An estrogen effect w as observed for caloric conversion ratios.
Caloric conversion ratios were lower for S vs. H (total) and E vs.
NonE (total). Total caloric intake w as higher in the OV treatm ents
when com pared to the S (total) with a trend toward lower caloric
intake with E.

3. In the aging female, palatable chocolate choices may be preferred
over a nutritious balanced diet. E&P preferred SW over NSW/CHO.
Exogenous female sex horm ones according to group contrasts
affected macronutrient choices: (a) More FAT w as consum ed by H
vs. OV (%), (b) More PRO w as consum ed by H vs. S (total), (c) More
CHO w as consum ed by H vs. S (total), OV vs. H (total &%), and
NonE vs. E (total).
4. The OV rats consuming the highest caloric levels of carbohydrates
(total & %) gained the most body weight. Of the OV treatm ents, those
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receiving horm ones (H) consum ed the highest levels of fat {%) and
gained the least amount of body weight (total & %).
5. Typical regimes of hormone replacement (E or E&P) therapy do not
produce increased body weight gain in the aging female rat.
Hormonal effects on changes in caloric conversion ratios could
indicate physiological and metabolic m echanism s which should be
investigated in future research.
POST MORTEM:
1. Variations in percent of fat intake (40% to 60%) did not result in
treatm ent differences in body composition. Mean body composition
w as 80% body water, 10 % fat, 10 % protein across all groups at the
conclusion of the 30 day study.
2. Cholesterol and HDL cholesterol levels were lower (total) in the
normally cycling rats (S) which produce endogenous horm ones a s
opposed to the OV rats implanted with exogenous female sex
horm ones.
3. Uterine weights confirmed estrogen bioactivity and serum levels of
progesterone verified the release of progesterone from the implants.
Livers of the H treated animals weighed significantly more than S
(total) or OV (total) and the (percent) fat content of the livers of the E
treated animals w as significantly higher than Non E.

This may

indicate a metabolic or hepatic influence on all of the results.
The caloric conversion ratios observed in this study may project future
research results in the human female taking hormone replacem ent therapy.
The body weight fluctuations in the first two p h ases may also reflect the
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metabolic implications of the ovariectomy and the effort by the body to stabilize
at a set-point. This physiological metabolic alteration may cdcbe a tem porary
weight gain that will stabilize in the human a s observed in rats in p h ase II
com pared to phase I of the present study. In the human, the perim enopausal
period (often 1 to 3 years) following the initial decline in estrogen may be the
most critical period regarding body weight gain.
Historically it h as been assum ed that fat is associated with satiety and
weight gain.

However, the story may be different for hum ans under the

influence of hormonal fluctuations. The role of carbohydrates (chow vs.
balanced macronutrient food cups) in the study of appetite and hunger h a s
received relatively little attention in the animal feeding literature. It h as b een
assum ed that all carbohydrates are satiating (Geiselman, et al., 1981).
However,

Geiselm an

and

her

colleagues

(1987)

have

shown

that

carbohydrates do not always produce satiety. Instead, carbohydrates (simple
sugars) appear to stimulate appetite and physiological

hunger.

This

information is of particular significance in this research. The group that gained
the most body weight also consum ed the highest levels of both sw eet and
non/sweet carbohydrates. Fat intake w as found to be elevated in the groups
implanted with exogenous female sex horm ones that gained less body weight.
The information from the present study should be accom panied by the
following warnings.

If novel food choices containing sw eets, fats and

chocolates are presented immediately following ovariectomy or natural
m enopause, body weight may be altered and conversion ratios of food intake
into body weight may also be increased. This research show s that timing an d
ag e with the free choice for chocolate may be a major risk factor. The anim als
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chose chocolate to the exclusion of other balanced macronutrient food choices
in the diet.

Poor nutrition in m enopause may confound hormonal effects and

add additional body weight. This body weight increase in the past may have
been blam ed on the hormones, when in fact, poor food choices may have
been the culprit. T hese observations may go unnoticed in the aging hum an
population. T aste responsivity reported by Rodin et al. (1976) and others is
known to play a major role in food choice. The novel flavor and the opioid
effect of chocolate may contribute to increased intake and resulting body
weight gain (Drewnowski et al., 1985).
A state of malnutrition can develop over time if this preference
dom inates to the exclusion of more nutritious foods. The aging fem ale who
lives alone may prefer the convenience and taste of sw eet, fat and chocolate
snack foods over more nutritious food choices that may be m ore labor intense
to prepare but physiologically devastating to bone loss, cardiovascular health
and obesity.

A potential positive outcome of macronutrient selection w as

shown in the increased choice of protein in the H treated anim als com pared to
S. This effect may be a positive influence in the anem ic postm enopausal
fem ale with break-through bleeding. If the protein is consum ed a s red m eat
sh e will consum e hem e iron which will help to combat anem ia. This research
indicates that food choices may be affected by female sex hormones.
Empirically, body weight is different in the younger a s opposed to the
older human (Epstein, et. al., 1995). Lifestyles, intensity of exercise, and
hormonal levels change with advancing years. The female sex horm ones
naturally produced in the human body cannot be duplicated in content or in
metabolic physiological effects. Exogenous female sex horm ones may provide
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a supplem ent that will provide cardioprotection, protect against bone loss and
improve the quality of life in fem ales in this century and beyond.

This is an

opportunity not afforded to our grandmothers.
The changes in caloric conversion

ratios reflect what could

be

happening in the human population. Body weight may be easier to maintain
with endogenous horm ones production a s observed in the normally cycling S.
Ovariectomy without supplemental horm ones may produce added

body

weight a s observed in the OV treated animals. After m enopause or surgical
removal of the ovaries, estrogen and E&P may help keep body weight at lower
levels. Progesterone may create additional body weight that the body se ek s
(successfully temporally but unsuccessfully under the influence of poor
nutrition) to lower through endogenous m echanism s not yet known.
The segm ent of the female population which motivated this research
question is the female who reports additional cravings for chocolate during the
luteal phase of the menstrual cycle when progesterone levels are elevated,
the female taking oral contraceptives, and the postm enopausal fem ale taking
exogenous female sex horm ones (Salhanic et., al.,1969). The progesterone
treatm ent group tried to recover from the abrupt weight gain in P h ase I. In
phase II with essentially the sam e caloric intake the body changed the ratio at
which calories were converted into body weight and the rate of gain w as
dramatically decreased. This looked hopeful, and yet under the influence of
chocolate (a model for a poor nutritional choice), an unbalanced diet (termed
poor nutrition),

body weight crept back up and caloric conversion ratios

converted very efficiently into increased body weight gain.
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This pattern is also seen in the female in the human population. This is
the physiological phenomonen which may have motivated the spending of the
$33 billion dollars in weight loss reported by Dr. Richard Atkinson, current
president of the Society for Clinical Nutrition (previously cited). Body weight
increase is a major problem in our country. Despite the difficulties with
treatment, Dr. Xavier Pi-Sunyer current president of the North American
Society for the Study of Obesity, reports that 25% of the men and 45% of
women are trying to lose weight at any one time. And that one in three adults
in the US is currently attempting to lose weight (Pi-Sunyer, 1995). The
answ ers to control are not currently known.
According to this study, the effects of exogenous female sex horm ones
on food intake and body weight gain in the aging female do not ap p ear to
contribute to the growing problem of obesity in this country. Typical regim es of
hormone replacement (E or E&P) therapy do not produce increased body
weight gain in the aging female rat. The perception that horm ones c a u se
ex cess body weight which would preclude the female from using HRT a s a
preventive

m easure

against osteoporosis,

cardiovascular

disease

and

m enopausal symptoms is not evident in these results. Hormonal effects on
changes

in caloric conversion ratios could

indicate

physiological

and

metabolic m echanism s which should be investigated in future research.
IMPLICATIONS FOR CLINICAL PRACTICE AND FUTURE RESEARCH
What do these results portend in term s of current body weight gain
concepts reported across the television screens, popular press and taught in
weight control clinics across the country? It may m ean that there are metabolic
regulators affecting body weight that go beyond merely counting calories.

It
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may m ean that during certain times of the month in the normally cycling
female, or the aging postm enopausal female taking cyclical HRT, food intake
is converted into body weight at different ratios. Or it may m ean that energy
expenditure changes, or hormonally induced lethargy occurs or that a totally
different concept exists that has not yet been fully discovered and reported.
As this research applies to the female human population, it is the desire
of this researcher to propose new individualized a ssessm en ts of d o sa g e
levels of HRT to protect against osteoporosis, cardiovascular d isease and
cancer. The risk assessm en ts calculated with each female individually, b a sed
on her genetic predisposition to th ese d ise ases prior to prescribing exogenous
supplem ents seem s appropriate. S he can then make decisions based on
medical and scientific evidence. Negative symptoms of m enopause which
impact compliance rates of HRT are typically not m easured in the hum an
(Lemer, 1995).

Further investigations are needed to m easure hormonal

effects on macronutrient food choice, caloric regulation, chocolate intake and
subsequent impacts on body weight and body composition in the human.
Additionally, of interest are current National Health and Nutrition
Examination Survey (NHANES III) reports that show 31.3% of men and 34.7%
of women were found to be obese. The percentages for those Americans
under the poverty line are even worse. In addition the prevalence for obesity
h as doubled since 1900 and increased 30% from 1980 to 1990 (Pi-Sunyer,
1995). There are those who would credit this national problem to d e creased
exercise and the “couch potato” syndrome.

And yet, is there another

unexplained hormonally influenced dimension which affects setpoint in body
weight, causing calories to be converted into additional body weight at
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different ratios? One of those differences recently reported in Science term ed
the hypothesis "a chronobiological solution” to metabolic alterations that affect
obesity and non-insulin dependent diabetes. The process involves “resetting"
hormonal rhythms to treat illness (Roush, 1995).
W e have shown hormonal differences in the rate at which caloric intake
is converted into body weight. Is the presence or absence of estrogen the only
reason?

This question would follow: if abnormal differences are detected,

how can corrections be made, and can the source of manipulation be
elim inated? The intake of dietary fat is clearly not the total picture a s many
current nutritionists report. The answ er involves more than “willpower.”
A recent answ er to this question w as revealed when researchers found
that injections of the protein product of the m ouse obesity gene caused both
overweight and normal mice to lose weight.
is reported to provide dual action.

This new discovery called “leptin”

It turns down the anim als’ appetites and

increases their energy use, causing them to bum more fat. The parallel to the
recent research is that mice with the sam e diets, treated with leptin tost 50%
more weight than did the untreated animals, suggesting that food intake alone
did not account for the weight loss.

Two answ ers were given, the protein

reduces the lethargy (increases activity) and sp eed s slow m etabolisms.
(Halaas, et. al., 1995). If ovariectomy slows the metabolism and produces a
lethargy resulting in increased body weight, does this indicate unreported
potential production of leptin by the ovary?

Could there be a correlation

betw een fem ale sex horm ones (estrogen and progesterone) and the rate at
which the leptin is produced in the body. Does the prolactin hormone and
resetting of chronological clocks play a role in the m echanism s of leptin and
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the way estrogen and progesterone affect body weight? The altering of
circadian rhythms (which may impact all metabolic regulators) may be a
solution to uncontrolled body weight gain, diabetes and other disease states
(Roush, 1995). Clearly there are m echanism s which are currently active in the
aging female rat that are not understood or reported.
Caloric regulation and eating patterns clearly need to be evaluated. Fat
and protein intake may provide satiating factors that offset the uncontrolled
consumption of highly refined, high carbohydrate snack foods. Total caloric
intake a s compared to the percentage of caloric intake derived from fat may be
misinterpreted by many consum ers. Increased dietary fat and protein levels in
this study did not increase body weight proportionately. Rather, higher levels
of carbohydrate intake were positively correlated to body weight gain and
higher fat and protein intake to less body weight gain.
Why does the body choose to convert calories into body weight at
different ratios?

Is this evidence of the setpoint hypothesis? Is this system

which has potentially worked well for centuries being altered by exogenous
progestins, estrogens, m enopause or endogenous progesterone, which could
c a u se setpoint to be altered in unexpected, unpredicted and undesirable
w ays? Is all of this the result of a biological “survival of the species” which
provides additional energy during the luteal phase when the body is
potentially preparing to support new life? This study contributes new
information in an aging model into the investigation of female body weight
gain, which will hopefully provide a basis for more extensive investigation in
the future and provide further information to this perplexing question. In clinics
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and future research studies that involve the aging female the following
implications should be considered:
1. The hormonal phase (endogenous levels) in the normally cycling
female may affect food intake and body weight data, and should
therefore be m easured and docum ented in all future research
studies.
2. The postm enopausal woman could em erge a s the model for
examining female health param eters. The female postbreeder rat
can provide preliminary data in a controlled environment.
3. There may be metabolic differences in the way calories are
converted

into body weight, which may be affected

by

both

endogenous and exogenous female sex hormones.
4. Eating behavior, food choices and caloric regulation may be affected
by endogenous and exogenous female sex hormones.

Higher

protein intake in the postm enopausal female with breakthrough
bleeding can be of value if she is deficient in hem e iron and
consum es red meat.
5. Postm enopausal women on hormone replacem ent therapy may
experience different caloric conversion ratios depending upon the
nature, combination and dosage of the exogenous female sex
horm ones. Progesterone caused early higher rate of body weight
gain which decreased

with time. Therefore at the onset of

m enopause or immediately following surgery when body weight
gain most often occurs, progesterone should be prescribed in
minimal dosages known to be protective against cancer.
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6. Various levels and sources of exogenous horm ones in addition to
various levels of endogenous female sex horm ones may affect food
intake and body weight and should therefore

be monitored.

D osages should be individualized based on risk a ssessm en t ratios.
7. Body weight changes in m enopause may occur a s the estrogen pool
declines.

In the future, perim enopausal fem ales could su p p re ss

midlife body weight gain by beginning HRT earlier.
8. New research is needed to "reset” the setpoint when stress, genetic
or environmental factors violate or disturb this hypothesized
metabolic m echanism (Roush, 1995).
9. Further research is needed to exam ine the effects of horm one
replacem ent therapy on cardiovascular disease, cancer, diabetes
mellitus and other related d iseases in the postm enopausal woman.
10. In the aging female model the absence of HRT with acc ess to novel
food choices and chocolate (with or without HRT) contributed most to
body weight gain. The data from the present study indicate that
hormone replacem ent therapy in levels typically prescribed to deter
m enopausal conditions in midlife do not necessarily contribute to
additional body weight gain.
The larger question encom passing all previously discussed param eters
is:

what determ ines body weight fluctuations?

Body weight gain in

m enopause a s it relates to hormonal profiles has been implied. This research
d o es not agree with earlier findings in the younger rat model which show
additional food intake resulting in additional body weight gain and a
progesterone effect with an accompanying increase in percent body fat stores.
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A recent commentary on classics in obesity by Dr. George Bray (1995)
exam ines the possibility that human beings might defy the first law of
therm odynam ics (termed “Luxuskonsumption") by being more of less efficient
in the conversion of calories into body weight. In the early 1900’s m ale
scientists studied the concept carefully using them selves a s subjects with
careful feeding and recording of body weight with differing results. Additional
and more current studies show a linear relationship in the degree of weight
gain of overfeeding both male and female subjects (Forbes, et al.t 1986).
However, the m easurem ent of endogenous female hormone levels, ag e and
time is not evident in the reported results. T hese param eters may affect energy
expenditure reported by Leibel et. al. (1995) and sympathetic activity
modulating to variable degrees the nutrient partitioning between carbohydrate
storage and metabolism and protein storage and catabolism with fat storage
being the pathway consuming the residual surplus energy (Bray, 1995). This
current research in the hormonal effects in the postbreeder female rat, reveals
that th ese param eters should be m easured and docum ented in future
research.

Another analysis of “Luxuskonsumption” in the human female

should be conducted to report documented hormonal effects.
The highly refined carbohydrate diet that is advertised and m arketed so
t

convincingly across the globe is the sam e product that Dr. Paula Geiselm an
stated in 1987 would stimulate appetite.

If the postbreeder female rat is a

model that parallels what could be happening in the postm enopausal female,
this research docum ents her findings. Highly refined carbohydrate foods may
stimulate body weight gain and possibly appetite. The wide spread pattern of
e x cess food consumption in a population motivated by convenience may
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contribute to the increase in insulin resistance and body weight gain. Satiety
may not be achieved at the sam e level a s with fat. The population consum ing
highly refined carbohydrate diets deficient in nutritious satiating foods with
resulting obesity, should be further investigated. The increase in Type II
diabetes and insulin resistance in this country with regard to the consum ption
of highly refined carbohydrate diets is a growing concern. The question is: is a
calorie a calorie in all physiological anatomical states. Is a calorie a calorie
with all foods or do som e macronutrients convert at different rates? Age,
surgical implications, metabolic m echanism s and hormonal effects on eating
behavior may reach beyond the female taking exogenous female sex
horm ones.
Data from the recent PEPI trial and the W omen’s Health Initiative to be
completed in the year 2005 (Healy, 1993) may provide new evidence to
correlate current research findings in the human female. Perhaps this research
can provide a small glimpse into what has been term ed a major health
problem, the uncontrolled increase of body weight in this country in a growing
segm ent of the population. The larger segm ent of the population who maintain
healthy life style patterns should be commended.
The effects of exogenous female sex horm ones on food intake and
body weight gain in the aging female do not appear to contribute to the
growing problem of obesity in this country. Genetic and environm ental
influences on hormonal effects of changes in caloric conversion ratios (also
term ed luxuskonsumption) indicate physiological and metabolic m echanism s
which should be investigated in future research.
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APPENDIX A P H A S E I
Phase I ANOVA(4-groups) Body weight
Type III Sums of Squares
Source
Treatment
Residual
Dependent: Body Weight

df Sum of Squares
3
2952.500
39
4154.012

Mean Square
984.167
106.513

F-Value
9.240

P-Value
.0001

P h a s e I ANOVA(4-groups) Body W eight %
Dependent: Wt % Ph1
Xj£jg<HII Sum s of S q u a re s
| Treatment
| Residual

^

Sum of Squares Mean Square
3
373.914
124.638
39
553.702
14.197

F-Value
8.779

P h ase I ANOVA(4-groups) Body WEIGHT %
Ovariec vs Hormones
Effect: Treatment
Dependent: Wt % Phi

Estrogen vs No Estrogen
Effect: Treatment
Dependent: Wt % Ph1

Cell Weight
Ovariec
Ovar-E&P
Ovar-E
Ovar-P

Cell Weight
-

1.000
-.333
-.333
-.333

df 1
Sum of Squares
Mean Square
F-Value
P-Value

Ovariec
Ovar-E&P
Ovar-E
Ovar-P
df
Sum of Squares
Mean Square
F-Value
P-Value

77.228
77.228
5.440
.0249

192

-.500
.500
.500
-.500
1
328.988
328.988
23.172
.0001

P-Value
.0001
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Phase I ANOVA(2x2 Factorial) Body weight
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Body Weight

df Sum of Squares
1
2562.836
1
353.567
1
69.583
4154.012
39

Mean Square
2562.836
353.567
69.583
106.513

F-Value

P-Value

24.061
3.319
.653

.0001
.0761
.4238

ANOVA f o r I n i t i a l Body Wt
Type III

Sums of Squares

Source
Treatm ent
Residual

df
4
50

Sum of Squares
2223.235
26318.111

Mean Squar e
555.809
526.362

F-Value
1.056

P-Value
.3881

P h a s e I ANOVA(2x2 Factorial) Total C a lo ries
Dependent: Total Calories
Type III Sums of Squares
„„
„
Source
df Sum of Squares Mean Square
83624.884
1
83624.884
Estrogen
1
4910.826
Progesterone
4910.826
14382.587
Estrogen * Progesterone
1
14382.587
825891.562
21176.707
Residual
39

_w ,
F-Value
3.949
.232
.679

„ W1
P-Value
.0540
.6328
.4149

F-Value
8.740

P-Value
.0001

P h a s e I ANOVA(4-groups) C aloric C on v ersio n
Type III Sums of Squares
Source
Treatment
Residual
Dependent: Caloric Conversion

df Sum of Squares
3059.814
3
39
4551.407

Mean Square
1019.938
116.703
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P h ase I ANOVA (4-groups) Caloric Conversion
Ovariec va Hormones
Effect: Treatment
Dependent: Feed Efficiency

Estrogen vs No Estrogen
Effect: Treatment
Dependent: Feed Efficiency

Cell Weight
C-Ovariec
E-Ovar-E&P
D-Ovar-E
F-Ovar-P
df
Sum of Squares
Mean Square
F-Vatue
P-Value

Cell Weight

1.000
-.333
-.333
-.333

C-Ovariec
E-Ovar-E&P
D-Ovar-E
F-Ovar-P

1
665.768
665.768
5.705
.0219

df
Sum of Squares
Mean Square
F-Value
P-Value

-.500
.500
.500
-.500
1
2713.328
2713.328
23.250
.0001

Phase I ANOVA(2x2 Factorial) Caloric Conversion
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Feed efficiency

df Sum of Squares
1
1
1
39

2713.328
275.162
104.109
4551.407

Mean Square
2713.328
275.162
104.109
116.703

F-Value
23.250
2.358
.892

P-Value
.0001
.1327
.3507

P h a s e I ANOVA(2x2 Factorial) Fat
Dependent: FatType III
Sum s of S q u a re s
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual

df Sum of Squares Mean Square
1
1370.862
1370.862
1
110195.286 110195.286
1
9949.363
9949.363
39
21042.925
820674.081

F-Value
.065
5.237
.473

P-Value
.7999
.0276
.4958
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Phase I ANOVA(2x2 Factorial) CHO
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Carbohydrate

df Sum of Squares
1
192654.016
92706.323
1
1
13725.693
731325.542
39

Mean Square
192654.816
92706.323
13725.693
18751.937

F-Value

P-Value

10.274
4.944
.732

.0027
.0320
.3975

APPENDIX B PHASE II
P hase II ANOVA(5-groups) Body Weight
Type III Sums of Squares
Source
_____________
TREATMENT

df
4

Residual

50

Sum of Squares
937.331
3087.778

Mean Square
234.333
61.756

F-Value

P-Value

3.795

.0090

Mean Square
27.848
7.788

F-Value
3.576

P-Value
.0122

Dependent: BODY WT

P hase II ANOVA(5-groups) Body Weight %
Type III Sums of Squares
Source______________________ df
4
Treatm ent
50
Residual
Dependent: Wt % Ph2

Sum ol Squares
111.394
389.412

P h ase II ANOVA (5-groups) Body Weight %
Ovar vs Hormones
Effect: Treatment
Dependent: Wt % Ph2

Prog vs No Prog
Effect: Treatment
Dependent: Wt % Ph2

Cell Weight
Ovariec
Ovar-E&P
Ovar-E
O var-P
df
Sum of Squares
Mean Square
F-Value
P-Value

Cell Weight
Ovariec
Ovar-E&P

1.000
-.3 3 3
-.3 3 3
-.3 3 3

-.5 0 0
.500
-.5 0 0
.500

Ovar-E
O var-P
df
Sum of Squares
Mean Square
F-Value
P-Value

1

82.507
8 2 .507
10.594
.0020
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1

6 7 .785
67.785
8.703
.0048
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P hase II ANOVA(2x2 Factorial) Body weight
Type III Sums of Squares
Source______________________ df
1
Estrogen
1
Progesterone
Estrogen * Progesterone
1
Residual
39
Dependent: Body-WT

Sum of Squares
152.253
507.751
184.751
2393.278

Mean Square
152.253
507.751
184.751
61.366

F-Value
2.461
8.274
3.011

P-Value
.1233
.0065
.0906

Sum of Squares

Mean Square

476458.703
916171.149

119114.676
18323.423

F-Value
6.501

P-Value
.0003

P hase II AN0VA(5-groups) Total Calories
Type III Sums of Squares
Source
TREATMENT
Residual
Dependent: TOTAL-CAL

df
4
50

Phase II ANOVA(2x2 F actorial) Caloric Conversion
Type III

Sums of Squares

Source
Estrogen
Progesterone
Est r ogen * Pr ogest er one
Residual

df
1
1
1
39

Sum of Squares
108.027
501.476
211.395
2637.060

Mean Square
108.027
501.476
211.395
67.617

F-Value P-Value
1.598
.2137
7.416
3.126

.0096
.0849

Mean Square
1344.946
216.557

F-Value
1.584
.255
19.979

P-Value
.2156
.6163
.0001

Dependent: Caloric Conversion

Phase II ANOVA(2x2 Factorial) Protein
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Protein

df
1
1
1
39

Sum of Squares
1344.946
216.557
16958.511
33104.202

16958.511
848.826
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P hase II ANOVA(2x2 Factorial) CHO(SW&NSW)
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual

df
1
1
1
39

Sum of Squares
216089.292
53816,213
35135.194
829046.029

Mean Square
218089.292
53616.213
35135.194
21257.590

F-Value
10.259
2.532
1.653

P-Value
.0027
.1197
.2062

Mean Square
149382.849
20846.903
8779.832
15589.758

F-Value
9.582
1.337
.563

P-Value
.0036
.2546
.4575

Mean Square
6480.634
7673.502
79042.356
7792.002

F-Value
.832

P-Value
.3674
.3271
.0028

Dependent: Total-CHO

P hase II ANOVA(2x2 Factorial) CHO/NSW
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: CHO/NSW

df
1
1
1
39

Sum of Squares
149382.849
20846.903
8779.832
608000.548

P hase II ANOVA(2x2 Factorial) CHO/SW
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: CHO/SW

df
1
1
1
39

Sum of Squares
6480.634
7673.502
79042.356
303888.087

.985
10.144

APPENDIX C P H A S E III
Phase III ANOVA(5-groups) Body Weight
Type III Sums of Squares
Source
Treatment
Residual
Dependent: Ph3 Body Wt

df Sum of Squares
4
4744.030
50
4921.970

Mean Square
1186.008
98.439

F-Value
12.048

P-Value
.0001

P hase III ANOVA(5-groups) Body Weight %
Type III Sums of Squares
Source
Treatment
Residual
Dependent: Wt % Ph3

df
4
50

Sum of Squares
567.626
549.802

Mean Square
141.907
10.996

F-Value
12.905

P-Value
.0001

F-Value
9.161

P-Value
.0001

P h ase III ANOVA (5 groups) body weight %
Sham vs Hormone
Effect: Treatment
Dependent: Wt % Ph3
Cell Weight
SHAM
Ovar-E&P
Ovar-E
O var-P
df
Sum of Squares
Mean Square
F-Value
P-Value

1.000
-.3 3 3
-.3 3 3
-.3 3 3
1
5 5 8 .094
558.094
50.754
.0001

P hase III ANOVA(5-groups) Total Calories
Type III Sums of Squares
Source
Treatment
Residual

df
4
50

Sum of Squares
733829.624
1001249.381

Dependent: Ph3 Total Cal
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Mean Square
183457.406
20024.988
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P hase III ANOVA(2x2 Factorial) Protein
Type III Sums of Squares
Source______________________ df
Estrogen
1
Progesterone
1
Estrogen * Progesterone
1
Residual
39
Dependent: PROTEIN

Sum of Squares
444.814
785.464
10557.041
59533.528

Mean Square_____ F-Value
444.814
.291
785.464
.515
10557.041
6.916
1526.501

P-Value
.5924
.4774
.0122

Mean Square
102.879
6306.571
2416.334
993.999

F-Value
.104

P-Value
.7494

6.345
2.431

.0160
.1270

P hase III ANOVA(2x2 Factorial) HF/LS
Type III Sums of Squares
Source______________________ df
Estrogen
1
Progesterone
1
Estrogen * Progesterone
1
Residual
39
Dependent: HF/LS

Sum of Squares
102.879
6306.571
2416.334
38765.961

APPENDIX D TOTAL STUDY
All P h ases ANOVA(4-groups) Body Weight
Type III Sums of Squares
Source
Treatm ent
Residual
Dependent: Total Weight

df
3
39

Sum of Squares
3358.855
11343.087

Mean Square
1119.618
290.848

All P h a se s ANOVA(4-groups) Body Weight
Ovariec vs Hormones
Effect: Treatment
Dependent: Total Weight

Estrogen vs No Estrogen
Effect: Treatment
Dependent: Total Weight

Cell Weight
Ovariec
Ovar-E&P
Ovar-E
O var-P
df
Sum of Squares
Mean Square
F-Value
P-Value

1.000
-.3 3 3
-.3 3 3
-.3 3 3
1
1495.316
1495.316
5.141
.0290

Cell Weight
Ovariec
Ovar-E&P
Ovar-E
Ovar-P
df
Sum of Squares
Mean Square
F-Value
P-Value

-.5 0 0
.500
.500
-.5 0 0
1
3199.449
3199.449
11.000
.0020

ALL PHASES ANOVA (4 GROUPS) BODY WEIGHT%
Ovariec vs Hormones
Effect: Treatment
Dependent: TotlWt %

Estrogen vs No Estrogen
Effect: Treatment
Dependent: TotlWt %

Cell Weight
Ovariec
Ovar-E&P
Ovar-E
O var-P

1.000
-.3 3 3
-.3 3 3
-.3 3 3

df 1
Sum of Squares 221.496
Mean Square 221.496
F-Value 5.311
P-Value .0266

Cell Weight
Ovariec
Ovar-E&P
Ovar-E
Ovar-P
df
Sum of Squares
Mean Square
F-Value
P-Value
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-.5 0 0
.500
.500
-.5 0 0
1
352.782
352.782
8.459
.0060

F-Value
3.849

P-Value
.0166
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All P h ases ANOVA(2x2 Factorial) Total Body weight
Type III Sums of Squares
Source______________________ df
Estrogen
1
1
Progesterone
Estrogen * Progesterone
1
39
Residual
Dependent: Total Weight

Sum of Squares
3579.215
18.766
99.631
11029.767

Mean Square
3579.215
18.766
99.631
282.815

F-Value
12.656
.066
.352

P-Value
.0010
.7981
.5562

F-Value
2.704

P-Value

All P h ases ANOVA(4-groups) Caloric Conversion
Type III Sums of Squares
Source
Treatm ent
Residual
Dependent: Feed Efficiency

df
3
39

Sum of Squares
289.708
1392.639

Mean Square
96.569
35.709

ALL P h a se s ANOVA (4-groups) Caloric Conversion
Estrogen vs No Estrogen
Effect: Treatment
Dependent: Feed Efficiency
Cell Weight
Ovariec
Ovar-E&P
Ovar-E
Ovar-P

-.5 0 0
.500
.500
-.5 0 0

df 1
Sum of Squares 281.835
Mean Square 281.835
F-Value 7.893
P-Value .0077

.0585
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All P h ases ANOVA(2x2 Factorial) Caloric Conversion
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Feed Efficiency

df
1
1
1
39

Sum of Squares
326.781
.072
2.645
1352.763

Mean Square
326.781
.072
2.645
34.666

F-Value
9.421
.002
.076

P-Value
.0039
.9639

F-Value
4.764

P-Value

F-Value
.700
.168
8.052

P-Value
.4078
.6845
.0072

.7839

All P hases ANOVA(4-groups) Total Protein
Type III Sums of Squares
Source
Treatment
Residual
Dependent: Total Pro

df
3
39

Sum of Squares
137560.651
375344.564

Mean Square
45853.550
9624.220

.0063

Scheffe's S
Effect: Treatment
Dependent: Total Pro
Significance level: .05
Diff.

Crit. diff.

P-Value

22.145
85.519

125.228

.9657

128.175
122.719
125.228
119.637
122.719

.2992
.0175
.5411
.0498
.6190

Vs.
O var-P

Ovar-E
Ovariec

Ovar-E
Ovariec
Ovar-E&P
Ovariec
Ovar-E&P
Ovar-E&P

141.865
6 3 .3 7 4
119.720
5 6 .346

S = Significantly different at this level.

All P h ases ANOVA(2x2 Factorial) Total Protein
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Total Pro

df
1
1
1
39

Sum of Squares
7417.964
1775.098
85279.127
413074.880

Mean Square
7417.964
1775.098
85279.127
10591.664
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All P h ases ANOVA(4-groups) Total CHO
Type III Sums of Squares
Source______________________ df
Treatment
3
Residual
39
Dependent: Total CHO

Sum of Squares
1259774.125
4763878.096

Mean Square
419924.708
122150.720

F*Value

P-Value

3.438

.0260

F-Value
10.870
1.334
.420

P-Value
.0021
.2551

ALL PHASES ANOVA (4-groups) Total CHO
Ovariec vs Hormones
Effect: Treatment
Dependent: Total CHO

Estrogen vs No Estrogen
Effect: Treatment
Dependent: Total CHO

Cell Weight
Ovariec
Ovar-E&P
Ovar-E
O var-P

Cell Weight

1.000
-.3 3 3
-.3 3 3
-.3 3 3

Ovariec
Ovar-E&P
Ovar-E
O var-P

-.5 0 0
.500
.500
-.5 0 0
df

df 1
Sum of Squares 1036668.197
Mean Square 1036668.197
F-Value 8 .4 8 7
P-Value .0059

Sum of Squares
Mean Square
F-Value
P-Value

1
921 5 2 9 .9 1 4
921529.914
7 .544
.0091

All P hases ANOVA(2x2 Factorial) Total CHO
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Total CHO

df
1
1
1
39

Sum of Squares
Mean Square
1259595.510
1259595.510
154576.336
154576.336
48634.523
48634.523
115876.810
4519195.579

.5209

APPENDIX E POST MORTEM
ANOVA(4-groups): Progesterone
Type III Sums of Squares
Source
TREAT

df
3
38

Residual
Dependent: PROG

Sum of Squares
1437.465
5510.928

Mean Square

F-Value

P-Value

479.155
145.024

3.304

.0304

Mean Square
.351
.020

F-Value
17.710

P-Value
.0001

ANOVA (4-GROUPS): TESTOSTERONE
Progest vs No Progest
Effect: TREAT
Dependent: TEST
Cell Weight
C-Ovariec
E-Ovar-E&P
D-Ovar-E
F-Ovar-P

-.5 0 0
.500
-.5 0 0
.500

df 1
Sum of Squares 2 .094
Mean Square 2 .094
F-Value 4.0 6 3
P-Value .0508

ANOVA(4-groups): Wt of Uterus
Type III Sums of Squares
Source
Treatment
Residual
Dependent: Wt of Uterus

df
3
39

Sum of Squares
1.053
.773
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Scheffe's S
Effect: Treatment
Dependent: Wt of Uterus
Significance level: .05

C-Ovariec

F-O var-P
E-Ovar-E&P

Vs.

Diff.

Crit. diff.

P-Value

F-Ovar-P
E-Ovar-E&P
D-Ovar-E

.160
.372
.376
.212
.216
.004

.184
.176
.180
.176
.180
.172

.1092

E-Ovar-E&P
D-Ovar-E
D-Ovar-E

.0001
.0001
.0123
.0125

S
S
S
S

.9999

S = Significantly different at this level.

ANOVA (4-GROUPS) WT OF UTERUS
Ovariec vs Hormones
Effect: Treatment
Dependent: Wt of Uterus

Estrogen vs No Estrogen
Effect: Treatment
Dependent: Wt of Uterus

Cell Weight
C-Ovariec
E-Ovar-E&P
D-Ovar-E
F-O var-P
df
Sum of Squares
Mean Square
F-Value
P-Value

Cell Weight

1.000
-.3 3 3
-.3 3 3
-.3 3 3

C-Ovarlec
E-Ovar-E&P
D-Ovar-E
F-Ovar-P

-.5 0 0
.500
.500
-.5 0 0

df 1
Sum of Squares .925
Mean Square .925
F-Value 4 6 .6 5 6
P-Value .0001

1
.703
.703
3 5.443

.0001

ANOVA(2x2 Factorial): Wt of Uterus
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: Wt of Uterus

df
1
1
1
39

Sum of Squares
.925
.072
.065
.773

Mean Square
.925
.072
.065
.020

F-Value
46.656
3.626
3.279

P-Value
.0001
.0643
.0779
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ANOVA(2x2 Factorial): Fat % of Liver
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progestero...
Residual
Dependent: %FAT OF LIVER

df Sum of Squa... Mean Squa...
1
4.955
4 .955
1
.083
.083
1
.267
'.267
39
30.625
.785

F-Value
6.310
.105
.340

P-Value
.0163
.7471
.5634

ANOVA(2x2 Factorial): Weight/Length ratio
Type III Sums of Squares
Source
Estrogen
Progesterone
Estrogen * Progesterone
Residual
Dependent: W/L ratio

df
1
1
1
39

Sum of Squares
17.434
.651
.487
79.277

Mean Square
17.434
.651
.487
2 .0 3 3

F-Value
8 .5 7 7
.320
.240

P-Value
.0057
.5748
.6272

APPENDIX F SUMMARY FIGURES
Phase I Weight Gain and Total Caloric Intake
30i

| □ Total calories (x100)

BBody Weight (g)

Figure 1.0 P h ase I Weight Gain and Total Caloric Intake
Treatment: 1. Sham, 2, No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase I Carbohydrate, Fat, Protein Intake
900 i
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Figure 2.0
Phase I Carbohydrate, Fat, Protein Intake
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase I % Fat Intake
60

1

2

3

4

Figure 3.0
Phase I % Fat Intake
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase I Caloric Conversion Ratio

Figure 4.0
Phase I Caloric Conversion Ratio
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized
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Phase II: Total Caloric Intake and Body Weight Gain
16 <

Caloric intake (100 kcal)
Body wt. gain (g)

1412

•

108 •
6

•

4 •
2
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0•
□Total Calories (x100)

B Body Weight

Figure 5.0
P hase II: Total Caloric Intake and Body Weight Gain
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Phase II Macronutrient Food Choices in kcal
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Figure 6.0
Phase II Macronutrient Food Choices in kcal
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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bw (g) / kcal intake

x 1000

Phase II Caloric Conversion Ratio

Figure 7.0 Phase II Caloric Conversion Ratio
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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P h a s e III: Total C alo ries a n d Body W eight
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□ Total C alo ries (x100)

4
H Body Weight

Figure 8.0
Phase III: Total Calories and Body Weight
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized
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Phase III: Macronutrient Composition and Chocolate
Intake
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Figure 9.0 P h ase III: Macronutrient Composition and Chocolate Intake
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized. Sham w as not
given chocolate sources.

gram/1000

kcal

Phase III: Caloric Conversion Ratio

Figure 10.0 Phase III: Caloric Conversion Ratio
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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Total Study: Caloric Intake and Body Weight Gain

□ Caloric Intake X 100

h Body Wt.

Gain (g)

Figure 11.0 Total study: Caloric Intake and Body Weight Gain
Treatm ent
1. Sham, 2. Estrogen, 3. Estrogen with Progesterone, 4.
Progesterone only, 5. Ovariectomized with no hormone. 2-5 were
ovariectomized. Gram s of body weight increase compared to caloric intake.
Group
Sham
Estrogen
Estrogen & Prog.
Progesterone
Ovariectomized

Grams consum ed
2184+69
2493 ±83
2650±93
2743±100
2794±144

Body Weight Gained (g):
27.3±4.3
39.9±5.19
44.63.19
57.7±5.96
61.4±6.54
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25

Total Study: Caloric Conversion Ratio

Figure 12.0 Total Study: Caloric Conversion Ratio
Treatment: 1. Sham (12), 2. No hormone (21) 3. Estrogen (15), 4. Estrogen
and Progesterone(16), 5. Progesterone (20). 2-5 were ovariectomized.

Body

Weight (g)

Body W eight In c re a se O ver 3 P h a s e s

□ Phase I

Q Phase II

□ Phase III

Figure 13.0 Body weight increases over three phases
Treatment: 1 Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone, 2-5 were ovariectomized.
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Total Study: Percent of Total Caloric Intake:
Fat, Carbohydrate and Protein
100%
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□ FAT %

Figure 14.0 Total Study: Percent of total caloric intake: fat, carbohydrate,
and protein
Treatment: 1. Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone. 2-5 were ovariectomized.
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T otal C aloric Intake o v er 3 P h a s e s
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•

H Phase I

o Phase II

□ Phase III

Figure 15.0 Total caloric intake over 3 phases
Treatment: 1 Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone, 2-5 were ovariectomized.
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Total Study Total Caloric Intake
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Figure 16.0 Total Study Total Caloric Intake
Treatment: 1 Sham, 2. No hormone, 3. Estrogen, 4. Estrogen and
Progesterone, 5. Progesterone, 2-5 were ovariectomized. Macronutrient
profile for macronutrients and chocolate choices.

224

335

Body W eight Gain of Total S tudy
m

325 •

3

305 ■

£ 295 ■
£ 285 •
275 ■

255

*4
■
C
£
<0
4*
n u > r » a > T " - c 9 U > h ' O > r - c 0 M N a >
r

r

r

r

f

-

N

N

N

N

N

3 1 th

265

Days
Ovar P

—0—Ovar

—A- O v a r E&P

A Sham

—0 —Ovar E

Figure 17.0 Body weight gain of total study
Line graph of variation of 30 day, body weight gain. P hase I data starts on day
I, P h ase II data starts on 11, P hase III data starts on day 21.
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Ja n Hamilton enjoyed science from early years and w as always curious
about why things happen. She grew up on a W est Texas ranch on land which
w as claimed by her great grandfather in the 1800s. Cattle and 4-H program s
w ere a happy part of her childhood. S he met personally with three U.S.
Presidents a s a result of leadership and citizenship aw ards.
entered Texas Tech University to study Nutrition.

In 1960 sh e

She graduated in three

years so that she could work and put her husband through law school. There
were five in his family in university, he had just finished a B.S. in Engineering,
and did not feel he could be a further drain on his family.

Tom has been

extremely supportive of Jan in the pursuit of her Ph.D. They have three sons,
John is an engineer, Brent is in law school and Rob is studying econom ics at
T exas Tech University. The whole family enjoys w eekends at the ranch.
During past years Jan worked a s a dietitian and nutritional consultant
both in hospitals and industry. She returned to Texas Tech University in 1987
to pursue a Ph.D in nutrition to qualify her for international nutritional
consulting opportunities. A hormone project in Biochemistry at the T exas Tech
University School of Medicine stimulated interest in the current research topic
and motivated Jan to make every effort to becom e eligible for further research
involving eating behavior, health param eters and states of disease.

To earn

the Ph.D at another university would greatly enhance her chance for future
employment there. Therefore, she chose LSU with the Pennington Biomedical
C enter to finish the Ph.D., and to continue to work in her chosen field of
Physiological Nutrition, Biochemistry and Ingestive Behavior.
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